var title_f24_51_25392="Endoscopic incision ring Endosc";
var content_f24_51_25392=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F59650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F59650&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 495px\">",
"   <div class=\"ttl\">",
"    Transendoscopic electrocautery incision of an esophageal ring",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 475px; height: 215px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Endoscopy demonstrating a mucosal ring in the distal esophagus (left panel), which has been incised using a needle-knife papillotome (right panel).",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Moises Guelrud, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25392=[""].join("\n");
var outline_f24_51_25392=null;
var title_f24_51_25393="White blood cell cast I";
var content_f24_51_25393=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEPH%2F54319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEPH%2F54319&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Photomicrograph of urine sediment with white blood cell cast (I)",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 247px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White cell cast in which blue stained white cells (arrow) are contained within a granular cast.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Frances Andrus, BA, Victoria Hospital, London, Ontario.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25393=[""].join("\n");
var outline_f24_51_25393=null;
var title_f24_51_25394="Cyclopentolate and phenylephrine: Drug information";
var content_f24_51_25394=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Cyclopentolate and phenylephrine: Drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/26/13731?source=see_link\">",
"    see \"Cyclopentolate and phenylephrine: Pediatric drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F155396\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Cyclomydril&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ex_sect_xr thclist drugH1Div drugBrandNames\" id=\"F155402\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacologic Category",
"    </span>",
"    <ul>",
"     <li>",
"      Ophthalmic Agent, Antiglaucoma",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block doa drugH1Div\" id=\"F155397\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Adult",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic aid (mydriasis and cycloplegia): Ophthalmic: Instill 1 drop into the eye every 5-10 minutes, for up to 3 doses, approximately 40-50 minutes before the examination",
"    </p>",
"   </div>",
"   <div class=\"block dop drugH1Div\" id=\"F155401\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Pediatric",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/26/13731?source=see_link\">",
"      see \"Cyclopentolate and phenylephrine: Pediatric drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Diagnostic aid: Ophthalmic: Infants and Children: Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block doe drugH1Div\" id=\"F155398\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Geriatric",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Refer to adult dosing.",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F155390\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Solution, ophthalmic:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;\">",
"     Cyclomydril&reg;: Cyclopentolate hydrochloride 0.2% and phenylephrine hydrochloride 1% (2 mL, 5 mL) [contains benzalkonium chloride]",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F155380\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     No",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F155392\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Finger pressure should be applied to lacrimal sac for 1-2 minutes after instillation to decrease risk of absorption and systemic reactions.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F155391\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Induce mydriasis greater than that produced with cyclopentolate HCl alone",
"    </p>",
"   </div>",
"   <div class=\"block ars drugH1Div\" id=\"F13897368\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions Significant",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13299108\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F155385\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha1-Blockers: May diminish the hypertensive effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize hypotensive effects of Alpha1-Blockers. Alpha1-Blockers may diminish the vasoconstricting effect of Alpha1-Agonists. Similarly, Alpha1-Agonists may antagonize Alpha1-Blocker vasodilation.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the hypertensive effect of Sympathomimetics. AtoMOXetine may enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Ergot Derivatives: May enhance the hypertensive effect of Alpha1-Agonists. Ergot Derivatives may enhance the vasoconstricting effect of Alpha1-Agonists.",
"     <b>",
"      Exceptions:",
"     </b>",
"     Ergoloid Mesylates.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the hypertensive effect of Alpha1-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the vasopressor effect of Alpha1-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F155387\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14287215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Animal reproduction studies have not been conducted with this combination.",
"    </p>",
"   </div>",
"   <div class=\"block lac drugH1Div\" id=\"F14287217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Lactation",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Excretion in breast milk unknown/use caution",
"    </p>",
"   </div>",
"   <div class=\"block fee drugH1Div\" id=\"F16323083\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pricing: U.S. (Medi-Span&reg;)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Solution",
"     </b>",
"     (Cyclomydril Ophthalmic)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     0.2-1% (2 mL): $26.70",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F155394\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics/Kinetics",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     See individual agents.",
"    </p>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 8722 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1005-83.177.194.223-B60670ABF6-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25394=[""].join("\n");
var outline_f24_51_25394=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155396\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155402\">",
"      Pharmacologic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155397\">",
"      Dosing: Adult",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155401\">",
"      Dosing: Pediatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155398\">",
"      Dosing: Geriatric",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155390\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155380\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155392\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155391\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13897368\">",
"      Adverse Reactions Significant",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13299108\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155385\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155387\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287215\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14287217\">",
"      Lactation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F16323083\">",
"      Pricing: U.S. (Medi-Span&reg;)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F155394\">",
"      Pharmacodynamics/Kinetics",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8722\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_GEN/8722|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/26/13731?source=related_link\">",
"      Cyclopentolate and phenylephrine: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_51_25395="Patient information: ECG and stress test (The Basics)";
var content_f24_51_25395=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div>",
"   &nbsp;",
"  </div>",
"  <div id=\"basicsTopicMinWidth\">",
"   <div id=\"basicsTopicRight\">",
"    <div id=\"placeholder\">",
"     <div id=\"basics-graphics\">",
"      <span class=\"basics-box-top\">",
"      </span>",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-graphics-title.png\"/>",
"       <span class=\"openRelatedGraphics\" id=\"PI/16424\" rel=\"graphic_box\">",
"        <a href=\"#\" title=\"View All Related Graphics\">",
"         View All",
"        </a>",
"       </span>",
"      </h4>",
"      <ul>",
"       <li>",
"        <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"         Person having an ECG",
"        </a>",
"        <li>",
"         <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"          Person having a stress test",
"         </a>",
"        </li>",
"       </li>",
"      </ul>",
"      <a href=\"#\" id=\"basics-seeall\">",
"       See All Graphics",
"      </a>",
"     </div>",
"     <script type=\"text/javascript\">",
"      if ($(\"#basics-graphics li\").length &lt;= 4) {",
"				$(\"#basics-seeall\").remove();",
"			} else {",
"				$(\"#basics-graphics li:gt(3)\").addClass(\"hidden\");",
"				$(\"#basics-seeall\").click(function(){",
"					$(\"#basics-graphics li.hidden\").removeClass(\"hidden\");",
"					$(this).remove();",
"					return false;",
"				});",
"			}",
"     </script>",
"     <div class=\"ieSpacer\">",
"     </div>",
"     <div id=\"basics-more\">",
"      <h4>",
"       <img src=\"file://www.uptodate.com/images/basics-more-title.png\"/>",
"      </h4>",
"      <dl>",
"       <dt class=\"basics\">",
"        The Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?20/32/20994\">",
"         Patient information: Atrial fibrillation (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?20/34/21027\">",
"         Patient information: Chest pain (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?27/10/27809\">",
"         Patient information: Coronary heart disease (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?21/13/21714\">",
"         Patient information: Dilated cardiomyopathy (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?24/13/24787\">",
"         Patient information: Echocardiogram (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?9/53/10068\">",
"         Patient information: Heart attack (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/12/17601\">",
"         Patient information: Heart failure (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?34/28/35266\">",
"         Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?19/25/19859\">",
"         Patient information: Long QT syndrome (The Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?31/30/32226\">",
"         Patient information: Nuclear heart testing (The Basics)",
"        </a>",
"       </dd>",
"       <dt class=\"beyondthebasics\">",
"        Beyond the Basics",
"       </dt>",
"       <dd>",
"        <a href=\"UTD.htm?0/16/261\">",
"         Patient information: Atrial fibrillation (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?42/9/43157\">",
"         Patient information: Chest pain (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?43/17/44305\">",
"         Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?39/16/40195\">",
"         Patient information: Heart attack (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?33/5/33877\">",
"         Patient information: Heart failure (Beyond the Basics)",
"        </a>",
"       </dd>",
"       <dd>",
"        <a href=\"UTD.htm?17/49/18197\">",
"         Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"        </a>",
"       </dd>",
"      </dl>",
"      <div id=\"tooltipper\">",
"      </div>",
"     </div>",
"    </div>",
"   </div>",
"   <div id=\"basicsTopicLeft\">",
"    <div id=\"topicTitle\">",
"     Patient information: ECG and stress test (The Basics)",
"    </div>",
"    <span class=\"view\">",
"     View in",
"     <a class=\"lang\" href=\"./es-419/ecg-and-stress-test-the-basics?source=topic_page\">",
"      Spanish",
"     </a>",
"    </span>",
"    <a class=\"contributor contributor_credentials\" href=\"./authors-and-editors/patient-information\">",
"     Written by the doctors and editors at UpToDate",
"    </a>",
"    <div id=\"topicText\">",
"     <p class=\"headingAnchor\" id=\"H98933463\">",
"      <span class=\"h1\">",
"       What is an ECG?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ECG (also called an &ldquo;electrocardiogram&rdquo; or &ldquo;EKG&rdquo;) is a test that records a person&rsquo;s heart rate (how fast it beats) and rhythm. It does this by measuring the electrical activity in the heart. A normal heartbeat happens when an electrical signal starts in a spot near the top of the heart. This signal follows a path to spread across the heart. As it spreads, the signal causes the heart muscle to squeeze. Each time the heart squeezes (&ldquo;beats&rdquo;), it pumps blood through the whole body.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98933470\">",
"      <span class=\"h1\">",
"       What is a stress test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;A stress test measures how well the heart works when it is beating fast and working hard. When the heart pumps fast, it needs more blood. A stress test helps doctors see if the heart is getting enough blood during these times. A stress test is sometimes called an &ldquo;exercise test&rdquo; or a &ldquo;treadmill test.&rdquo;",
"     </p>",
"     <p>",
"      A person can have an ECG without having a stress test. But if a person has a stress test, he or she will always have an ECG with it.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98933477\">",
"      <span class=\"h1\">",
"       Why might my doctor order an ECG or a stress test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Your doctor might order an ECG to:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        See if you are having or had a heart attack",
"       </li>",
"       <li>",
"        Look for other heart conditions or follow a known heart condition",
"       </li>",
"       <li>",
"        Help figure out why you have chest pain, trouble breathing, dizziness, a fast heart rate, or other symptoms",
"       </li>",
"       <li>",
"        Check how healthy your heart is before you have surgery",
"       </li>",
"       <li>",
"        Check how well your heart medicines or other heart treatments are working",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Doctors usually order stress tests to check for problems that can happen when the heart works hard. Your doctor might order a stress test to:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        See if you have coronary heart disease, heart failure, or another heart condition &mdash; Coronary heart disease is a condition that puts you at risk for a heart attack and other types of heart disease. Some people have symptoms of coronary heart disease only when they exercise. Heart failure is a condition in which the heart doesn&rsquo;t pump well.",
"       </li>",
"       <li>",
"        Check how well your heart works after heart surgery.",
"       </li>",
"       <li>",
"        Help figure out why you have chest pain, trouble breathing, or other symptoms.",
"       </li>",
"       <li>",
"        See if you can safely exercise after a heart attack.",
"       </li>",
"      </ul>",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98933484\">",
"      <span class=\"h1\">",
"       How do I prepare for an ECG or a stress test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;Before an ECG, you don&rsquo;t need do anything special. But you should tell your doctor what medicines you take, because they might affect the test results.",
"     </p>",
"     <p>",
"      To prepare for a stress test, you will probably need to avoid eating, drinking, or smoking for 3 hours beforehand. If you are on any heart medicines, you might also need to change or stop some of them before the test.",
"     </p>",
"     <p>",
"      For your stress test, you should wear comfortable clothes that you can exercise in. You should also bring any inhalers that you use to help your breathing.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98933491\">",
"      <span class=\"h1\">",
"       What happens during an ECG and stress test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;For an ECG, a doctor, nurse, or technician will first stick patches (called &ldquo;electrodes&rdquo;) onto your chest, arms, and legs (",
"      <a class=\"graphic graphic_figure graphicRef53145 \" href=\"UTD.htm?6/63/7154\">",
"       figure 1",
"      </a>",
"      ). Wires connect the patches to the ECG machine. The machine will measure and record your heart&rsquo;s electrical activity and print out the results. Having an ECG doesn&rsquo;t hurt.",
"     </p>",
"     <p>",
"      For a stress test, the doctor, nurse, or technician will first do an ECG and measure your blood pressure. Then he or she will &ldquo;stress&rdquo; your heart and increase your heart rate by doing 1 of the following things:",
"     </p>",
"     <p>",
"      <ul class=\"bullet-block\">",
"       <li>",
"        Have you run or walk on a treadmill (",
"        <a class=\"graphic graphic_figure graphicRef60855 \" href=\"UTD.htm?31/21/32085\">",
"         figure 2",
"        </a>",
"        )",
"       </li>",
"       <li>",
"        Have you pedal a stationary bike (a bike that doesn&rsquo;t move, except for the pedals)",
"       </li>",
"       <li>",
"        Give you medicine to make your heart beat faster &mdash; People who can&rsquo;t run or walk can get medicine instead of exercising.",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      Sometimes, doctors do imaging tests during a stress test. These kinds of tests can create images of the blood flow to the heart.",
"     </p>",
"     <p>",
"      During your stress test, the doctor or nurse will watch you. He or she will check your blood pressure, do several ECGs, and ask how you feel. You might also need to breathe into a tube at certain times during the test. The test will end when you can&rsquo;t exercise anymore or when your doctor or nurse tells you the test is over.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98933498\">",
"      <span class=\"h1\">",
"       What are the downsides of an ECG and stress test?",
"      </span>",
"      &nbsp;&mdash;&nbsp;An ECG has very few downsides. Some people get a mild rash where the patches were placed.",
"     </p>",
"     <p>",
"      A stress test can have some downsides. When people exercise and their heart pumps fast, they can have symptoms such as:",
"     </p>",
"     <p>",
"      <ul class=\"bulletCompact-block\">",
"       <li>",
"        An abnormal heartbeat",
"       </li>",
"       <li>",
"        Trouble breathing",
"       </li>",
"       <li>",
"        Feeling dizzy or faint",
"       </li>",
"      </ul>",
"     </p>",
"     <p>",
"      The medicines used during a stress test can also cause side effects, including headaches, dizziness, or nausea.",
"     </p>",
"     <p class=\"headingAnchor\" id=\"H98933594\">",
"      <span class=\"h1\">",
"       More on this topic",
"      </span>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=see_link\">",
"       Patient information: Chest pain (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=see_link\">",
"       Patient information: Coronary heart disease (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=see_link\">",
"       Patient information: Heart failure (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=see_link\">",
"       Patient information: Heart attack (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=see_link\">",
"       Patient information: Atrial fibrillation (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=see_link\">",
"       Patient information: Nuclear heart testing (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=see_link\">",
"       Patient information: Echocardiogram (The Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=see_link\">",
"       Patient information: Long QT syndrome (The Basics)",
"      </a>",
"     </p>",
"     <p>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=see_link\">",
"       Patient information: Chest pain (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=see_link\">",
"       Patient information: Heart failure (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=see_link\">",
"       Patient information: Heart attack (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=see_link\">",
"       Patient information: Atrial fibrillation (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=see_link\">",
"       Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"      </a>",
"      <br/>",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=see_link\">",
"       Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"      </a>",
"     </p>",
"    </div>",
"    <div id=\"reviewProcess\">",
"     <span>",
"      All topics are updated as new evidence becomes available and our",
"      <a class=\"policy policy_editorialpolicy\" href=\"/home/editorial-policy\">",
"       peer review process",
"      </a>",
"      is complete.",
"     </span>",
"    </div>",
"    <div id=\"topicRetrievedDate\">",
"     <span class=\"emphasis\">",
"      This topic retrieved from UpToDate on:",
"     </span>",
"     Apr 20, 2013.",
"    </div>",
"    <div class=\"patTopicTool\" id=\"patTopicToolBottom\">",
"     <a class=\"toolbutton findicon findInPageLink\" href=\"#\" title=\"Find in Topic\">",
"      Find",
"     </a>",
"     <a class=\"toolbutton printicon\" href=\"UTD.htm?24/51/25395?view=print\" title=\"Print This Topic\">",
"      Print",
"     </a>",
"     <a class=\"toolbutton emailicon etacLink\" href=\"#\" title=\"Email This Topic\">",
"      Email",
"     </a>",
"    </div>",
"    <div id=\"disclaimer\">",
"     The content on the UpToDate website is not intended nor recommended as a substitute for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or other qualified health care professional regarding any medical questions or conditions.",
"The use of UpToDate content is governed by the",
"     <a class=\"legal legal_termsofuse\" href=\"/home/terms-use\" target=\"_blank\">",
"      UpToDate Terms of Use",
"     </a>",
"     . &copy;2013 UpToDate, Inc. All rights reserved.",
"    </div>",
"    <div id=\"topicVersionRevision\">",
"     Topic 16424 Version 2.0",
"    </div>",
"   </div>",
"   <!--  basicsTopicLeft -->",
"  </div>",
"  <!-- basicsTopicMinWidth -->",
" </div>",
" <!-- topicContent -->",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-190.111.122.2-5368725AE9-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25395=[""].join("\n");
var outline_f24_51_25395=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98933463\">",
"      What is an ECG?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98933470\">",
"      What is a stress test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98933477\">",
"      Why might my doctor order an ECG or a stress test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98933484\">",
"      How do I prepare for an ECG or a stress test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98933491\">",
"      What happens during an ECG and stress test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98933498\">",
"      What are the downsides of an ECG and stress test?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H98933594\">",
"      More on this topic",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PI/16424\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li>",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?6/63/7154\">",
"      Person having an ECG",
"     </a>",
"     <li>",
"      <a class=\"graphic graphic_figure\" href=\"UTD.htm?31/21/32085\">",
"       Person having a stress test",
"      </a>",
"     </li>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?0/16/261?source=related_link\">",
"      Patient information: Atrial fibrillation (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/32/20994?source=related_link\">",
"      Patient information: Atrial fibrillation (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?42/9/43157?source=related_link\">",
"      Patient information: Chest pain (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?20/34/21027?source=related_link\">",
"      Patient information: Chest pain (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?27/10/27809?source=related_link\">",
"      Patient information: Coronary heart disease (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?43/17/44305?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?21/13/21714?source=related_link\">",
"      Patient information: Dilated cardiomyopathy (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?24/13/24787?source=related_link\">",
"      Patient information: Echocardiogram (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?39/16/40195?source=related_link\">",
"      Patient information: Heart attack (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/53/10068?source=related_link\">",
"      Patient information: Heart attack (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?33/5/33877?source=related_link\">",
"      Patient information: Heart failure (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?17/12/17601?source=related_link\">",
"      Patient information: Heart failure (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?17/49/18197?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?34/28/35266?source=related_link\">",
"      Patient information: Hypertrophic cardiomyopathy in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?19/25/19859?source=related_link\">",
"      Patient information: Long QT syndrome (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/30/32226?source=related_link\">",
"      Patient information: Nuclear heart testing (The Basics)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_51_25396="Gram stain lung 1A answer";
var content_f24_51_25396=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ID%2F56800%7EID%2F68568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ID%2F56800%7EID%2F68568&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Legionella in lung biopsy",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 289px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Gram stain of lung biopsy (x1000) shows rare, difficult to see, small, Gram negative coccobacillary forms consistent with Legionella. Other stains or techniques better confirm the presence of this organism.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Legionella micdadei",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 377px; height: 240px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Modified acid-fast stain of lung biopsy (x1000) shows small reddish coccobacilli; Legionella micdadei grew on culture.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Harriet Provine.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25396=[""].join("\n");
var outline_f24_51_25396=null;
var title_f24_51_25397="Terbutaline: Pediatric drug information";
var content_f24_51_25397=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"drugTitle\">",
"   Terbutaline: Pediatric drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   (For additional information",
"   <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"    see \"Terbutaline: Drug information\"",
"   </a>",
"   and",
"   <a class=\"drug drug_patient\" href=\"UTD.htm?25/42/26277?source=see_link\">",
"    see \"Terbutaline: Patient drug information\"",
"   </a>",
"   )",
"   <br/>",
"   For abbreviations and symbols that may be used in Lexicomp (",
"   <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\">",
"    show table",
"   </a>",
"   )",
"   <div class=\"block black-box-warn drugH1Div\" id=\"F14640925\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     ALERT: U.S. Boxed Warning",
"    </span>",
"    <p style=\"text-indent:0em;\">",
"     The FDA-approved labeling includes a boxed warning. See Warnings/Precautions section for a concise summary of this information.  For verbatim wording of the boxed warning, consult the product labeling or www.fda.gov.",
"    </p>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F225677\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Bricanyl&reg; Turbuhaler&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list_set htclist drugH1Div drugBrandNames\" id=\"F1062438\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Therapeutic Category",
"    </span>",
"    <ul>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Adrenergic Agonist Agent",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Antiasthmatic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Beta",
"       <sub>",
"        2",
"       </sub>",
"       -Adrenergic Agonist",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Bronchodilator",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Sympathomimetic",
"      </span>",
"     </li>",
"     <li>",
"      <span class=\"list-set-name\">",
"       Tocolytic Agent",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"block dos drugH1Div\" id=\"F1062433\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosing: Usual",
"    </span>",
"    <p>",
"     (For additional information",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=see_link\">",
"      see \"Terbutaline: Drug information\"",
"     </a>",
"     )",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &lt;12 years:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: Initial: 0.05 mg/kg/dose every 8 hours, increase gradually, up to 0.15 mg/kg/dose; maximum daily dose: 5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 0.005-0.01 mg/kg/dose to a maximum of 0.4 mg/dose every 15-20 minutes for 3 doses; may repeat every 2-6 hours as needed",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     <b>",
"      Note:",
"     </b>",
"     Continuous I.V. infusion has been used successfully in children with asthma; a 2-10 mcg/kg loading dose followed by an 0.08-0.4 mcg/kg/minute continuous infusion; depending upon the clinical response, the dosage may require titration in increments of 0.1-0.2 mcg/kg/minute every 30 minutes; doses as high as 10 mcg/kg/minute have been used.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Children &ge;12 years and Adults:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 2.5-5 mg/dose every 6-8 hours; maximum daily dose:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     12-15 years: 7.5 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:6em;text-align:justify;\">",
"     &gt;15 years: 15 mg",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 0.25 mg/dose repeated in 20 minutes for 3 doses; a total dose of 0.75 mg should not be exceeded",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Nebulization: Children and Adults: 0.01-0.03 mL/kg (1 mg = 1 mL using injection); minimum dose: 0.1 mL; maximum dose: 2.5 mL every 4-6 hours",
"    </p>",
"   </div>",
"   <div class=\"block foc drugH1Div\" id=\"F225654\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Dosage Forms: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;text-align:justify;display:inline\">",
"     Excipient information presented when available (limited, particularly for generics); consult specific product labeling.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Injection, solution, as sulfate: 1 mg/mL (1 mL)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Tablet, oral, as sulfate: 2.5 mg, 5 mg",
"    </p>",
"   </div>",
"   <div class=\"block geq drugH1Div\" id=\"F225639\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Generic Equivalent Available: U.S.",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Yes",
"    </p>",
"   </div>",
"   <div class=\"block adm drugH1Div\" id=\"F1062442\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Administration",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Oral: May administer without regard to food",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Parenteral: May administer undiluted, direct I.V. over 5-10 minutes; for continuous infusion, dilute to a maximum concentration of 1 mg/mL in D",
"     <sub>",
"      5",
"     </sub>",
"     W or NS",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Inhalation: Nebulization: Dilute dose with 1-2 mL NS",
"    </p>",
"   </div>",
"   <div class=\"block scp drugH1Div\" id=\"F225732\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Compatibility",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Stable in D",
"     <sub>",
"      5",
"     </sub>",
"     W,",
"     <sup>",
"      1",
"     </sup>",
"     /",
"     <sub>",
"      2",
"     </sub>",
"     NS, NS.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Y-site administration: Compatible:",
"     </b>",
"     Calcium gluconate, diltiazem, dobutamine, dopamine, epinephrine, insulin (regular), potassium chloride.",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     <b>",
"      Compatibility in syringe: Compatible:",
"     </b>",
"     Doxapram.",
"    </p>",
"   </div>",
"   <div class=\"block use drugH1Div\" id=\"F1062441\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Use",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Bronchodilator for relief of reversible bronchospasm in patients with asthma, bronchitis, and emphysema",
"    </p>",
"   </div>",
"   <div class=\"block mst drugH1Div\" id=\"F225734\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Medication Safety Issues",
"    </span>",
"    <div class=\"collapsible\">",
"     <span class=\"collapsible-title\">",
"      Sound-alike/look-alike issues:",
"     </span>",
"     <div class=\"collapsible-wrap\">",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Brethine may be confused with Methergine&reg;",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Terbutaline may be confused with terbinafine, TOLBUTamide",
"      </p>",
"      <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"       Terbutaline and methylergonovine parenteral dosage forms look similar. Due to their contrasting indications, use care when administering these agents.",
"      </p>",
"     </div>",
"    </div>",
"   </div>",
"   <div class=\"block arm drugH1Div\" id=\"F225731\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Adverse Reactions",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Cardiovascular: Hypertension, pounding heartbeat, tachycardia",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Central nervous system: Nervousness, restlessness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Endocrine &amp; metabolic: Decreased serum potassium, increased serum glucose",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Gastrointestinal: Bad taste in mouth, dry mouth, nausea, vomiting",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Neuromuscular &amp; skeletal: Dizziness, drowsiness, headache, insomnia, lightheadedness, muscle cramps, trembling, weakness",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Miscellaneous: Diaphoresis",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Rare but important or life-threatening: Arrhythmia, cardiac arrest (preterm labor), chest pain, hyperglycemia (preterm labor),  hypokalemia (preterm labor), hypotension (preterm labor), paradoxical bronchospasm, myocardial infarction (preterm labor), myocardial ischemia (preterm labor), pulmonary edema (preterm labor)",
"    </p>",
"   </div>",
"   <div class=\"block coi drugH1Div\" id=\"F1062447\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Contraindications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Hypersensitivity to terbutaline, other sympathomimetic amines, or any component; cardiac arrhythmias associated with tachycardia; tachycardia caused by digitalis intoxication",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Injection: Additional contraindications: Prolonged (&gt;72 hours) prevention or management of preterm labor",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Oral: Additional contraindications: Prevention or treatment of preterm labor",
"    </p>",
"   </div>",
"   <div class=\"block pre drugH1Div\" id=\"F1062432\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Precautions",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Use with caution in patients with diabetes mellitus, hypertension, hyperthyroidism, history of seizures, or cardiac disease; excessive or prolonged use may lead to tolerance. Children may experience a higher frequency of some adverse effects than adults, including: Congestion, cough, fever, nasopharyngitis, pharyngeal pain, rhinorrhea, toothache, and vomiting.",
"    </p>",
"   </div>",
"   <div class=\"block war drugH1Div\" id=\"F1062431\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warnings",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Terbutaline is not FDA approved for and should not be used for prolonged tocolysis (&gt;48-72 hours)",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     ; use for maintenance tocolysis should not be done in the outpatient setting. Adverse events observed in pregnant women include arrhythmias, increased heart rate, hyperglycemia (transient), hypokalemia, myocardial ischemia, and pulmonary edema. Heart rate may be increased in the fetus and hypoglycemia may occur in the neonate. Oral terbutaline is contraindicated for acute or chronic use in the management of preterm labor. Paradoxical bronchoconstriction may occur with excessive use; if it occurs, discontinue terbutaline immediately",
"    </p>",
"   </div>",
"   <div class=\"block cyt drugH1Div\" id=\"F13300114\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Metabolism/Transport Effects",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     None known.",
"    </p>",
"   </div>",
"   <div class=\"block dri drugH1Div\" id=\"F225648\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Drug Interactions",
"    </span>",
"    <br/>",
"    <br/>",
"    <div class=\"lexi\" id=\"lexiInteractAddInfo\">",
"     (For additional information:",
"     <a class=\"dip\" href=\"./drug-interaction\" target=\"_blank\">",
"      Launch Lexi-Interact&trade; Drug Interactions Program",
"     </a>",
"     )",
"    </div>",
"    <div class=\"lexi\" id=\"lexiInteractImgB\">",
"     <img border=\"0\" height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"    </div>",
"    <div class=\"clear\">",
"    </div>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Alpha-/Beta-Blockers: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk D: Consider therapy modification",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     AtoMOXetine: May enhance the tachycardic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Atosiban: Beta2-Agonists may enhance the adverse/toxic effect of Atosiban. Specifically, there may be an increased risk for pulmonary edema and/or dyspnea.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Beta1 Selective): May diminish the bronchodilatory effect of Beta2-Agonists. Of particular concern with nonselective beta-blockers or higher doses of the beta1 selective beta-blockers.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Beta-Blockers (Nonselective): May diminish the bronchodilatory effect of Beta2-Agonists.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Betahistine: May diminish the therapeutic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Cannabinoids: May enhance the tachycardic effect of Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Iobenguane I 123: Sympathomimetics may diminish the therapeutic effect of Iobenguane I 123.",
"     <i>",
"      Risk X: Avoid combination",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Loop Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Loop Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     MAO Inhibitors: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Sympathomimetics: May enhance the adverse/toxic effect of other Sympathomimetics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Thiazide Diuretics: Beta2-Agonists may enhance the hypokalemic effect of Thiazide Diuretics.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;\">",
"     Tricyclic Antidepressants: May enhance the adverse/toxic effect of Beta2-Agonists.",
"     <i>",
"      Risk C: Monitor therapy",
"     </i>",
"    </p>",
"   </div>",
"   <div class=\"block prf drugH1Div\" id=\"F225650\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Risk Factor",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     C (",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?16/42/17068\">",
"      show table",
"     </a>",
"     )",
"    </p>",
"   </div>",
"   <div class=\"block pri drugH1Div\" id=\"F14206279\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pregnancy Implications",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Adverse events have been observed in animal reproduction studies. Terbutaline crosses the placenta; umbilical cord concentrations are ~11% to 48% of maternal blood levels.",
"     <b>",
"      [U.S. Boxed Warning]",
"     </b>",
"     : Terbutaline is not FDA approved for and should not be used for prolonged tocolysis (&gt;48-72 hours). Use for maintenance tocolysis should not be done in the outpatient setting. Adverse events observed in pregnant women include arrhythmias, increased heart rate, hyperglycemia (transient), hypokalemia, myocardial ischemia, and pulmonary edema. Heart rate may be increased in the fetus and hypoglycemia may occur in the neonate. Terbutaline has been used in the management of preterm labor. Tocolytics may be used for the short-term (48 hour) prolongation of pregnancy to allow for the administration of antenatal steroids and should not be used prior to fetal viability or when the risks of use to the fetus or mother are greater than the risk of preterm birth (ACOG, 2012).",
"    </p>",
"   </div>",
"   <div class=\"block mop drugH1Div\" id=\"F1062437\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Monitoring Parameters",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Heart rate, blood pressure, respiratory rate, serum potassium, arterial or capillary blood gases (if applicable)",
"    </p>",
"   </div>",
"   <div class=\"block pha drugH1Div\" id=\"F1062430\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Mechanism of Action",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     Relaxes bronchial smooth muscle and muscles of peripheral vasculature by action on beta",
"     <sub>",
"      2",
"     </sub>",
"     -receptors with less effect on heart rate",
"    </p>",
"   </div>",
"   <div class=\"block phd drugH1Div\" id=\"F1062445\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacodynamics",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Onset of action:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral inhalation: 5-30 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 6-15 minutes",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Duration:",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral: 4-8 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     Oral inhalation: 3-6 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">",
"     SubQ: 1.5-4 hours",
"    </p>",
"   </div>",
"   <div class=\"block phk drugH1Div\" id=\"F1062446\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Pharmacokinetics (Adult data unless noted)",
"    </span>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Absorption: 33% to 50%",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Distribution: Breast milk to plasma ratio: &lt;2.9",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Metabolism: Possible first-pass metabolism after oral use",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Half-life: 5.7 hours (range: 2.9-14 hours)",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Time to peak serum concentration: SubQ: 0.5 hours",
"    </p>",
"    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">",
"     Elimination: Primarily (60%) unchanged in urine after parenteral use",
"    </p>",
"   </div>",
"   <div class=\"block exp drugH1Div\" id=\"F225659\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Extemporaneous Preparations",
"    </span>",
"    <p style=\"text-indent:0em;display:inline\">",
"     A 1 mg/mL oral suspension may be made with tablets. Crush twenty-four 5 mg tablets in a mortar and reduce to a fine powder. Add 5 mL purified water USP and mix to a uniform paste; mix while adding simple syrup, NF in incremental proportions to",
"     <b>",
"      almost",
"     </b>",
"     120 mL; transfer to a calibrated bottle, rinse mortar with vehicle, and add  quantity of simple syrup, NF sufficient to make 120 mL. Label \"shake well\" and \"refrigerate\".  Stable for 30 days.",
"    </p>",
"    <div class=\"reference\">",
"     Nahata MC, Pai VB, and Hipple TF,",
"     <i>",
"      Pediatric Drug Formulations",
"     </i>",
"     , 5th ed, Cincinnati, OH: Harvey Whitney Books Co, 2004.",
"    </div>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <div class=\"reference\">",
"      ACOG Practice Bulletin No. 127: &ldquo;Management of Preterm Labor,&rdquo;",
"      <i>",
"       Obstet Gynecol",
"      </i>",
"      , 2012, 119(6):1308.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/22617615/pubmed\" id=\"22617615\" target=\"_blank\">",
"        22617615",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Bohn D, Kalloghlian A, Jenkins J, et al, &ldquo;Intravenous Salbutamol in the Treatment of Status Asthmaticus in Children,&rdquo;",
"      <i>",
"       Crit Care Med",
"      </i>",
"      , 1984, 12(10):892-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/6435957/pubmed\" id=\"6435957\" target=\"_blank\">",
"        6435957",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Canny GJ and Levison H, &ldquo;Aerosols - Therapeutic Use and Delivery in Childhood Asthma,&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1988, 60(1):11-9.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/3276242/pubmed\" id=\"3276242\" target=\"_blank\">",
"        3276242",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Expert Panel Report 2, &ldquo;Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 94-4051, April, 1997.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Fuglsang G, Pedersen S, and Borgstrom L, &ldquo;Dose-Response Relationships of I.V. Administered Terbutaline in Children With Asthma,&rdquo;",
"      <i>",
"       J Pediatr",
"      </i>",
"      , 1989, 114(2):315-20.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/2915294/pubmed\" id=\"2915294\" target=\"_blank\">",
"        2915294",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Goldenhersh N and Rachelefsky GS, &ldquo;Childhood Asthma: Management,&rdquo;",
"      <i>",
"       Pediatr Rev",
"      </i>",
"      , 1989, 10(9):259-67.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/2652119 /pubmed\" id=\"2652119 \" target=\"_blank\">",
"        2652119",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      &ldquo;Guidelines for the Diagnosis and Management of Asthma. NAEPP Expert Panel Report 3,&rdquo; August 2007, www.nhlbi.nih.gov/guidelines/asthma/asthgdln.pdf.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Hearne AE and Nagey DA, \"Therapeutic Agents in Preterm Labor: Tocolytic Agents,\"",
"      <i>",
"       Clin Obstet Gynecol",
"      </i>",
"      , 2000, 43(4):787-801.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/11100296/pubmed\" id=\"11100296\" target=\"_blank\">",
"        11100296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      National Asthma Education and Prevention Program (NAEPP), &ldquo;Expert Panel Report 3 (EPR-3): Guidelines for the Diagnosis and Management of Asthma,&rdquo;",
"      <i>",
"       Clinical Practice Guidelines",
"      </i>",
"      , National Institutes of Health, National Heart, Lung, and Blood Institute, NIH Publication No. 08-4051, prepublication 2007; available at file://www.nhlbi.nih.gov/guidelines/asthma/asthgdln.htm.",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Rachelefsky GS and Siegel SC, &ldquo;Asthma in Infants and Children - Treatment of Childhood Asthma: Part ll,&rdquo;",
"      <i>",
"       J Allergy Clin Immunol",
"      </i>",
"      , 1985, 76(3):409-25.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/ 2863296 /pubmed\" id=\" 2863296 \" target=\"_blank\">",
"        2863296",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"    <li>",
"     <div class=\"reference\">",
"      Tipton WR and Nelson HS, &ldquo;Frequent Parenteral Terbutaline in the Treatment of Status Asthmaticus in Children,&rdquo;",
"      <i>",
"       Ann Allergy",
"      </i>",
"      , 1987, 58(4):252-6.",
"      <span class=\"pubmed-id\">",
"       [PubMed",
"       <a href=\"UTD.htm?24/51/25397/abstract-text/3565860 /pubmed\" id=\"3565860 \" target=\"_blank\">",
"        3565860",
"       </a>",
"       ]",
"      </span>",
"     </div>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 12826 Version 37.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-180.241.123.62-A6501CF067-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25397=[""].join("\n");
var outline_f24_51_25397=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14640925\">",
"      ALERT: U.S. Boxed Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225677\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062438\">",
"      Therapeutic Category",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062433\">",
"      Dosing: Usual",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225654\">",
"      Dosage Forms: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225639\">",
"      Generic Equivalent Available: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062442\">",
"      Administration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225732\">",
"      Compatibility",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062441\">",
"      Use",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225734\">",
"      Medication Safety Issues",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225731\">",
"      Adverse Reactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062447\">",
"      Contraindications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062432\">",
"      Precautions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062431\">",
"      Warnings",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F13300114\">",
"      Metabolism/Transport Effects",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225648\">",
"      Drug Interactions",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225650\">",
"      Pregnancy Risk Factor",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F14206279\">",
"      Pregnancy Implications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062437\">",
"      Monitoring Parameters",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062430\">",
"      Mechanism of Action",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062445\">",
"      Pharmacodynamics",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F1062446\">",
"      Pharmacokinetics (Adult data unless noted)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F225659\">",
"      Extemporaneous Preparations",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12826\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"DRUG_PED/12826|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?23/39/24183\" title=\"Lexicomp clinical abbreviations\">",
"      Lexicomp clinical abbreviations",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?11/55/12151?source=related_link\">",
"      Terbutaline: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_patient\" href=\"UTD.htm?25/42/26277?source=related_link\">",
"      Terbutaline: Patient drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_51_25398="Outcome of infants with bronchopulmonary dysplasia";
var content_f24_51_25398=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/wk_utd-rgb.myextg\" width=\"220px\">",
"   </img>",
"  </div>",
"  <div id=\"printHeaderText\">",
"   Official reprint from  UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"   <a href=\"file://www.uptodate.com\">",
"    www.uptodate.com",
"   </a>",
"   <br>",
"    &copy;2013 UpToDate",
"    <sup>",
"     &reg;",
"    </sup>",
"   </br>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Outcome of infants with bronchopulmonary dysplasia",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25398/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25398/contributors\">",
"     James M Adams, Jr, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25398/contributors\">",
"     Ann R Stark, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25398/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25398/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25398/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25398/contributors\">",
"     Melanie S Kim, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/51/25398/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 10, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Despite important advances in perinatal care and a steady decline in mortality rates among very low birth weight (VLBW) infants (&lt;1500 grams), bronchopulmonary dysplasia (BPD) remains a major complication of prematurity resulting in significant mortality and morbidity. The increasing rates of survival among the smallest of premature infants due to changes in antenatal and postnatal respiratory management, such as antenatal steroids and surfactant replacement, contribute to an overall increase in the incidence of BPD despite advances in the care of premature infants that reduce the risk or severity of BPD. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=see_link\">",
"     \"Prevention of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The outcome of infants with BPD is reviewed here. Pathogenesis and clinical features, management, and potential strategies to prevent BPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=see_link\">",
"     \"Management of bronchopulmonary dysplasia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=see_link\">",
"     \"Prevention of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TERMINOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Different degrees of prematurity are defined by gestational age (GA), which is calculated from the first day of the mother's last period, or birthweight (BW). Data on BPD is often based upon the following classification of preterm infants categorized by birthweight as follows:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Low birth weight (LBW) - BW less than 2500 g",
"     </li>",
"     <li>",
"      Very low birth weight (VLBW) - BW less than 1500 g",
"     </li>",
"     <li>",
"      Extremely low birth weight (ELBW) - BW less than 1000 g",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These terms are used throughout this discussion.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     TRENDS OVER TIME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The pathology and clinical course of BPD has been altered by the widespread use of surfactant after its introduction in 1980, use of less aggressive ventilation, and the increased survival rate of extremely low birth weight. As a result, the long-term outcome of BPD continues to change along with these factors. In particular, results vary depending upon whether the study was performed prior to or after the introduction of surfactant in the 1980s. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=see_link\">",
"     \"Pathogenesis and clinical features of bronchopulmonary dysplasia\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     MORTALITY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with severe BPD have a higher risk of mortality than unaffected infants or those with mild disease at the same GA. Death usually is caused by respiratory failure, unremitting pulmonary hypertension with cor pulmonale, or sepsis.",
"   </p>",
"   <p>",
"    The risk of mortality rises with increased duration of mechanical ventilation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. In one study in the presurfactant era of 144 newborns who required prolonged mechanical ventilation after birth, death occurred in 35 percent of infants ventilated for two months, and 90 percent of those ventilated for more than four months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/2\">",
"     2",
"    </a>",
"    ]. At 30 days of age, the mean airway pressure and a diagnosis of bacterial sepsis during the previous month were significant predictors of mortality. In patients who still required ventilation at 60 days of age, mean airway pressure and inspired oxygen concentration were the best predictors of mortality. In a multicenter study from 1995 to 1998, death occurred in 90 of 372 (24.2 percent) ELBW infants ventilated for more than 60 days [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/3\">",
"     3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although the prevalence of pulmonary artery hypertension in infants with BPD is unknown, infants with BPD and severe pulmonary artery hypertension (PAH) have a high mortality rate.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study of patients with BPD who developed PAH, and were treated during the surfactant era, 16 of 42 patients died within six months of diagnosis (median postnatal age at diagnosis and death; 4.8 months and 10.9 months, respectively) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/4\">",
"       4",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In multivariate analyses, small for gestational age and severe PAH, defined as systemic or suprasystemic right ventricular pressure, were associated with poorer survival rates. Twenty-three of the 26 survivors (median follow-up 9.8 months) demonstrated improvement of their PAH.",
"     </li>",
"     <li>",
"      In another study of 78 ELBW infants with BPD, treated with positive pressure ventilation for more than 28 days and who had echocardiograms, mortality was greater in patients with PAH compared with those without PAH (38 versus 14 percent) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    PAH as a long-term complication of BPD is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link&amp;anchor=H12#H12\">",
"     \"Pulmonary outcomes of bronchopulmonary dysplasia\", section on 'Pulmonary artery hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h1\">",
"     PULMONARY OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Respiratory illnesses contribute to high rates of rehospitalization for survivors of BPD, especially in the first year [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/6-8\">",
"     6-8",
"    </a>",
"    ]. In one report, preterm survivors with BPD were rehospitalized more often than those without BPD during the first year (58 versus 35 percent) and more likely to be readmitted for respiratory illness (39 versus 20 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Respiratory infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infants with BPD are at increased risk for respiratory infections, including respiratory syncytial virus (RSV), which may be life-threatening [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/9\">",
"     9",
"    </a>",
"    ]. &nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?40/0/40964?source=see_link\">",
"     Palivizumab",
"    </a>",
"    is a humanized monoclonal antibody against the RSV F glycoprotein. It is licensed for use in selected infants and children including infants and young children younger than 24 months with BPD. We suggest that palivizumab be administered to these patients if they have required medical therapy for their pulmonary disease within 6 months of the anticipated RSV season to reduce their risk of RSV infection. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=see_link\">",
"     \"Respiratory syncytial virus infection: Clinical features and diagnosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=see_link&amp;anchor=H104278863#H104278863\">",
"     \"Respiratory syncytial virus infection: Prevention\", section on 'Palivizumab'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Asthma-like disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;Episodes of wheezing suggest bronchiolitis or asthma and are common in preterm survivors with BPD before first two years of age. Asthma-like disease in patients who had BPD is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link&amp;anchor=H11#H11\">",
"     \"Pulmonary outcomes of bronchopulmonary dysplasia\", section on 'Asthma-like symptoms'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Pulmonary function",
"    </span>",
"    &nbsp;&mdash;&nbsp;Persistent abnormalities in pulmonary function are common in patients who had BPD as infants and depend upon the severity of BPD. The long-term pulmonary function and abnormalities in preterm survivors with BPD are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link&amp;anchor=H4#H4\">",
"     \"Pulmonary outcomes of bronchopulmonary dysplasia\", section on 'Pulmonary function'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Pulmonary artery hypertension",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary artery hypertension (PAH) and the resultant right heart failure (cor pulmonale) associated with severe BPD are caused by both structural and functional changes within the lung. It is one of the most severe complications of BPD and is an important risk factor for mortality. The pathogenesis of PAH, its course and, management are discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link&amp;anchor=H12#H12\">",
"     \"Pulmonary outcomes of bronchopulmonary dysplasia\", section on 'Pulmonary artery hypertension'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h1\">",
"     NEURODEVELOPMENT OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;Preterm survivors who had BPD compared to those without BPD are at increased risk for neurodevelopmental impairment.",
"   </p>",
"   <p>",
"    Both motor and cognitive performances are affected as demonstrated by the following studies, after the introduction of surfactant:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In a large cohort of ELBW infants born in 1993 and 1994 and cared for in the centers of the National Institute of Child Health and Human Development (NICHD) Neonatal Research Network and evaluated at 18 to 22 months corrected age, BPD and steroid treatment for BPD were a significant risk factors for abnormal neurologic examination and scores &lt;70 (&gt;2 standard deviations below the mean) on the mental (MDI) and motor (PDI) scales of the Bayley Scales of Infant Development [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a cohort of infants treated at a single tertiary center, VLBW infants with BPD compared to control groups of unaffected VLBW infants and term infants were more likely to have scores &lt;70 for MDI (21 versus 11 and 4 percent) and PDI (20 versus 9 and 1 percent) at three years of age [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/11\">",
"       11",
"      </a>",
"      ]. In another report from the same center, children with BPD had poorer receptive and expressive language skills at three years of age compared to both control groups [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/12\">",
"       12",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The severity of BPD increases the risk of neurodevelopmental impairment as illustrated by a study from the NICHD Neonatal Research Network [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/3\">",
"     3",
"    </a>",
"    ]. In this study of 5364 ELBW infants born between 1995 and 1998, abnormal neurodevelopmental outcomes were documented in 76 percent of surviving infants who were ventilated for &ge;60 days, 93 percent of those ventilated for &ge;90 days, and all of those who were ventilated for &ge;120 days.",
"   </p>",
"   <p>",
"    In addition, neurodevelopmental outcomes are poorer with increasing severity of BPD.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Analysis of the data from the NICHD Neonatal Research Network cohort study demonstrated that the incidence of any neurodevelopment impairment, cerebral palsy, mental and psychomotor developmental indices scores &lt;70, blindness, and hearing impairment requiring amplification at 18 to 22 months corrected age increased as the severity of BPD increased [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/13\">",
"       13",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In a follow-up study of 99 children who were assessed at three and eight years of age, severity of their BPD was grouped into three categories based upon their gestational age and oxygen treatment beyond 28 days of age [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/14\">",
"       14",
"      </a>",
"      ]. Children who had severe BPD did poorer on IQ tests than children with mild or moderate BPD at three and eight years of age and required more special education services at eight years of age.",
"     </li>",
"     <li>",
"      In a study of 1047 infants born before 28 weeks gestation, 536 had BPD, defined as receipt of supplemental oxygen with or without mechanical ventilation at 36 weeks postmenstrual age. A time-oriented multivariate analysis showed patients that had BPD and were treated with mechanical ventilation had a nearly sixfold risk of quadriparesis and a fourfold increased risk of diparesis, the two most common cerebral palsy phenotypes (CP) [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/15\">",
"       15",
"      </a>",
"      ]. Patients with milder BPD, who received supplemental oxygen without mechanical ventilation, did not have an increased risk for any of the three cerebral palsy phenotypes.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     School age",
"    </span>",
"    &nbsp;&mdash;&nbsp;The effect of BPD on neurodevelopmental outcome persists through school age.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In one study, VLBW infants with BPD tested at eight to ten years of age scored poorest on all eight measures of cognitive performance, compared to control groups of term and unaffected VLBW infants [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/16\">",
"       16",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, neuromotor outcome was evaluated at approximately 10 years of age in children who had severe BPD and required home oxygen therapy [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/17\">",
"       17",
"      </a>",
"      ]. Compared to unaffected preterm controls, neurologic abnormalities, including subtle neurologic signs, cerebral palsy, microcephaly, and behavioral problems, were significantly more prevalent in the BPD group (71 versus 19 percent). More than one-half of the BPD group had abnormalities of gross",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      fine motor skills.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Neonatal practice changes",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although changes in neonatal practice have the potential to affect the neurodevelopment outcome of infants with BPD, limited data suggest that the overall neurodevelopmental outcome of infants with BPD remains unchanged over the last two decades. This was illustrated in a study from a single tertiary center, in which, outcomes of infants with BPD who were either ELBW or extremely low gestational age (ELGA, gestational age less than 28 weeks) were compared from two time periods (1996 to 1999 and 2000 to 2003) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/18\">",
"     18",
"    </a>",
"    ]. Between the two periods, practice changes included increased use of surfactant and therapy for patent ductus arteriosus (ie,",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?17/27/17848?source=see_link\">",
"     indomethacin",
"    </a>",
"    therapy or surgical ligation), and decreased use of postnatal glucocorticoids. There were no differences in the incidences of BPD, MDI Bayley scores below 70, or overall neurologic impairment. In contrast, the incidence of neurosensory abnormalities was lower in the later compared to the earlier time period (ELBW infants: 29 versus 16 percent, and ELGA infants: 31 versus 16 percent).",
"   </p>",
"   <p>",
"    Postnatal glucocorticoid treatment used to prevent or treat BPD is a risk-factor for long-term neurodevelopmental disability, especially cerebral palsy. The association of glucocorticoid therapy and cerebral palsy is discussed in detail elsewhere. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3353?source=see_link&amp;anchor=H6#H6\">",
"     \"Postnatal use of glucocorticoids in bronchopulmonary dysplasia\", section on 'Long-term outcome'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h2\">",
"     Confounding factors",
"    </span>",
"    &nbsp;&mdash;&nbsp;In interpreting follow-up studies such as those cited above, it is important to recognize that many factors influence neurodevelopmental outcome. These include the incidence of neurologic risk factors (eg, cranial ultrasound abnormalities), neurosensory problems (eg, retinopathy of prematurity, hearing impairment), hospital course, or poor social environment. In one study from the presurfactant era, for example, infants with BPD evaluated at eight years had significantly poorer psychoeducational and school performance test scores than controls [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/19\">",
"     19",
"    </a>",
"    ]. However, most variance in academic achievement was attributed to the lowest recorded pH or PaO2 and the father's socioeconomic status.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     GROWTH",
"    </span>",
"    &nbsp;&mdash;&nbsp;It is clear that poor growth is observed in infants with BPD during their NICU hospitalization and after discharge. This is due to the increased energy expenditure associated with their respiratory disease, and the difficulty of maintaining full nutrient and mineral intake in patients requiring severe fluid restriction and diuretics. However, the effect of BPD on long-term growth is uncertain. In some follow-up studies performed in the presurfactant era, poorer growth was reported in infants with BPD compared to unaffected infants through two years of age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/20,21\">",
"     20,21",
"    </a>",
"    ]. In contrast, other studies of patients treated from the same period found no difference in growth after adjustment for confounding variables in older children and adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/19,22,23\">",
"     19,22,23",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Poor growth of survivors with BPD was noted in a study that followed 20 preterm infants with BPD for two years after postmenstrual age [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/20\">",
"     20",
"    </a>",
"    ]. At term-adjusted age, infants were severely growth-restricted with average weight and height &le;3rd percentile. Growth accelerated as respiratory symptoms improved. At two years, weight for boys and girls was 3rd to 10th percentile, and height was 10th to 25th and 25th percentiles for boys and girls, respectively. In another series of 16 affected children evaluated at two years of age, height and weight were &lt;10th percentile in 37 and 25 percent, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In a study of premature survivors at eight and ten years of age, although survivors with BPD were significantly smaller than unaffected children, after adjustment for confounding variables, no significant differences in growth were detected [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25398/abstract/22\">",
"     22",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?31/24/32129?source=see_link\">",
"       \"Patient information: Bronchopulmonary dysplasia (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     SUMMARY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Bronchopulmonary dysplasia (BPD) remains a major complication of prematurity resulting in significant mortality and morbidity.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Infants with severe BPD have a higher risk of mortality than unaffected infants or those with mild disease of the same GA. Death usually is caused by respiratory failure, unremitting pulmonary hypertension with cor pulmonale, or sepsis. Increased mortality is associated with longer duration of mechanical ventilation, episodes of sepsis, and pulmonary artery hypertension (PAH). (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mortality'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Survivors of prematurity and BPD are at increased risk for respiratory disease, including respiratory infection, asthma-like disease, and pulmonary artery hypertension. Persistent abnormalities in pulmonary function are also common in patients who had BPD as infants, and depend upon the severity of BPD. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=see_link\">",
"       \"Pulmonary outcomes of bronchopulmonary dysplasia\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      BPD is associated with an increased risk for neurodevelopmental impairment, which affects both motor and cognitive function. The severity of BPD increases both the risk and severity of neurodevelopmental disability. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Neurodevelopment outcome'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It remains uncertain whether BPD has a direct impact on long-term growth. After adjusting for confounding factors, no significant differences were detected in growth at school age in children who had BPD compared to those who did not have BPD. (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Growth'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/1\">",
"      Wheater M, Rennie JM. Poor prognosis after prolonged ventilation for bronchopulmonary dysplasia. Arch Dis Child Fetal Neonatal Ed 1994; 71:F210.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/2\">",
"      Overstreet DW, Jackson JC, van Belle G, Truog WE. Estimation of mortality risk in chronically ventilated infants with bronchopulmonary dysplasia. Pediatrics 1991; 88:1153.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/3\">",
"      Walsh MC, Morris BH, Wrage LA, et al. Extremely low birthweight neonates with protracted ventilation: mortality and 18-month neurodevelopmental outcomes. J Pediatr 2005; 146:798.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/4\">",
"      Khemani E, McElhinney DB, Rhein L, et al. Pulmonary artery hypertension in formerly premature infants with bronchopulmonary dysplasia: clinical features and outcomes in the surfactant era. Pediatrics 2007; 120:1260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/5\">",
"      Slaughter JL, Pakrashi T, Jones DE, et al. Echocardiographic detection of pulmonary hypertension in extremely low birth weight infants with bronchopulmonary dysplasia requiring prolonged positive pressure ventilation. J Perinatol 2011; 31:635.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/6\">",
"      Chye JK, Gray PH. Rehospitalization and growth of infants with bronchopulmonary dysplasia: a matched control study. J Paediatr Child Health 1995; 31:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/7\">",
"      Gross SJ, Iannuzzi DM, Kveselis DA, Anbar RD. Effect of preterm birth on pulmonary function at school age: a prospective controlled study. J Pediatr 1998; 133:188.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/8\">",
"      Smith VC, Zupancic JA, McCormick MC, et al. Rehospitalization in the first year of life among infants with bronchopulmonary dysplasia. J Pediatr 2004; 144:799.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/9\">",
"      Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82:199.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/10\">",
"      Vohr BR, Wright LL, Dusick AM, et al. Neurodevelopmental and functional outcomes of extremely low birth weight infants in the National Institute of Child Health and Human Development Neonatal Research Network, 1993-1994. Pediatrics 2000; 105:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/11\">",
"      Singer L, Yamashita T, Lilien L, et al. A longitudinal study of developmental outcome of infants with bronchopulmonary dysplasia and very low birth weight. Pediatrics 1997; 100:987.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/12\">",
"      Singer LT, Siegel AC, Lewis B, et al. Preschool language outcomes of children with history of bronchopulmonary dysplasia and very low birth weight. J Dev Behav Pediatr 2001; 22:19.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/13\">",
"      Ehrenkranz RA, Walsh MC, Vohr BR, et al. Validation of the National Institutes of Health consensus definition of bronchopulmonary dysplasia. Pediatrics 2005; 116:1353.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/14\">",
"      Short EJ, Kirchner HL, Asaad GR, et al. Developmental sequelae in preterm infants having a diagnosis of bronchopulmonary dysplasia: analysis using a severity-based classification system. Arch Pediatr Adolesc Med 2007; 161:1082.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/15\">",
"      Van Marter LJ, Kuban KC, Allred E, et al. Does bronchopulmonary dysplasia contribute to the occurrence of cerebral palsy among infants born before 28 weeks of gestation? Arch Dis Child Fetal Neonatal Ed 2011; 96:F20.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/16\">",
"      Hughes CA, O'Gorman LA, Shyr Y, et al. Cognitive performance at school age of very low birth weight infants with bronchopulmonary dysplasia. J Dev Behav Pediatr 1999; 20:1.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/17\">",
"      Majnemer A, Riley P, Shevell M, et al. Severe bronchopulmonary dysplasia increases risk for later neurological and motor sequelae in preterm survivors. Dev Med Child Neurol 2000; 42:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/18\">",
"      Kobaly K, Schluchter M, Minich N, et al. Outcomes of extremely low birth weight (&lt;1 kg) and extremely low gestational age (&lt;28 weeks) infants with bronchopulmonary dysplasia: effects of practice changes in 2000 to 2003. Pediatrics 2008; 121:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/19\">",
"      Robertson CM, Etches PC, Goldson E, Kyle JM. Eight-year school performance, neurodevelopmental, and growth outcome of neonates with bronchopulmonary dysplasia: a comparative study. Pediatrics 1992; 89:365.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/20\">",
"      Markestad T, Fitzhardinge PM. Growth and development in children recovering from bronchopulmonary dysplasia. J Pediatr 1981; 98:597.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/21\">",
"      Yu VY, Orgill AA, Lim SB, et al. Growth and development of very low birthweight infants recovering from bronchopulmonary dysplasia. Arch Dis Child 1983; 58:791.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/22\">",
"      Vrlenich LA, Bozynski ME, Shyr Y, et al. The effect of bronchopulmonary dysplasia on growth at school age. Pediatrics 1995; 95:855.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25398/abstract/23\">",
"      Doyle LW, Faber B, Callanan C, et al. Bronchopulmonary dysplasia in very low birth weight subjects and lung function in late adolescence. Pediatrics 2006; 118:108.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4982 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.3 - C21.34",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     Morehouse School of Medicine",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-85.214.214.87-1759BFA714-S473950.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25398=[""].join("\n");
var outline_f24_51_25398=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H15\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TERMINOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      TRENDS OVER TIME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      MORTALITY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      PULMONARY OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Respiratory infection",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Asthma-like disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Pulmonary function",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Pulmonary artery hypertension",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      NEURODEVELOPMENT OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      School age",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Neonatal practice changes",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      Confounding factors",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      GROWTH",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      SUMMARY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/24/15753?source=related_link\">",
"      Management of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/22/18793?source=related_link\">",
"      Pathogenesis and clinical features of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?31/24/32129?source=related_link\">",
"      Patient information: Bronchopulmonary dysplasia (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/17/3353?source=related_link\">",
"      Postnatal use of glucocorticoids in bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/14/27880?source=related_link\">",
"      Prevention of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/40/17034?source=related_link\">",
"      Pulmonary outcomes of bronchopulmonary dysplasia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/56/7050?source=related_link\">",
"      Respiratory syncytial virus infection: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/17/15640?source=related_link\">",
"      Respiratory syncytial virus infection: Prevention",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_51_25399="Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1";
var content_f24_51_25399=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Genetic disorders of the collecting tubule sodium channel: Liddle's syndrome and pseudohypoaldosteronism type 1",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25399/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25399/contributors\">",
"     William F Young, Jr, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25399/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25399/contributors\">",
"     Richard H Sterns, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25399/contributors\">",
"     Andre Lacroix, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25399/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25399/contributors\">",
"     John P Forman, MD, MSc",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/51/25399/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 18, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liddle's syndrome and autosomal recessive pseudohypoaldosteronism type 1 are rare genetic disorders associated with abnormalities in the function of the collecting tubule sodium channel, also called the epithelial sodium channel (ENaC) or the",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    -sensitive sodium channel:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      ENaC function is increased in Liddle's syndrome, leading to manifestations similar to those caused by mineralocorticoid excess, such as hypertension and, in some patients, hypokalemia and metabolic alkalosis. Presentation at a young age, which occurs in most patients, suggests the possibility of a genetic disorder rather than an adrenal adenoma. In addition, plasma and urinary aldosterone levels are reduced, not increased as in primary aldosteronism.",
"     </li>",
"     <li>",
"      ENaC function is decreased in autosomal recessive pseudohypoaldosteronism type 1, resulting in aldosterone resistance. Affected patients present in infancy with sodium wasting, hypovolemia, and hyperkalemia. These findings are similar to those in other forms of hypoaldosteronism in children, except that plasma aldosterone levels are elevated, not reduced.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The clinical presentation, genetics, and management of Liddle's syndrome and pseudohypoaldosteronism will be reviewed here. Other causes of hypertension and hypokalemia, and of hypoaldosteronism are reviewed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=see_link\">",
"     \"Approach to the patient with hypertension and hypokalemia\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     COLLECTING TUBULE SODIUM CHANNEL",
"    </span>",
"    &nbsp;&mdash;&nbsp;The cortical collecting tubule contains two cell types with different functions: principal cells (about 65 percent) and intercalated cells. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33352?source=see_link\">",
"     \"Chapter 5B: Collecting tubules\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The principal cells have sodium and potassium channels in the luminal (apical) membrane and, as in all sodium reabsorbing cells, Na-K-ATPase pumps in the basolateral membrane (",
"      <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"       figure 1",
"      </a>",
"      )&nbsp;[",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/1-3\">",
"       1-3",
"      </a>",
"      ]. Aldosterone-sensitive sodium channels, also called epithelial sodium channels, are present in the colon and sweat glands as well as the collecting tubule.",
"     </li>",
"     <li>",
"      The intercalated cells are primarily involved in hydrogen, bicarbonate, and potassium handling (",
"      <a class=\"graphic graphic_figure graphicRef51361 \" href=\"UTD.htm?38/43/39613\">",
"       figure 2",
"      </a>",
"      ). They do not reabsorb sodium, since they have a lower level of Na-K-ATPase activity and few, if any, apical membrane sodium channels [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/3,4\">",
"       3,4",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The principal cells contribute to net sodium reabsorption and are the primary site of potassium secretion. The entry of sodium into these cells primarily occurs down a concentration gradient through the luminal sodium channels (",
"    <a class=\"graphic graphic_figure graphicRef60693 \" href=\"UTD.htm?12/31/12797\">",
"     figure 1",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Aldosterone plays a central role in these processes, mainly by increasing the number of open luminal sodium channels [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/5,6\">",
"     5,6",
"    </a>",
"    ]. As an example, going from a high to a low sodium diet (which is associated with enhanced aldosterone release and increased sodium reabsorption in the cortical collecting tubule) can increase the number of open sodium channels per cell from less than 100 to approximately 3000 [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/2\">",
"     2",
"    </a>",
"    ]. There is also a later increase in Na-K-ATPase activity and open luminal potassium channels. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=see_link\">",
"     \"Chapter 6C: Aldosterone\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Although increased intracellular sodium concentrations downregulate the activity of the luminal sodium channels, increased export of cell sodium via increased Na-K-ATPase activity assures that increased numbers of sodium channels remain open [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     Amiloride",
"    </a>",
"    blocks the collecting tubule sodium channels, leading to natriuresis and potassium retention [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/1\">",
"     1",
"    </a>",
"    ]. Data derived from cloned sodium channel genes indicate that the site of amiloride binding is distinct from the channel pore [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/1,8\">",
"     1,8",
"    </a>",
"    ]. Within the kidney, the sodium channel is primarily expressed in the late distal tubule and cortical and outer medullary portions of the collecting tubule [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     LIDDLE'S SYNDROME",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Clinical presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liddle's syndrome (MIM #177220) is a rare autosomal dominant condition in which there is a primary increase in collecting tubule sodium reabsorption and, in most cases, potassium secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/10,11\">",
"     10,11",
"    </a>",
"    ]. Affected patients typically present with hypertension, hypokalemia, and metabolic alkalosis, findings that are similar to those seen in other disorders caused by mineralocorticoid excess. Most patients present at a young age, but some are not detected until well into adulthood [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/12\">",
"     12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, some patients with Liddle's syndrome are not hypokalemic at presentation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/10,13\">",
"     10,13",
"    </a>",
"    ]. In one kindred, for example, the average serum potassium of 18 affected family members was 3.6",
"    <span class=\"nowrap\">",
"     meq/L",
"    </span>",
"    [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/10\">",
"     10",
"    </a>",
"    ]. In the absence of hypokalemia, the positive family history of early onset hypertension and, in some members, hypokalemia would be the major findings suggesting possible Liddle's syndrome. Absence of hypokalemia has also been demonstrated in an appreciable proportion of patients with primary aldosteronism. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=see_link&amp;anchor=H6#H6\">",
"     \"Clinical features of primary aldosteronism\", section on 'Hypokalemia: an inconsistent finding'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Pathogenesis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Correction of the hypokalemia and hypertension in one patient with Liddle's syndrome by renal transplantation suggested that enhanced activity of the luminal membrane sodium channels, not increased secretion of a nonaldosterone mineralocorticoid, was the underlying defect [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This hypothesis was confirmed by the demonstration that the genetic abnormality in Liddle's syndrome involves mutations in genes on chromosome 16p12 that encode the beta and gamma subunits of the collecting tubule sodium channel, which are called SCNN1B and SCNN1G, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/14-16\">",
"     14-16",
"    </a>",
"    ]. Deletions or substitutions in a short proline-rich segment of the intracytoplasmic C-terminus cause an inability of these subunits to bind with an intracellular ubiquitin protein ligase (Nedd4) that normally removes the luminal sodium channel from the cell surface [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/17,18\">",
"     17,18",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Failure to remove sodium channels results in an inability to reduce their number in response to low levels of aldosterone that result from the volume expansion-mediated suppression of renin secretion. These mutations result in a \"gain-of-function'' that mimics the effects of hyperaldosteronism [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/13,14,16,19-22\">",
"     13,14,16,19-22",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Expression of these abnormal genes in the Xenopus oocyte is associated with a marked increase in sodium transport and loss of inhibition of channel activity by elevated intracellular sodium concentrations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/7,20,22,23\">",
"     7,20,22,23",
"    </a>",
"    ]. On the other hand, the ability to respond to aldosterone is maintained [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/24\">",
"     24",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with Liddle's syndrome classically present with the triad of hypertension, hypokalemia, and metabolic alkalosis at a relatively young age. The consistent findings among such individuals are low plasma renin activity and, in contrast to primary aldosteronism, reductions in both the plasma aldosterone concentration and urinary excretion of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The differential diagnosis of this constellation of abnormalities includes some forms of congenital adrenal hyperplasia, familial cortisol resistance, the syndrome of apparent mineralocorticoid excess, licorice ingestion, Cushing's syndrome, and a DOC-producing adrenal tumor. (See appropriate topic reviews).",
"   </p>",
"   <p>",
"    A positive family history of hypertension at a young age with some members being hypokalemic should lead to the suspicion of a genetic disorder. However, sporadic cases of Liddle's syndrome have been described [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/25\">",
"     25",
"    </a>",
"    ]. As a result, the absence of a family history does not preclude the diagnosis.",
"   </p>",
"   <p>",
"    Genetic testing is the most reliable method for establishing the diagnosis of Liddle's syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/26\">",
"     26",
"    </a>",
"    ]. Clinical genetic testing is available; exon 13 of both SCNN1B and SCNN1G is sequenced (",
"    <a class=\"external\" href=\"file://www.genetests.org/\">",
"     www.genetests.org",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h2\">",
"     Therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Therapy in Liddle's syndrome consists of prescribing",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"     amiloride",
"    </a>",
"    or",
"    <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"     triamterene",
"    </a>",
"    , potassium-sparing diuretics that directly block the collecting tubule sodium channels and can correct both the hypertension and, if present, the hypokalemia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/19,22,27-30\">",
"     19,22,27-30",
"    </a>",
"    ]. The mineralocorticoid antagonist",
"    <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"     spironolactone",
"    </a>",
"    is ineffective, since the increase in sodium channel activity in Liddle's syndrome is not mediated by aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/10,30,31\">",
"     10,30,31",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h1\">",
"     PSEUDOHYPOALDOSTERONISM TYPE 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pseudohypoaldosteronism type 1 is a rare hereditary disorder characterized by generalized resistance to the actions of aldosterone. It typically presents in infancy with sodium wasting, hypovolemia, and hyperkalemia. These features are similar to other forms of hypoaldosteronism in children except that plasma aldosterone levels are markedly elevated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"     \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Two different modes of inheritance of pseudohypoaldosteronism type 1 have been described with somewhat different clinical features [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/32-35\">",
"     32-35",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Autosomal recessive pseudohypoaldosteronism type 1 (MIM #264350), involving the epithelial sodium channel, in which the defect is permanent and affects all aldosterone target organs (including the kidney, colon, and sweat glands).",
"     </li>",
"     <li>",
"      Autosomal dominant or sporadic pseudohypoaldosteronism type 1 (MIM #177735) is due to heterozygous mutations in the NR3C2 gene coding for the mineralocorticoid receptor, in which the defect is limited to the kidney. This renal variant has an estimated prevalence of 1 in 80,000 newborns [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/35\">",
"       35",
"      </a>",
"      ], and is associated with milder salt wasting than autosomal recessive disease, and often improves with age. This disorder and pseudohypoaldosteronism type 2 (also called Gordon's syndrome), which also does not involve the sodium channel, are discussed elsewhere. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link&amp;anchor=H13#H13\">",
"       \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\", section on 'Pseudohypoaldosteronism type 2 (Gordon's syndrome)'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=see_link\">",
"       \"Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Autosomal recessive disease",
"    </span>",
"    &nbsp;&mdash;&nbsp;The genetic defect in the autosomal recessive form of pseudohypoaldosteronism type 1 involves the alpha, beta, or gamma subunits (SCNN1A, SCNN1B, SCNN1G) of the sodium channel, resulting in resistance to the stimulatory effect of aldosterone [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/34,36\">",
"     34,36",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The majority of reported mutations are in the alpha subunit, most commonly frameshift or premature stop codon defects. Studies in the Xenopus oocyte expression system suggest that, although these abnormalities frequently result in marked reductions in channel activity, even a mild defect can cause salt-wasting, hyponatremia, hyperkalemia, acidosis, and volume depletion.",
"     </li>",
"     <li>",
"      Beta and gamma mutations, due to frameshift and premature stop codon defects, are less common. Given the paucity of data relating to these abnormalities, an accurate correlation between genotype and clinical phenotype has not been performed.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In addition to the typically severe fluid and electrolyte disturbances, sodium channel activity is also impaired in the lung, often leading to frequent lower respiratory tract infections and excess airway liquid [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/34,37,38\">",
"     34,37,38",
"    </a>",
"    ]. This manifestation plus associated increases in sweat sodium and chloride concentrations results in a clinical picture that can mimic cystic fibrosis, including recurrent episodes of chest congestion, coughing, and wheezing [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/38\">",
"     38",
"    </a>",
"    ]. Two features different from cystic fibrosis are a reduction in respiratory symptoms after age five and the absence of an increase in lung infections due to Pseudomonas aeruginosa [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/38\">",
"     38",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=see_link\">",
"     \"Cystic fibrosis: Clinical manifestations of pulmonary disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    \"Knockout\" mice lacking the alpha subunit of the epithelial sodium channel die in the neonatal period because of defective lung liquid clearance, while mice without either the beta or gamma subunit die of hyperkalemia but not defective lungs [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/34,39,40\">",
"     34,39,40",
"    </a>",
"    ]. These findings suggest that only the alpha subunit is required for an air-filled lung, while all three subunits are required for an adequate response to aldosterone.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Treatment",
"    </span>",
"    &nbsp;&mdash;&nbsp;Initial therapy of autosomal recessive pseudohypoaldosteronism type 1 consists of a high salt diet, which prevents volume depletion and, by enhancing sodium delivery to the potassium secretory site in the collecting tubules, increases potassium excretion and lowers the plasma potassium concentration. High dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"     fludrocortisone",
"    </a>",
"    (1 to 2",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    [versus 0.05 to 0.1",
"    <span class=\"nowrap\">",
"     mg/day",
"    </span>",
"    in adrenal insufficiency]) or carbenoxolone can be added if a high salt intake is ineffective or not well tolerated [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/41\">",
"     41",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The efficacy of carbenoxolone in autosomal recessive pseudohypoaldosteronism type 1 is presumably related to its antagonism of cortisol metabolism, thereby allowing cortisol (which circulates in much higher concentrations than aldosterone) to activate mineralocorticoid receptors. Indirect proof for this mechanism, which is the same as that seen with the active ingredient in licorice, was shown by the response to the administration of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?33/4/33856?source=see_link\">",
"     dexamethasone",
"    </a>",
"    , a potent glucocorticoid with minimal mineralocorticoid activity. Dexamethasone abolished the effect of carbenoxolone, presumably by diminishing endogenous cortisol secretion [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25399/abstract/41\">",
"     41",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=see_link\">",
"     \"Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Liddle's syndrome and autosomal recessive pseudohypoaldosteronism type 1 are rare genetic disorders associated with abnormalities in the function of the collecting tubule sodium channel: increased function in Liddle's syndrome; and decreased function and resistance to aldosterone in pseudohypoaldosteronism.",
"   </p>",
"   <p>",
"    Patients with Liddle's syndrome typically present at a relatively young age with hypertension and, in most cases, hypokalemia and metabolic alkalosis. These findings are similar to those caused by primary aldosteronism, except that both the plasma aldosterone concentration and urinary excretion of aldosterone are reduced.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A positive family history of hypertension at a young age with some members being hypokalemic should lead to the suspicion of a genetic disorder. The diagnosis of Liddle's syndrome is established by genetic testing. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend treatment with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?37/12/38085?source=see_link\">",
"       amiloride",
"      </a>",
"      or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?42/60/43973?source=see_link\">",
"       triamterene",
"      </a>",
"      &nbsp;(",
"      <a class=\"grade\" href=\"._grade_2?title=Grade 1B\">",
"       Grade 1B",
"      </a>",
"      ). These potassium-sparing diuretics directly treat the primary defect in this disorder by blocking the collecting tubule sodium channels. The mineralocorticoid antagonist",
"      <a class=\"drug drug_general\" href=\"UTD.htm?17/22/17767?source=see_link\">",
"       spironolactone",
"      </a>",
"      is ineffective, since the increase in sodium channel activity is not mediated by aldosterone. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with autosomal recessive pseudohypoaldosteronism type 1 typically present in infancy with sodium wasting, hypovolemia, and hyperkalemia. These features are similar to other forms of hypoaldosteronism in children, except that both the plasma aldosterone concentration and urinary excretion of aldosterone are markedly increased. (See",
"    <a class=\"local\" href=\"#H8\">",
"     'Pseudohypoaldosteronism type 1'",
"    </a>",
"    above.)",
"   </p>",
"   <p>",
"    Sodium channel activity is also impaired in the lung and sweat glands, often leading to frequent lower respiratory tract infections and increased sweat sodium and chloride concentrations that mimic those in cystic fibrosis.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      We recommend treatment with a high salt diet (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ), which prevents volume depletion and, by enhancing sodium delivery to the potassium secretory site in the collecting tubules, increases potassium excretion and lowers the plasma potassium concentration. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      If a high salt diet is not sufficiently effective or not well tolerated, we recommend high dose",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/9/21655?source=see_link\">",
"       fludrocortisone",
"      </a>",
"      (1 to 2",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      [versus 0.05 to 0.1",
"      <span class=\"nowrap\">",
"       mg/day",
"      </span>",
"      in adrenal insufficiency]) or carbenoxolone (",
"      <a class=\"grade\" href=\"._grade_3?title=Grade 1C\">",
"       Grade 1C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Treatment'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/1\">",
"      Canessa CM, Schild L, Buell G, et al. Amiloride-sensitive epithelial Na+ channel is made of three homologous subunits. Nature 1994; 367:463.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/2\">",
"      Frindt G, Sackin H, Palmer LG. Whole-cell currents in rat cortical collecting tubule: low-Na diet increases amiloride-sensitive conductance. Am J Physiol 1990; 258:F562.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/3\">",
"      Sauer M, Flemmer A, Thurau K, Beck FX. Sodium entry routes in principal and intercalated cells of the isolated perfused cortical collecting duct. Pflugers Arch 1990; 416:88.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/4\">",
"      Katz AI. Distribution and function of classes of ATPases along the nephron. Kidney Int 1986; 29:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/5\">",
"      Sansom S, Muto S, Giebisch G. Na-dependent effects of DOCA on cellular transport properties of CCDs from ADX rabbits. Am J Physiol 1987; 253:F753.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/6\">",
"      Schafer JA, Hawk CT. Regulation of Na+ channels in the cortical collecting duct by AVP and mineralocorticoids. Kidney Int 1992; 41:255.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/7\">",
"      Kellenberger S, Gautschi I, Rossier BC, Schild L. Mutations causing Liddle syndrome reduce sodium-dependent downregulation of the epithelial sodium channel in the Xenopus oocyte expression system. J Clin Invest 1998; 101:2741.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/8\">",
"      Li XJ, Xu RH, Guggino WB, Snyder SH. Alternatively spliced forms of the alpha subunit of the epithelial sodium channel: distinct sites for amiloride binding and channel pore. Mol Pharmacol 1995; 47:1133.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/9\">",
"      Duc C, Farman N, Canessa CM, et al. Cell-specific expression of epithelial sodium channel alpha, beta, and gamma subunits in aldosterone-responsive epithelia from the rat: localization by in situ hybridization and immunocytochemistry. J Cell Biol 1994; 127:1907.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/10\">",
"      Botero-Velez M, Curtis JJ, Warnock DG. Brief report: Liddle's syndrome revisited--a disorder of sodium reabsorption in the distal tubule. N Engl J Med 1994; 330:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/11\">",
"      Palmer BF, Alpern RJ. Liddle's syndrome. Am J Med 1998; 104:301.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/12\">",
"      Findling JW, Raff H, Hansson JH, Lifton RP. Liddle's syndrome: prospective genetic screening and suppressed aldosterone secretion in an extended kindred. J Clin Endocrinol Metab 1997; 82:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/13\">",
"      Rayner BL, Owen EP, King JA, et al. A new mutation, R563Q, of the beta subunit of the epithelial sodium channel associated with low-renin, low-aldosterone hypertension. J Hypertens 2003; 21:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/14\">",
"      Snyder PM, Price MP, McDonald FJ, et al. Mechanism by which Liddle's syndrome mutations increase activity of a human epithelial Na+ channel. Cell 1995; 83:969.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/15\">",
"      Hansson JH, Nelson-Williams C, Suzuki H, et al. Hypertension caused by a truncated epithelial sodium channel gamma subunit: genetic heterogeneity of Liddle syndrome. Nat Genet 1995; 11:76.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/16\">",
"      Devonald MA, Karet FE. Renal epithelial traffic jams and one-way streets. J Am Soc Nephrol 2004; 15:1370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/17\">",
"      Goulet CC, Volk KA, Adams CM, et al. Inhibition of the epithelial Na+ channel by interaction of Nedd4 with a PY motif deleted in Liddle's syndrome. J Biol Chem 1998; 273:30012.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/18\">",
"      Abriel H, Loffing J, Rebhun JF, et al. Defective regulation of the epithelial Na+ channel by Nedd4 in Liddle's syndrome. J Clin Invest 1999; 103:667.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/19\">",
"      Shimkets RA, Warnock DG, Bositis CM, et al. Liddle's syndrome: heritable human hypertension caused by mutations in the beta subunit of the epithelial sodium channel. Cell 1994; 79:407.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/20\">",
"      Schild L, Canessa CM, Shimkets RA, et al. A mutation in the epithelial sodium channel causing Liddle disease increases channel activity in the Xenopus laevis oocyte expression system. Proc Natl Acad Sci U S A 1995; 92:5699.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/21\">",
"      Hansson JH, Schild L, Lu Y, et al. A de novo missense mutation of the beta subunit of the epithelial sodium channel causes hypertension and Liddle syndrome, identifying a proline-rich segment critical for regulation of channel activity. Proc Natl Acad Sci U S A 1995; 92:11495.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/22\">",
"      Furuhashi M, Kitamura K, Adachi M, et al. Liddle's syndrome caused by a novel mutation in the proline-rich PY motif of the epithelial sodium channel beta-subunit. J Clin Endocrinol Metab 2005; 90:340.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/23\">",
"      Rossi E, Farnetti E, Debonneville A, et al. Liddle's syndrome caused by a novel missense mutation (P617L) of the epithelial sodium channel beta subunit. J Hypertens 2008; 26:921.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/24\">",
"      Auberson M, Hoffmann-Pochon N, Vandewalle A, et al. Epithelial Na+ channel mutants causing Liddle's syndrome retain ability to respond to aldosterone and vasopressin. Am J Physiol Renal Physiol 2003; 285:F459.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/25\">",
"      Yamashita Y, Koga M, Takeda Y, et al. Two sporadic cases of Liddle's syndrome caused by De novo ENaC mutations. Am J Kidney Dis 2001; 37:499.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/26\">",
"      Achard JM, Hadchouel J, Faure S, Jeunemaitre X. Inherited sodium avid states. Adv Chronic Kidney Dis 2006; 13:118.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/27\">",
"      Jeunemaitre X, Bassilana F, Persu A, et al. Genotype-phenotype analysis of a newly discovered family with Liddle's syndrome. J Hypertens 1997; 15:1091.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/28\">",
"      Wang C, Chan TK, Yeung RT, et al. The effect of triamterene and sodium intake on renin, aldosterone, and erythrocyte sodium transport in Liddle's syndrome. J Clin Endocrinol Metab 1981; 52:1027.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/29\">",
"      Ono F, Harada H, Komatsu K, et al. Two cases of pseudoaldosteronism (Liddle's syndrome) in siblings. Endocrinol Jpn 1975; 22:163.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/30\">",
"      Mutoh S, Hirayama H, Ueda S, et al. Pseudohyperaldosteronism (Liddle's syndrome): a case report. J Urol 1986; 135:557.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/31\">",
"      Sakamoto N, Uda M, Kojima S, et al. Hypertension, hypokalemia and hypoaldosteronism with suppressed renin: a clinical study of a patient with Liddle's syndrome. Endocrinol Jpn 1981; 28:357.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/32\">",
"      Hanukoglu A. Type I pseudohypoaldosteronism includes two clinically and genetically distinct entities with either renal or multiple target organ defects. J Clin Endocrinol Metab 1991; 73:936.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/33\">",
"      Kuhnle U, Nielsen MD, Tietze HU, et al. Pseudohypoaldosteronism in eight families: different forms of inheritance are evidence for various genetic defects. J Clin Endocrinol Metab 1990; 70:638.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/34\">",
"      Bonny O, Rossier BC. Disturbances of Na/K balance: pseudohypoaldosteronism revisited. J Am Soc Nephrol 2002; 13:2399.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/35\">",
"      Zennaro MC, Hubert EL, Fernandes-Rosa FL. Aldosterone resistance: structural and functional considerations and new perspectives. Mol Cell Endocrinol 2012; 350:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/36\">",
"      Chang SS, Grunder S, Hanukoglu A, et al. Mutations in subunits of the epithelial sodium channel cause salt wasting with hyperkalaemic acidosis, pseudohypoaldosteronism type 1. Nat Genet 1996; 12:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/37\">",
"      Hanukoglu A, Bistritzer T, Rakover Y, Mandelberg A. Pseudohypoaldosteronism with increased sweat and saliva electrolyte values and frequent lower respiratory tract infections mimicking cystic fibrosis. J Pediatr 1994; 125:752.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/38\">",
"      Kerem E, Bistritzer T, Hanukoglu A, et al. Pulmonary epithelial sodium-channel dysfunction and excess airway liquid in pseudohypoaldosteronism. N Engl J Med 1999; 341:156.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/39\">",
"      Hummler E, Barker P, Gatzy J, et al. Early death due to defective neonatal lung liquid clearance in alpha-ENaC-deficient mice. Nat Genet 1996; 12:325.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/40\">",
"      McDonald FJ, Yang B, Hrstka RF, et al. Disruption of the beta subunit of the epithelial Na+ channel in mice: hyperkalemia and neonatal death associated with a pseudohypoaldosteronism phenotype. Proc Natl Acad Sci U S A 1999; 96:1727.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25399/abstract/41\">",
"      Arai K, Tsigos C, Suzuki Y, et al. Physiological and molecular aspects of mineralocorticoid receptor action in pseudohypoaldosteronism: a responsiveness test and therapy. J Clin Endocrinol Metab 1994; 79:1019.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 2371 Version 5.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0504-125.39.66.147-4554544F47-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25399=[""].join("\n");
var outline_f24_51_25399=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H11\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      COLLECTING TUBULE SODIUM CHANNEL",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      LIDDLE'S SYNDROME",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Clinical presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Pathogenesis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      Therapy",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      PSEUDOHYPOALDOSTERONISM TYPE 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Autosomal recessive disease",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Treatment",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"NEPH/2371\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"NEPH/2371|FIG\">",
"      <a href=\"#\" title=\"FIGURES\">",
"       FIGURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?12/31/12797\" title=\"figure 1\">",
"      Collecting tubule transport",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_figure\" href=\"UTD.htm?38/43/39613\" title=\"figure 2\">",
"      Distal acid secretion",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/56/40838?source=related_link\">",
"      Apparent mineralocorticoid excess syndromes (including chronic licorice ingestion)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/13/5338?source=related_link\">",
"      Approach to the patient with hypertension and hypokalemia",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?32/36/33352?source=related_link\">",
"      Chapter 5B: Collecting tubules",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/20/2376?source=related_link\">",
"      Chapter 6C: Aldosterone",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/1/37911?source=related_link\">",
"      Clinical features of primary aldosteronism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/45/27351?source=related_link\">",
"      Cystic fibrosis: Clinical manifestations of pulmonary disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/44/9930?source=related_link\">",
"      Etiology, diagnosis, and treatment of hypoaldosteronism (type 4 RTA)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_51_25400="Treatment and prognosis of Graves' disease in children and adolescents";
var content_f24_51_25400=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Treatment and prognosis of Graves' disease in children and adolescents",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25400/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25400/contributors\">",
"     Stephen LaFranchi, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25400/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25400/contributors\">",
"     Mitchell Geffner, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25400/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25400/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/51/25400/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 11, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Hyperthyroidism in children and adolescents has unique effects on growth and development in addition to causing many of the same symptoms that it does in adults. Graves' disease occurs in approximately 0.02 percent of children (1 in 5000) and is almost always the cause of hyperthyroidism in this age group [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/1\">",
"     1",
"    </a>",
"    ]. Nearly all children with Graves' disease have a diffuse goiter; Graves' ophthalmopathy also may be present, but is less severe than in adults.",
"   </p>",
"   <p>",
"    The treatment and prognosis of Graves' disease in childhood and adolescence will be discussed here. The clinical manifestations and diagnosis are presented separately. Treatment of the other conditions causing hyperthyroidism is similar to that for adults, except that children with nodular goiters are generally treated with surgery rather than radioactive iodine. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=see_link\">",
"     \"Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     TREATMENT APPROACHES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Children and adolescents with Graves' hyperthyroidism can be treated with an antithyroid drug, radioactive iodine, or thyroidectomy. The choice of therapy is determined by individual consideration of the risks and benefits of the three treatment modalities (",
"    <a class=\"graphic graphic_table graphicRef67833 \" href=\"UTD.htm?33/40/34443\">",
"     table 1",
"    </a>",
"    ). Regardless of the choice of treatment, all patients will require lifelong monitoring.",
"   </p>",
"   <p>",
"    Most pediatric endocrinologists recommend antithyroid drug therapy as initial treatment in the hope that the patient will have a remission of the Graves' disease and therefore will remain euthyroid after treatment is discontinued. There is, however, a growing acceptance of radioactive iodine therapy for children older than 10 years and adolescents as a second, and in some cases, initial treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/2\">",
"     2",
"    </a>",
"    ]. Surgical near-total thyroidectomy is an equally effective and safe treatment. The experience of using each of these modalities to treat Graves' disease in adults is discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=see_link\">",
"     \"Treatment of Graves' hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The primary considerations for each of these therapies are:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Antithyroid drugs are the best-established treatment in this age group, and provide a chance of permanent remission with euthyroidism. Improvement is gradual, the course of treatment is long, and patients must be monitored for potential side effects.",
"     </li>",
"     <li>",
"      Radioiodine (in a high enough dose) permanently cures hyperthyroidism, replacing it with hypothyroidism, which requires lifelong thyroid hormone replacement therapy. There are general concerns about the radiation exposure; small studies in children have not shown increased long-term risks of thyroid cancer or other cancers.",
"     </li>",
"     <li>",
"      Surgery provides the most rapid resolution of hyperthyroidism and avoids the theoretical risk of radiation exposure. The patient is exposed to modest surgical risks, is rendered hypothyroid, and requires lifelong thyroid hormone replacement therapy.",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Antithyroid drugs",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most children and adolescents with Graves' hyperthyroidism respond well to an antithyroid drug, with 87 to 100 percent becoming euthyroid within a few weeks to a few months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. We recommend using",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     methimazole",
"    </a>",
"    (MMI, 0.25 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day).",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"     Propylthiouracil",
"    </a>",
"    (PTU, 5 to 10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    per day) is also effective, but has more frequent and severe side effects, including a small risk of severe hepatotoxicity [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Because of these safety concerns, the Endocrine Society and the American Thyroid Association recommend AGAINST the use of PTU as first-line treatment for Graves' disease in children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/8,9\">",
"     8,9",
"    </a>",
"    ], and the U.S. Food and Drug Administration has issued a black-box warning [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/10\">",
"     10",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H10\">",
"     'Side effects'",
"    </a>",
"    below and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=see_link\">",
"     \"Thionamides in the treatment of Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Initiating and adjusting therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;We choose an initial",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     methimazole",
"    </a>",
"    dose between 0.25 and 1.0",
"    <span class=\"nowrap\">",
"     mg/kg/day,",
"    </span>",
"    based on clinical severity, size of goiter, and biochemical severity. Patients with mild features of hyperthyroidism, a small goiter, and milder elevations of serum free T4 and T3 are started at the lower end of the dose range (around 0.25",
"    <span class=\"nowrap\">",
"     mg/kg/day).",
"    </span>",
"    Patients with more severe clinical features of hyperthyroidism, a large goiter, and more severe elevations of serum free T4 and T3 are started at the higher end of the dose range (0.5 to 1.0",
"    <span class=\"nowrap\">",
"     mg/kg/day).",
"    </span>",
"    Since methimazole is available as 5 mg or 10 mg tablets, for practical purposes we round off the dose so that whole tablets can be used.",
"   </p>",
"   <p>",
"    We measure serum free T4 and total T3 every four to six weeks initially. At present, assays for free T3 are less accurate than total T3, and age-reference ranges for children are still being established. If these values are elevated, then we increase the dose of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     methimazole",
"    </a>",
"    by approximately 0.25",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    increments (again rounding the dose to whole tablets) until thyroid function is normal. After thyroid function has normalized, follow-up visits, with measurement of serum free T4, T3, and TSH, can be scheduled at three- to four-month intervals. If the free T4 falls below the normal range, the dose is titrated down.",
"   </p>",
"   <p>",
"    Because patients with hyperthyroidism can have slightly low white blood cell counts (WBC) and slightly high serum aminotransferase and gamma glutamyltranspeptidase concentrations due to the disease itself, we measure these before beginning antithyroid drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/11\">",
"     11",
"    </a>",
"    ]. A potential complication of antithyroid drug treatment is a drop in WBC, and, rarely, agranulocytosis or even pancytopenia, which can be life-threatening if not detected promptly [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/12\">",
"     12",
"    </a>",
"    ].While routine monitoring of WBC may occasionally detect early agranulocytosis, it is not recommended because of the rarity of the condition and its sudden onset, which is generally associated with symptoms [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/9\">",
"     9",
"    </a>",
"    ]. If a patient develops a febrile illness or pharyngitis, antithyroid drug treatment (usually",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     methimazole",
"    </a>",
"    ) should be stopped immediately and WBC measured. If the granulocyte count is normal, antithyroid drug treatment may be restarted. If the granulocyte count is low but not meeting criteria for agranulocytosis (ie,",
"    <span class=\"nowrap\">",
"     &lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    neutrophil counts usually recover spontaneously within one to two weeks [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/13\">",
"     13",
"    </a>",
"    ]. Agranulocytosis",
"    <span class=\"nowrap\">",
"     (&lt;500/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    is a contraindication to future antithyroid drug treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/9\">",
"     9",
"    </a>",
"    ]. We re-measure liver enzymes and serum bilirubin only if we note any clinical evidence of liver disease, such as jaundice, and not on a routine basis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=see_link\">",
"     \"Drug-induced neutropenia and agranulocytosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Adding beta blockers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Symptoms of adrenergic overactivity, such as palpitations, and tremor, if prominent, can be treated with beta blockers until thyroid secretion declines in response to therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/13\">",
"     13",
"    </a>",
"    ]. We suggest",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"     atenolol",
"    </a>",
"    , because it is cardio-selective, with reduced risk of bronchospasm as compared with other beta blockers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Adding thyroxine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Adding thyroxine to the treatment regimen does not affect the likelihood of sustained remission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/14-16\">",
"     14-16",
"    </a>",
"    ], but does make it more difficult to judge when a remission is likely to have occurred, and therefore when the antithyroid drug can be discontinued.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Stopping therapy",
"    </span>",
"    &nbsp;&mdash;&nbsp;Rather than giving an antithyroid drug for an arbitrary time period and then stopping it, we prefer to titrate the dose against the clinical and biochemical response. When only a low dose is needed to maintain a euthyroid state (eg, 5 to 10 mg of",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     methimazole",
"    </a>",
"    ), which typically occurs with a decrease in size of the thyroid gland, we stop the drug and follow the patient closely. We do not rely on measurements of serum TSH receptor antibody titers (TSHR-Ab) to make this decision, although others find it useful. (See",
"    <a class=\"local\" href=\"#H9\">",
"     'Relapse rate'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Remission rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;The rate of remission of Graves' hyperthyroidism in children and adolescents (defined as the proportion of patients who remain euthyroid for at least six months after discontinuation of antithyroid drug therapy) varied from 25 to 65 percent in different series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/1-5,17,18\">",
"     1-5,17,18",
"    </a>",
"    ]. Studies in adults suggest that remission rates are higher if therapy is continued for more than six months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/19\">",
"     19",
"    </a>",
"    ], but rates of remission are not improved if therapy is continued beyond 18 months [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to adults, prolonged courses of antithyroid drugs are often necessary and efficacious in children. Many pediatric endocrinologists, and their patients and parents, are willing to use antithyroid drugs for many years until a remission occurs. Remission rates in children are illustrated by the following examples:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A large and well-designed study of antithyroid drug treatment in children suggests that prolonged use of antithyroid drugs leads to remission in many children. In this study, 25 percent of children went into a remission every two years, with a 50 percent remission rate at 4.5 years of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/5\">",
"       5",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      In another report, 154 French children were treated with an antithyroid drug for three consecutive treatment cycles, each lasting two years [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/21\">",
"       21",
"      </a>",
"      ]. The thionamide drug used in most of these patients was carbimazole, which is not available in the United States. Estimated remission rates were 20, 37, 45, and 49 percent after 4, 6, 8, and 10 years of follow-up, respectively. &nbsp; &nbsp;",
"     </li>",
"     <li>",
"      In a prospective multicenter trial, 29 percent of children achieved a remission after two years of treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Predictors of remission in the same multicenter trial were lower thyroid hormone concentrations at presentation, older age, and euthyroid status after three months of antithyroid drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/22\">",
"     22",
"    </a>",
"    ]. Similarly, another series found that prepubertal children may take longer to enter remission than pubertal children (median time to remission eight versus four years) and are also less likely to enter remission even after prolonged treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/23\">",
"     23",
"    </a>",
"    ]. In two retrospective studies, smaller goiter size and higher body mass index (BMI) were predictors of an early remission [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/24,25\">",
"     24,25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Patients who enter remission need lifelong monitoring after antithyroid drugs are stopped. (See",
"    <a class=\"local\" href=\"#H15\">",
"     'Lifelong monitoring'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Relapse rate",
"    </span>",
"    &nbsp;&mdash;&nbsp;Once remission occurs, the relapse rate in children varied from 3 to 47 percent in different series [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Most relapses occur within one year, but later relapses do occur. The risk of relapse is higher in non-Caucasians and in patients with higher initial free T4; the risk decreases with increasing age and with longer duration of antithyroid drug therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/26\">",
"     26",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Among biochemical tests, measurement of TSH (thyrotropin) receptor antibodies (TSHR-Ab) is the most useful predictor of subsequent outcome. In one report, for example, 100 percent of children who had recurrent hyperthyroidism after antithyroid drug therapy was discontinued had detectable TSHR-Ab in their serum when therapy was discontinued; in contrast, 78 percent of those who remained euthyroid had no detectable serum TSHR-Ab when treatment was discontinued [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/27\">",
"     27",
"    </a>",
"    ]. As a matter of clinical practice, however, it is simpler to discontinue drug therapy and follow the patients at regular intervals.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"     Methimazole",
"    </a>",
"    (MMI) and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"     propylthiouracil",
"    </a>",
"    (PTU) are associated with similar types of side effects. However, side effects tend to be more frequent and more severe with PTU [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/28\">",
"     28",
"    </a>",
"    ]. Because of these safety concerns, the Endocrine Society, the American Thyroid Association, and the Food and Drug Administration recommend AGAINST the use of PTU as first-line treatment for Graves' disease in children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/8-10\">",
"     8-10",
"    </a>",
"    ]. PTU may be reserved for children who experience an adverse effect with MMI other than agranulocytosis, and for whom radioactive iodine or surgery are not treatment options [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/9\">",
"     9",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Minor side effects are also more common with PTU than with MMI (30 versus 13 percent in one series) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/28\">",
"     28",
"    </a>",
"    ]. These include papular or urticarial skin rashes, arthralgias, nausea, and abnormal taste sensation. In another series of 100 patients treated with MMI, the following minor side effects were reported: pruritus and hives in eight percent, diffuse arthralgia in three percent, neutropenia in two percent, and Stevens-Johnson syndrome and cholestatic jaundice each in one percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/29\">",
"     29",
"    </a>",
"    ]. In patients who have one of these minor side effects, we discontinue the drug for a few days until the symptom subsides, and then resume it.",
"   </p>",
"   <p>",
"    Major side effects include agranulocytosis (granulocyte count",
"    <span class=\"nowrap\">",
"     &lt;250/mm3),",
"    </span>",
"    vasculitis (lupus-like syndrome), hepatitis, and liver failure:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Agranulocytosis occurs in 0.2 to 0.5 percent of patients treated with either PTU or MMI, although the risk is dose-related for MMI and not for PTU [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/28\">",
"       28",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Antinuclear cytoplasmic antibodies (ANCA), markers of vasculitis, are more common with PTU treatment [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/30,31\">",
"       30,31",
"      </a>",
"      ]",
"     </li>",
"     <li>",
"      Severe hepatitis develops in up to 0.1 percent of children treated with PTU, with liver failure occurring in 1:2000 to 1:4000 [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/6,28\">",
"       6,28",
"      </a>",
"      ]. Almost all cases of severe hepatitis have been associated with PTU treatment. Routine biochemical surveillance of liver function probably is not effective in avoiding the risk of liver failure.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Any patient who has a major side effect should be treated with radioactive iodine or surgery instead of antithyroid medication. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=see_link\">",
"     \"Pharmacology and toxicity of thionamides\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h2\">",
"     Radioactive iodine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Radioactive iodine (131-I) therapy (RAI) is an effective alternative treatment for children and adolescents with Graves' hyperthyroidism. We recommend it for patients who have recurrent hyperthyroidism after long-term treatment with an antithyroid drug and for those who have a major side effect while receiving an antithyroid drug. However, some pediatric endocrinologists consider it the initial treatment of choice in older children and adolescents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/2,32,33\">",
"     2,32,33",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In our practice, we generally use radioactive iodine only in children older than 10 years of age. This approach is based on observations suggesting that the young thyroid gland may be particularly sensitive to radiation and that young children might therefore have an increased risk for thyroid cancer after radiation exposure. This concern arose from observations of the increased incidence of thyroid cancer in infants and children who were exposed to external radiation during the 1940s and 1950s for a variety of \"indications\" including enlarged tonsils, croup (large thymus), or acne [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/34\">",
"     34",
"    </a>",
"    ]. In addition, there was a dramatic rise in thyroid cancer in children exposed to radiation from the Chernobyl nuclear accident [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/35\">",
"     35",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    However, there is increasing evidence to suggest that exposure to therapeutic or diagnostic doses of RAI does not increase the risk of thyroid cancer [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/36\">",
"     36",
"    </a>",
"    ]. The exposures at Hiroshima, Chernobyl, and to external beam radiation all included ionizing radiation. By contrast, among children whose environmental exposure was limited to radioactive iodine, there is no increase in thyroid cancer or autoimmune thyroid disease with up to 50 years follow-up [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Thus, there is no direct evidence that the RAI doses (5 to 15 mCi) used to treat children with Graves' disease increase the risk of thyroid or other cancers. Many responsible pediatric endocrinologists are using RAI as secondary or primary therapy for hyperthyroidism, including in young children [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/38\">",
"     38",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Traditionally, the goal of treatment was to achieve euthyroidism, but not hypothyroidism. For this purpose, patients were generally treated with one to three doses of 50 to 200 microCi (1.85-7.4 MBq) of 131-I per gram (estimated) of thyroid tissue divided by the fractional 24-hour 131-I uptake. In one study in which the dose was 200 microCi (7.4",
"    <span class=\"nowrap\">",
"     MBq)/g",
"    </span>",
"    thyroid, 88 percent of children were euthyroid after one dose, 96 percent after a second dose, and 97 percent after a third dose [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Another study described the following predictors of a poor response to RAI treatment in children (defined as requiring a second RAI dose or not achieving hypothyroidism by six months) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/40\">",
"     40",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Graves&rsquo; eye disease (58 versus 8 percent)",
"     </li>",
"     <li>",
"      Prior use of an antithyroid drug (37 versus 0 percent)",
"     </li>",
"     <li>",
"      An interval of greater than 12 months from diagnosis to RAI treatment (50 versus 10 percent)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The presence of these risk factors should not preclude RAI treatment for several reasons: It is possible that children with Graves&rsquo; eye disease have a more severe form of hyperthyroidism, and so perhaps they need a higher dose of RAI. Regarding prior use of antithyroid drugs, it should be noted that the drug was discontinued three to five days before RAI administration in this study. This short interval may have been the cause of the poor response to RAI (a metaanalysis recommends stopping antithyroid drugs seven days before RAI administration [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/41\">",
"     41",
"    </a>",
"    ]). Although the greater interval from diagnosis might be interpreted as an argument to bypass antithyroid drugs and go straight to RAI treatment, it should be noted that the majority of patients in the study had been treated with antithyroid drugs, and response rates in this group were reasonably good; 89 percent of these patients became hypothyroid after one dose of RAI (using a dose of 160 microCi (5.9",
"    <span class=\"nowrap\">",
"     MBq)/g",
"    </span>",
"    thyroid), while the other 11 percent responded to a second dose of RAI [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/40\">",
"     40",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    There is a growing opinion among pediatric endocrinologists that if radioactive iodine is to be used, it is better to use a higher dose such that most children become hypothyroid. Higher dosing will ensure that hyperthyroidism will not recur, and it may reduce the risk of thyroid tumor development [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/38\">",
"     38",
"    </a>",
"    ]. To achieve this goal, doses of radioactive iodine generally above 300",
"    <span class=\"nowrap\">",
"     microCi/gram",
"    </span>",
"    of thyroid tissue are used. In one study, doses of 110",
"    <span class=\"nowrap\">",
"     microCi/g,",
"    </span>",
"    220",
"    <span class=\"nowrap\">",
"     microCi/g,",
"    </span>",
"    and 330",
"    <span class=\"nowrap\">",
"     microCi/g",
"    </span>",
"    resulted in hypothyroidism in 50, 70, and 95 percent of children with Graves' hyperthyroidism, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/42\">",
"     42",
"    </a>",
"    ]. In a separate study, a fixed dose of 14.7 milliCi (range 13.8 to 15.6 milliCi) produced permanent hypothyroidism in all patients, at an average of 77 days (range 28 to 194 days) after receiving the radioactive iodine [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/43\">",
"     43",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    There is no evidence that radioactive iodine causes or worsens Graves' ophthalmopathy in children or adolescents, as has been described in adults [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/44-46\">",
"     44-46",
"    </a>",
"    ]. Because the antithyroid action of radioactive iodine is relatively slow, patients with many or bothersome symptoms may benefit from treatment with a beta blocker (",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?33/58/34726?source=see_link\">",
"     atenolol",
"    </a>",
"    preferred) or an antithyroid drug for four to eight weeks after being given a therapeutic dose of radioactive iodine.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Hypothyroidism",
"    </span>",
"    &nbsp;&mdash;&nbsp;As in adults, the major consequence of radioactive iodine treatment is hypothyroidism. With the conventional doses used in the past, from 20 to 40 percent of patients become hypothyroid in the first year and 2 to 3 percent per year thereafter. With the higher doses described above, virtually all will become hypothyroid. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=see_link\">",
"     \"Radioiodine in the treatment of hyperthyroidism\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    We measure serum free T4 and TSH six weeks after radioactive iodine treatment, and then at three-month intervals. When these tests indicate hypothyroidism, thyroid hormone treatment is started. Laboratory monitoring can be performed less frequently thereafter, usually every six months.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Other side effects",
"    </span>",
"    &nbsp;&mdash;&nbsp;Reservations about the use of radioactive iodine in children and adolescents have centered on the possibility that the treatment could result in thyroid or other tumors, affect fertility, or damage sperm or ova, thereby affecting the patient's offspring. In one older study in children treated with lower doses of radioactive iodine, there was a small increase in the incidence of benign thyroid adenomas, but no increase in thyroid carcinoma [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/47\">",
"     47",
"    </a>",
"    ]. Subsequent studies have not revealed an increased risk of thyroid cancer, leukemia, or other cancers [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/48\">",
"     48",
"    </a>",
"    ]. However, it should be emphasized that due to the relatively small number of children treated with radioactive iodine, a small risk of other cancers cannot be excluded.",
"   </p>",
"   <p>",
"    Among children of women treated with radioactive iodine during childhood or adolescence, 3 percent have congenital anomalies, a value that is not different from the general population [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/49\">",
"     49",
"    </a>",
"    ], and the incidence of infertility, miscarriage, and prematurity is not increased [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/50\">",
"     50",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Although thyroidectomy is not often recommended as initial therapy for children or adolescents with Graves' hyperthyroidism, it is an effective therapy for the disorder. When antithyroid drug therapy fails or causes side effects, many clinicians, children or adolescents, or their parents prefer surgery to radioactive iodine. Surgery may be particularly appropriate for those with very large goiter, as studies in adults suggest that individuals with large thyroid glands (greater than 80 g) are unlikely to respond to RAI treatment [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/51\">",
"     51",
"    </a>",
"    ]. If surgery is planned, the patient should be treated with an antithyroid drug, if possible, or at least a beta blocker and inorganic iodine before surgery is undertaken. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link\">",
"     \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The operation of choice is near-total thyroidectomy, to reduce the risk of persistent hyperthyroidism as much as possible.",
"   </p>",
"   <p>",
"    The complications of surgery in children are similar to those in adults, and mortality is very rare. Transient hypocalcemia occurs in approximately 10 percent of children, and permanent hypoparathyroidism in 2 percent. Injury to the recurrent laryngeal nerve occurs in approximately 1 percent, and postoperative hemorrhage in 0.7 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25400/abstract/52\">",
"     52",
"    </a>",
"    ]. Hypothyroidism occurs in approximately one-half of patients within the first year after surgery, and in about 1 to 2 percent per year thereafter.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h1\">",
"     LIFELONG MONITORING",
"    </span>",
"    &nbsp;&mdash;&nbsp;No matter how children and adolescents with Graves' hyperthyroidism are treated, those who remain euthyroid after antithyroid drug therapy is discontinued or after radioactive iodine or surgery are at risk for both hyperthyroidism and hypothyroidism. Thus, lifelong monitoring of thyroid function is indicated.",
"   </p>",
"   <p>",
"    Until growth and puberty are complete, we monitor serum free T4 and TSH every six months. After completion of growth, we monitor yearly. Females should be counseled that when they reach reproductive age there is a risk of neonatal Graves' disease in their offspring. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=see_link\">",
"     \"Evaluation and management of neonatal Graves' disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Children and adolescents with Graves' hyperthyroidism can be effectively treated with antithyroid drug therapy, radioactive iodine, or thyroidectomy. The choice of therapy is determined by individual consideration of the risks and benefits of the three treatment modalities (",
"      <a class=\"graphic graphic_table graphicRef67833 \" href=\"UTD.htm?33/40/34443\">",
"       table 1",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Treatment approaches'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      For most children we suggest initial treatment with antithyroid medication (thionamides) (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). This is generally the treatment choice with the lowest risk, and a significant percentage of children will become euthyroid.",
"     </li>",
"     <li>",
"      When antithyroid medication is chosen, we recommend treating with",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?20/50/21286?source=see_link\">",
"       methimazole",
"      </a>",
"      (MMI) rather than",
"      <a class=\"drug drug_pediatric\" href=\"UTD.htm?14/50/15142?source=see_link\">",
"       propylthiouracil",
"      </a>",
"      (PTU) because it has fewer side effects (",
"      <a class=\"grade\" href=\"._grade_1?title=Grade 1A\">",
"       Grade 1A",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Antithyroid drugs'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Radioactive iodine or surgery are acceptable primary treatment choices, preferred by some older children and their parents; these may also be more appropriate treatment modalities than antithyroid drugs where close follow-up is unlikely. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radioactive iodine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We recommend radioactive iodine or surgery as secondary therapy for patients who have recurrent hyperthyroidism after long-term treatment with an antithyroid drug and for those who have a major side effect while receiving an antithyroid drug.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      For patients with hyperthyroidism due to a very large thyroid, we suggest surgery (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H14\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=see_link\">",
"       \"Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      As secondary therapy, we generally use radioactive iodine in children older than 10 years, and surgery in children younger than 10 years (for reasons discussed above), although some pediatric endocrinologists are using radioactive iodine in younger children. (See",
"      <a class=\"local\" href=\"#H11\">",
"       'Radioactive iodine'",
"      </a>",
"      above.) Children on antithyroid drugs who are to be treated with radioactive iodine should have their antithyroid drug discontinued at least seven days before RAI administration.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      All children with a history of hyperthyroidism should have lifelong monitoring of thyroid function, regardless of treatment choice and outcome. All children have a risk of recurrent hyperthyroidism or developing hypothyroidism, and this may occur at any time. Offspring of women with a history of hyperthyroidism have an increased risk for Graves' disease in the neonatal period. (See",
"      <a class=\"local\" href=\"#H15\">",
"       'Lifelong monitoring'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/1\">",
"      Barnes HV, Blizzard RM. Antithyroid drug therapy for toxic diffuse goiter (Graves disease): thirty years experience in children and adolescents. J Pediatr 1977; 91:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/2\">",
"      Rivkees SA, Sklar C, Freemark M. Clinical review 99: The management of Graves' disease in children, with special emphasis on radioiodine treatment. J Clin Endocrinol Metab 1998; 83:3767.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/3\">",
"      Vaidya VA, Bongiovanni AM, Parks JS, et al. Twenty-two years' experience in the medical management of juvenile thyrotoxicosis. Pediatrics 1974; 54:565.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/4\">",
"      Gorton C, Sadeghi-Nejad A, Senior B. Remission in children with hyperthyroidism treated with propylthiouracil. Long-term results. Am J Dis Child 1987; 141:1084.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/5\">",
"      Lippe BM, Landaw EM, Kaplan SA. Hyperthyroidism in children treated with long term medical therapy: twenty-five percent remission every two years. J Clin Endocrinol Metab 1987; 64:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/6\">",
"      Rivkees SA, Mattison DR. Ending propylthiouracil-induced liver failure in children. N Engl J Med 2009; 360:1574.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/7\">",
"      Rivkees SA, Szarfman A. Dissimilar hepatotoxicity profiles of propylthiouracil and methimazole in children. J Clin Endocrinol Metab 2010; 95:3260.",
"     </a>",
"    </li>",
"    <li>",
"     Endocrine Society Statement, April 14th, 2009. Available at: www.endo-society.org/advocacy/legislative/SocietyStatementontheNEJMLettetotheEditoronPTUUseInChildren.cfm (Accessed April 28th 2009).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/9\">",
"      Bahn RS, Burch HS, Cooper DS, et al. The Role of Propylthiouracil in the Management of Graves' Disease in Adults: report of a meeting jointly sponsored by the American Thyroid Association and the Food and Drug Administration. Thyroid 2009; 19:673.",
"     </a>",
"    </li>",
"    <li>",
"     U.S. Food and Drug Administration, update 4/21/2010:  file://www.fda.gov/Safety/MedWatch/SafetyInformation/SafetyAlertsforHumanMedicalProducts/ucm164162.htm (Accessed on September 09, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/11\">",
"      Cooper DS. Antithyroid drugs. N Engl J Med 2005; 352:905.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/12\">",
"      Watanabe N, Narimatsu H, Noh JY, et al. Antithyroid drug-induced hematopoietic damage: a retrospective cohort study of agranulocytosis and pancytopenia involving 50,385 patients with Graves' disease. J Clin Endocrinol Metab 2012; 97:E49.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/13\">",
"      Birrell G, Cheetham T. Juvenile thyrotoxicosis; can we do better? Arch Dis Child 2004; 89:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/14\">",
"      Rittmaster RS, Abbott EC, Douglas R, et al. Effect of methimazole, with or without L-thyroxine, on remission rates in Graves' disease. J Clin Endocrinol Metab 1998; 83:814.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/15\">",
"      McIver B, Rae P, Beckett G, et al. Lack of effect of thyroxine in patients with Graves' hyperthyroidism who are treated with an antithyroid drug. N Engl J Med 1996; 334:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/16\">",
"      Grebe SK, Feek CM, Ford HC, et al. A randomized trial of short-term treatment of Graves' disease with high-dose carbimazole plus thyroxine versus low-dose carbimazole. Clin Endocrinol (Oxf) 1998; 48:585.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/17\">",
"      Raza J, Hindmarsh PC, Brook CG. Thyrotoxicosis in children: thirty years' experience. Acta Paediatr 1999; 88:937.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/18\">",
"      Barrio R, L&oacute;pez-Capap&eacute; M, Martinez-Bad&aacute;s I, et al. Graves' disease in children and adolescents: response to long-term treatment. Acta Paediatr 2005; 94:1583.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/19\">",
"      Weetman AP. Graves' hyperthyroidism: how long should antithyroid drug therapy be continued to achieve remission? Nat Clin Pract Endocrinol Metab 2006; 2:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/20\">",
"      Maugendre D, Gatel A, Campion L, et al. Antithyroid drugs and Graves' disease--prospective randomized assessment of long-term treatment. Clin Endocrinol (Oxf) 1999; 50:127.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/21\">",
"      L&eacute;ger J, Gelwane G, Kaguelidou F, et al. Positive impact of long-term antithyroid drug treatment on the outcome of children with Graves' disease: national long-term cohort study. J Clin Endocrinol Metab 2012; 97:110.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/22\">",
"      Glaser NS, Styne DM, Organization of Pediatric Endocrinologists of Northern California Collaborative Graves' Disease Study Group. Predicting the likelihood of remission in children with Graves' disease: a prospective, multicenter study. Pediatrics 2008; 121:e481.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/23\">",
"      Shulman DI, Muhar I, Jorgensen EV, et al. Autoimmune hyperthyroidism in prepubertal children and adolescents: comparison of clinical and biochemical features at diagnosis and responses to medical therapy. Thyroid 1997; 7:755.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/24\">",
"      Tan SH, Lee BW, Wong HB, Uma R. Relapse markers in childhood thyrotoxicosis. Clin Pediatr (Phila) 1987; 26:136.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/25\">",
"      Glaser NS, Styne DM. Predictors of early remission of hyperthyroidism in children. J Clin Endocrinol Metab 1997; 82:1719.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/26\">",
"      Kaguelidou F, Alberti C, Castanet M, et al. Predictors of autoimmune hyperthyroidism relapse in children after discontinuation of antithyroid drug treatment. J Clin Endocrinol Metab 2008; 93:3817.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/27\">",
"      Foley TP Jr, White C, New A. Juvenile Graves disease: usefulness and limitations of thyrotropin receptor antibody determinations. J Pediatr 1987; 110:378.",
"     </a>",
"    </li>",
"    <li>",
"     Eunice Kennedy Shriver National Institute of Child Health and Human Development. Hepatic toxicity following treatment for Pediatric Graves' disease meeting: October 28, 2008. file://bpca.nichd.nih.gov/collaborativeefforts/upload/Hepatic-Toxicity-10-28-08-final-final-01-09-09.pdf (Accessed on September 20, 2010).",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/29\">",
"      Rivkees SA, Stephenson K, Dinauer C. Adverse events associated with methimazole therapy of graves' disease in children. Int J Pediatr Endocrinol 2010; 2010:176970.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/30\">",
"      Sato H, Hattori M, Fujieda M, et al. High prevalence of antineutrophil cytoplasmic antibody positivity in childhood onset Graves' disease treated with propylthiouracil. J Clin Endocrinol Metab 2000; 85:4270.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/31\">",
"      Panamonta O, Sumethkul V, Radinahmed P, et al. Propylthiouracil associated antineutrophil cytoplasmic antibodies (ANCA) in patients with childhood onset Graves' disease. J Pediatr Endocrinol Metab 2008; 21:539.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/32\">",
"      Levy WJ, Schumacher OP, Gupta M. Treatment of childhood Graves' disease. A review with emphasis on radioiodine treatment. Cleve Clin J Med 1988; 55:373.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/33\">",
"      Clark JD, Gelfand MJ, Elgazzar AH. Iodine-131 therapy of hyperthyroidism in pediatric patients. J Nucl Med 1995; 36:442.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/34\">",
"      Ron E, Lubin JH, Shore RE, et al. Thyroid cancer after exposure to external radiation: a pooled analysis of seven studies. Radiat Res 1995; 141:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/35\">",
"      Becker DV, Robbins J, Beebe GW, et al. Childhood thyroid cancer following the Chernobyl accident: a status report. Endocrinol Metab Clin North Am 1996; 25:197.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/36\">",
"      Boice JD Jr. Thyroid disease 60 years after Hiroshima and 20 years after Chernobyl. JAMA 2006; 295:1060.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/37\">",
"      Davis S, Kopecky KJ, Hamilton TE, et al. Thyroid neoplasia, autoimmune thyroiditis, and hypothyroidism in persons exposed to iodine 131 from the hanford nuclear site. JAMA 2004; 292:2600.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/38\">",
"      Rivkees SA, Dinauer C. An optimal treatment for pediatric Graves' disease is radioiodine. J Clin Endocrinol Metab 2007; 92:797.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/39\">",
"      Hamburger JI. Management of hyperthyroidism in children and adolescents. J Clin Endocrinol Metab 1985; 60:1019.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/40\">",
"      McCormack S, Mitchell DM, Woo M, et al. Radioactive iodine for hyperthyroidism in children and adolescents: referral rate and response to treatment. Clin Endocrinol (Oxf) 2009; 71:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/41\">",
"      Walter MA, Briel M, Christ-Crain M, et al. Effects of antithyroid drugs on radioiodine treatment: systematic review and meta-analysis of randomised controlled trials. BMJ 2007; 334:514.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/42\">",
"      Rivkees SA, Cornelius EA. Influence of iodine-131 dose on the outcome of hyperthyroidism in children. Pediatrics 2003; 111:745.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/43\">",
"      Nebesio TD, Siddiqui AR, Pescovitz OH, Eugster EA. Time course to hypothyroidism after fixed-dose radioablation therapy of Graves' disease in children. J Pediatr 2002; 141:99.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/44\">",
"      Bartalena L, Marcocci C, Bogazzi F, et al. Relation between therapy for hyperthyroidism and the course of Graves' ophthalmopathy. N Engl J Med 1998; 338:73.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/45\">",
"      Krassas GE. Ophthalmic complications in juvenile Graves' Disease - clinic and therapeutic approaches. Pediatr Endocrinol Rev 2003; 1 Suppl 2:223.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/46\">",
"      Ma C, Kuang A, Xie J, Liu G. Radioiodine treatment for pediatric Graves' disease. Cochrane Database Syst Rev 2008; :CD006294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/47\">",
"      Dobyns BM, Sheline GE, Workman JB, et al. Malignant and benign neoplasms of the thyroid in patients treated for hyperthyroidism: a report of the cooperative thyrotoxicosis therapy follow-up study. J Clin Endocrinol Metab 1974; 38:976.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/48\">",
"      Read CH Jr, Tansey MJ, Menda Y. A 36-year retrospective analysis of the efficacy and safety of radioactive iodine in treating young Graves' patients. J Clin Endocrinol Metab 2004; 89:4229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/49\">",
"      Foley TP Jr, Charron M. Radioiodine treatment of juvenile Graves disease. Exp Clin Endocrinol Diabetes 1997; 105 Suppl 4:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/50\">",
"      Sarkar SD, Beierwaltes WH, Gill SP, Cowley BJ. Subsequent fertility and birth histories of children and adolescents treated with 131I for thyroid cancer. J Nucl Med 1976; 17:460.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/51\">",
"      Peters H, Fischer C, Bogner U, et al. Treatment of Graves' hyperthyroidism with radioiodine: results of a prospective randomized study. Thyroid 1997; 7:247.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25400/abstract/52\">",
"      Zimmerman D, Gan-Gaisano M. Hyperthyroidism in children and adolescents. Pediatr Clin North Am 1990; 37:1273.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 5854 Version 7.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0503-200.131.240.2-22DD962998-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25400=[""].join("\n");
var outline_f24_51_25400=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H16\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      TREATMENT APPROACHES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Antithyroid drugs",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Initiating and adjusting therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Adding beta blockers",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Adding thyroxine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Stopping therapy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Remission rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Relapse rate",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      Radioactive iodine",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Hypothyroidism",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Other side effects",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      LIFELONG MONITORING",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/5854\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/5854|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?33/40/34443\" title=\"table 1\">",
"      Treatment Graves",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/29/7641?source=related_link\">",
"      Clinical manifestations and diagnosis of hyperthyroidism in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/21/21850?source=related_link\">",
"      Drug-induced neutropenia and agranulocytosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?0/6/97?source=related_link\">",
"      Evaluation and management of neonatal Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/21/41303?source=related_link\">",
"      Pharmacology and toxicity of thionamides",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/7/12410?source=related_link\">",
"      Radioiodine in the treatment of hyperthyroidism",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/8/12424?source=related_link\">",
"      Surgery in the treatment of hyperthyroidism: Indications, preoperative preparation, and postoperative follow-up",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/25/12696?source=related_link\">",
"      Thionamides in the treatment of Graves' disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/41/21143?source=related_link\">",
"      Treatment of Graves' hyperthyroidism",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_51_25401="Cutaneous innervation from cervical plexus";
var content_f24_51_25401=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=SURG%2F74987%7ESURG%2F54142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=SURG%2F74987%7ESURG%2F54142&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=3\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 544px\">",
"   <div class=\"ttl\">",
"    Cutaneous innervation from cervical plexus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 524px; height: 622px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cervical plexus supplies the skin of the anterior and lateral neck, and scalp, as well as the muscles of the neck including the scalenes and strap muscles. It also innervates the diaphragm via the phrenic nerve.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 538px\">",
"   <div class=\"ttl\">",
"    Cervical plexus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 518px; height: 616px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The cervical plexus is composed of the ventral rami of the first four cervical spinal nerves (ie, C1 through C4). The anterior rami of C2 through C4 emerge from the posterior border of the sternocleidomastoid muscle.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25401=[""].join("\n");
var outline_f24_51_25401=null;
var title_f24_51_25402="Approach to the immunocompromised patient with fever and pulmonary infiltrates";
var content_f24_51_25402=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"3\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Approach to the immunocompromised patient with fever and pulmonary infiltrates",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25402/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25402/contributors\">",
"     Jay A Fishman, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25402/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25402/contributors\">",
"     Kieren A Marr, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?24/51/25402/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?24/51/25402/contributors\">",
"     Anna R Thorner, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?24/51/25402/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Feb 24, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The spectrum of immunocompromised hosts has expanded with prolonged survival for solid organ and hematopoietic cell transplant recipients and patients with congenital immune deficits or autoimmune disorders, and the epidemic of human immunodeficiency",
"    <span class=\"nowrap\">",
"     syndrome/acquired",
"    </span>",
"    immunodeficiency syndrome",
"    <span class=\"nowrap\">",
"     (HIV/AIDS).",
"    </span>",
"    Novel immunosuppressive therapies create a diverse set of immune deficits that create the substrate for opportunistic infections. These patients are defined by their susceptibility to infection with organisms of low native virulence for immunologically normal hosts. Survival has improved with the availability of newer antimicrobial agents, including azole antifungals, macrolides, antivirals, and antiretroviral drugs.",
"   </p>",
"   <p>",
"    Despite these advances, pulmonary infection remains the most common form of tissue-invasive infection in these hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/1-8\">",
"     1-8",
"    </a>",
"    ]. The incidence of fungal infection of the lungs is increasing in immunocompromised individuals in spite of advances in antifungal prophylaxis and therapy [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/9,10\">",
"     9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The approach to the immunocompromised patient with fever and pulmonary infiltrates will be reviewed here. An overview of pulmonary infections in immunocompromised hosts is presented separately. Empiric therapy for adult patients with fever and neutropenia is also discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=see_link\">",
"     \"Pulmonary infections in immunocompromised patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"     \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"     \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     GENERAL PRINCIPLES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Early diagnosis and specific therapy of opportunistic infections is the cornerstone of successful management. The general rule is to be aggressive in pursuing a specific microbiologic diagnosis in immunocompromised patients with pulmonary infiltrates; invasive diagnostic techniques are often required. A specific diagnosis avoids the potential toxicities of broad-spectrum antimicrobial therapies, most notably nephrotoxicity, drug interactions, and Clostridium difficile colitis.",
"   </p>",
"   <p>",
"    A number of general principles are useful for the evaluation of immunocompromised patients presenting with fever and pulmonary infiltrates:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Most immunocompromised patients with any sign of possible invasive infection should be hospitalized for evaluation.",
"     </li>",
"     <li>",
"      Awareness of the epidemiology of infection in the community (eg, respiratory viruses, tuberculosis) and the individual (eg, travel history, sexual history, occupational exposures) often provide helpful clues.",
"     </li>",
"     <li>",
"      Multiple simultaneous pulmonary processes are common. These include infectious (eg, viral, bacterial, fungal, parasitic), and noninfectious (eg, pulmonary edema, malignancy) etiologies. Routine chest radiography and sputum sampling may fail to detect these concomitant diseases.",
"     </li>",
"     <li>",
"      Serologic testing is generally not useful in the acute management of immunocompromised patients. These patients often fail to generate an adequate antibody response to infection. Microbiologic testing should include antigen detection",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      nucleic acid detection-based assays as well as cultures.",
"     </li>",
"     <li>",
"      The presence or absence of pulmonary infiltrates should be defined by chest imaging. A chest radiograph is not sufficient to exclude pulmonary involvement if there are any respiratory symptoms or historical features that suggest a possible pulmonary process. Thus, minor abnormalities on a chest radiograph in the immunocompromised host merit further evaluation, generally including computed tomography (CT) scanning. Comparison with old imaging studies is essential.",
"     </li>",
"     <li>",
"      In some patients, radiographic evidence of pneumonitis may appear only with immune reconstitution, notably engraftment after neutropenia. In such patients, there are few data to guide decisions regarding empiric antimicrobial therapies [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/11\">",
"       11",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The differential diagnosis of pulmonary infiltrates in immunocompromised patients is broad and includes both infectious and noninfectious conditions. Given the potential toxicity of antimicrobial regimens, establishing a specific diagnosis is essential. Thus, tissue samples for histology, special staining (eg, for fungi and mycobacteria), and microbiologic evaluation are generally needed in the majority of patients.",
"     </li>",
"     <li>",
"      After obtaining microbiologic samples, empiric antimicrobial therapy is initiated and is continued until specific microbiologic data are available to guide therapy. Specific guidelines such as those for fever and neutropenia must be modified based on physical and radiologic findings and past medical history, including exposures, previous infections and prior antimicrobial therapies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY AND RISK OF PNEUMONIA",
"    </span>",
"    &nbsp;&mdash;&nbsp;The incidence and severity of pneumonia vary with the characteristics of the affected individual, including the nature and duration of any immune deficits (",
"    <a class=\"graphic graphic_table graphicRef57336 \" href=\"UTD.htm?11/32/11789\">",
"     table 1",
"    </a>",
"    ) and epidemiologic exposures. The epidemiology and risk for pneumonia in immunocompromised hosts have shifted with the increased intensities of chemotherapeutic",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    immunosuppressive regimens and with patterns of antimicrobial use. Routine prophylaxis has increased the risk for unusual pathogens that are resistant to prophylactic agents including fluoroquinolone-resistant streptococci, azole-resistant molds, and ganciclovir-resistant cytomegalovirus [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/12-14\">",
"     12-14",
"    </a>",
"    ]. As a result, empiric therapies for infection require use of agents not used for prophylaxis in the recent past. &nbsp;",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h2\">",
"     Neutropenia",
"    </span>",
"    &nbsp;&mdash;&nbsp;Neutropenia is the most common risk factor for pulmonary infection in immunocompromised patients. Whether due to underlying malignancy, chemotherapy, or the side effects of other drugs, the depth and duration of neutropenia are correlated with the risk for infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/15\">",
"     15",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Rates of infection vary depending upon the host. Nosocomial infections in neutropenic cancer patients occur at a rate of 46.3 episodes per 1000 neutropenic days (48.3 episodes per 100 neutropenic patients) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/16\">",
"     16",
"    </a>",
"    ]. The rate of infection was similar in another study that included patients with acute leukemia, non-Hodgkin&rsquo;s lymphoma, or after conditioning for hematopoietic cell transplantation (37.7 episodes per 1000 neutropenic days), although over 64 percent of patients had febrile episodes while neutropenic [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/17\">",
"     17",
"    </a>",
"    ]. Rates of infection in solid tumor patients and solid organ transplant recipients are somewhat less. &nbsp;",
"   </p>",
"   <p>",
"    No originating site of infection can be determined in 20 to 50 percent of febrile cancer patients [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/4,5\">",
"     4,5",
"    </a>",
"    ]. When identified, common sources of infection in the febrile, neutropenic patient are colonizing organisms from the upper and lower respiratory tract, the gastrointestinal tract (including the perineal and perirectal areas), the urinary tract, and the skin (including intravenous lines and wounds). Pulmonary infections predominate in series of non-hematologic cancer patients. Many infections are detected only at autopsy, particularly disseminated fungal or combined fungal and bacterial infections. Over 20 percent of these patients will have a documented bacteremia.",
"   </p>",
"   <p>",
"    Mismatched allogeneic hematopoietic cell transplant recipients (eg, umbilical cord blood or matched unrelated donor transplants) being treated for hematologic malignancies require intensive induction chemotherapy, which may result in prolonged neutropenia. Such patients also require immunosuppression to prevent and treat graft-versus-host disease (GVHD). These patients are therefore at particularly high risk of infection.",
"   </p>",
"   <p>",
"    Overall mortality among febrile, neutropenic patients is 30 to 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/4,5\">",
"     4,5",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354232681\">",
"    <span class=\"h2\">",
"     Glucocorticoids",
"    </span>",
"    &nbsp;&mdash;&nbsp;Glucocorticoids have an important role in the pathogenesis of pneumonia due to depression of phagocytic function of alveolar macrophages and neutrophils, decreased mobilization of inflammatory cells into areas of infection, and alterations in antigen presentation and lymphocyte mobilization. These effects increase the risk of bacterial and fungal infections (including those due to Pneumocystis jirovecii, Nocardia spp, and Aspergillus spp) and the risk for pulmonary involvement in the setting of certain herpes virus infections (eg, cytomegalovirus, varicella zoster virus). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=see_link\">",
"     \"Glucocorticoid effects on the immune system\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354232690\">",
"    <span class=\"h2\">",
"     Biologic agents and lymphocyte depletion",
"    </span>",
"    &nbsp;&mdash;&nbsp;The use of T-lymphocyte depleting agents has increased the risk of certain infections based on the prolonged duration of lymphocytopenia and, depending on the preparation used, depletion of other cell types (eg, NK cells) with increased risk for infection, notably due to latent herpesviruses and molds [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/18\">",
"     18",
"    </a>",
"    ]. B-lymphocyte depletion is used in the treatment of certain hematologic malignancies and for antibody-mediated graft rejection and may predispose to infection due to encapsulated bacteria [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/19\">",
"     19",
"    </a>",
"    ]. Inhibitors of tumor necrosis factor (TNF-alpha) predispose to infection with intracellular pathogens (mycobacteria, Legionella species), as well as systemic viral and fungal (Aspergillus spp, Cryptococcus spp, Mucorales) infections including the endemic fungi (Histoplasma capsulatum, Coccidioides spp) and Pneumocystis jirovecii. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H354232721\">",
"    <span class=\"h2\">",
"     T-cell suppression",
"    </span>",
"    &nbsp;&mdash;&nbsp;Many of the agents used to suppress T-lymphocyte activation predispose to some of the infections observed in AIDS. These include the calcineurin (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?31/39/32368?source=see_link\">",
"     cyclosporine",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/14/32992?source=see_link\">",
"     tacrolimus",
"    </a>",
"    ) and mTOR (mammalian target of rapamycin) inhibitors (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    ). Viral infections including malignancies related to viral activation (eg, Epstein Barr virus associated post-transplant lymphoproliferative disorder, skin cancers) are the most common complications of these agents [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Autoimmune and inflammatory conditions",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with hematopoietic malignancies, and to a lesser extent, acquired deficiencies (eg, glomerulonephritis with proteinuria or Goodpasture's syndrome) may be susceptible to opportunistic infections similar to those of cancer and transplant patients. Bacterial infections are of greater importance in such patients, possibly related to deficiencies in opsonization and phagocytosis. Dual infections (respiratory virus followed by bacterial or fungal infections) are also common. The severity and nature of these infections depend on the type, duration, and intensity of immunosuppression.",
"   </p>",
"   <p>",
"    In the past, therapy for autoimmune",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    inflammatory conditions was limited to glucocorticoids; individuals receiving the equivalent of 15 to 20 mg of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/43/38585?source=see_link\">",
"     prednisone",
"    </a>",
"    per day for more than three weeks were at increased risk, particularly for P. jirovecii (formerly P. carinii) pneumonia (PCP) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/20\">",
"     20",
"    </a>",
"    ]. PCP prophylaxis is often overlooked in these patients. Contemporary steroid-sparing strategies include use of calcineurin inhibitors,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"     sirolimus",
"    </a>",
"    , costimulatory blockade, and antibody therapies (both antilymphocyte and anti-tumor necrosis factor [TNF]-alpha preparations).",
"   </p>",
"   <p>",
"    In patients with primary connective",
"    <span class=\"nowrap\">",
"     tissue/collagen",
"    </span>",
"    vascular diseases, infection may be difficult to distinguish from the effects of the primary disease or toxicities of therapy. Pulmonary manifestations of these diseases are discussed below. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Other mimics of infection'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1418604\">",
"    <span class=\"h2\">",
"     HIV infection/AIDS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Pulmonary infections associated with AIDS are discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=see_link\">",
"     \"Approach to the HIV-infected patient with pulmonary symptoms\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=see_link\">",
"     \"Bacterial pulmonary infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=see_link\">",
"     \"Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36310?source=see_link\">",
"     \"Parasitic pulmonary infections in HIV-infected patients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"     \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1418611\">",
"    <span class=\"h2\">",
"     Transplantation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The risk of infection in solid organ and hematopoietic cell transplant recipients is reviewed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=see_link\">",
"     \"Evaluation for infection before solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=see_link\">",
"     \"Prophylaxis of infections in solid organ transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=see_link\">",
"     \"Evaluation for infection before hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=see_link\">",
"     \"Prophylaxis of infections in hematopoietic cell transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     ETIOLOGY OF PULMONARY INFILTRATES",
"    </span>",
"    &nbsp;&mdash;&nbsp;Both infectious and noninfectious causes of pulmonary infiltrates are found in immunocompromised hosts. Aspiration is an important source of pulmonary infection in all immunocompromised patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Infectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;The etiology of infectious pneumonitis in cancer patients, when documented, is diverse [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/3-6,21-26\">",
"     3-6,21-26",
"    </a>",
"    ]. The spectrum of infection may be altered by antimicrobial prophylaxis. The approximate frequency of identification of common organisms is:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Conventional bacteria &mdash; 37 percent",
"     </li>",
"     <li>",
"      Fungi &mdash;14 percent",
"     </li>",
"     <li>",
"      Viruses &mdash; 15 percent",
"     </li>",
"     <li>",
"      Pneumocystis jirovecii (formerly P. carinii) &mdash; 8 percent",
"     </li>",
"     <li>",
"      Nocardia asteroides &mdash; 7 percent",
"     </li>",
"     <li>",
"      Mycobacterium tuberculosis &mdash; 1 percent",
"     </li>",
"     <li>",
"      Mixed infections &mdash; 20 percent",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The spectrum of pulmonary fungal infection has broadened to include infection with non-fumigatus Aspergillus spp, Fusarium spp, Scedosporium spp, and the Mucorales in patients with neutropenia",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    in association with graft-versus-host disease. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link\">",
"     \"Epidemiology and clinical manifestations of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=see_link\">",
"     \"Mycology, pathogenesis, and epidemiology of Fusarium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=see_link\">",
"     \"Epidemiology and clinical manifestations of Scedosporium infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"     \"Mucormycosis (zygomycosis)\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Mixed infections with combinations of respiratory viruses, CMV, Aspergillus spp,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    gram-negative bacilli are common in neutropenic hosts and after solid organ and hematopoietic cell transplantation (HCT) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/27-33\">",
"     27-33",
"    </a>",
"    ]. Pneumocystis pneumonia (PCP) is most common in patients receiving glucocorticoids as a part of a chemotherapeutic or maintenance regimen [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/20\">",
"     20",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Invasive CMV disease is often difficult to distinguish from noninvasive infection with viral shedding in the immunocompromised host. The presence of CMV in lung washings suggests a high risk for invasive disease. Confirmation of CMV pneumonitis using assays from blood samples (eg, CMV viral load or antigenemia assay)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    tissue histology, may be useful (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef65546 \" href=\"UTD.htm?4/10/4266\">",
"     image 1",
"    </a>",
"    ). CMV is most common after HCT as viral reactivation in seropositive individuals (CMV donor seronegative, recipient seropositive; CMV",
"    <span class=\"nowrap\">",
"     D-/R+)",
"    </span>",
"    after the completion of prophylaxis (late infection) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/34,35\">",
"     34,35",
"    </a>",
"    ]. This contrasts with the risk profile of CMV pneumonitis in solid organ transplantation, which is greatest in seronegative recipients of seropositive organs (CMV",
"    <span class=\"nowrap\">",
"     D+/R-).",
"    </span>",
"    (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=see_link\">",
"     \"Overview of infections following hematopoietic cell transplantation\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=see_link\">",
"     \"Infection in the solid organ transplant recipient\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=see_link\">",
"     \"Prevention of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420650\">",
"    <span class=\"h3\">",
"     Site of entry",
"    </span>",
"    &nbsp;&mdash;&nbsp;A number of infections, especially those due to mycobacteria, Nocardia spp, and Cryptococcus spp, generally enter via the lungs, but metastasize to other sites. These other sites may be more accessible than the lungs for establishing a microbiologic diagnosis. (See",
"    <a class=\"local\" href=\"#H1420235\">",
"     'Skin and CSF sampling'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The lungs can also be a site for hematogenous spread of infection (eg, septic emboli due to Staphylococcus aureus). Peripheral pulmonary lesions in the lungs can be a clue that there is important disease elsewhere (eg, line sepsis, hepatosplenic candidiasis, infective endocarditis) (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef76610 \" href=\"UTD.htm?7/19/7472\">",
"     image 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Noninfectious",
"    </span>",
"    &nbsp;&mdash;&nbsp;Noninfectious etiologies for pulmonary infiltrates are common in immunocompromised patients, including pulmonary embolus, tumor, radiation pneumonitis, atelectasis with pulmonary edema, drug allergy or toxicity, and pulmonary hemorrhage. Often, the resolution of fever in response to a trial of antibiotics is the only evidence suggesting that infection was present.",
"   </p>",
"   <p>",
"    In a series of patients who underwent open lung biopsy at Memorial Sloan Kettering Cancer Center, inflammatory processes (such as bronchiolitis obliterans organizing pneumonia [BOOP] or drug toxicity) and malignancy accounted for 67 percent of the specific diagnoses made; the remaining 33 percent were due to infection [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/36\">",
"     36",
"    </a>",
"    ]. Drug toxicities (",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"     cyclophosphamide",
"    </a>",
"    , and sulfonamides), leukoagglutinin reactions, radiation injury, pulmonary emboli, pulmonary hemorrhage, and cancer metastases may coexist with opportunistic infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Radiation-induced injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinically apparent injury due to radiation therapy can occur acutely or more than six months after the initial exposure to a dose of over 2000 rads. Vascular damage, mononuclear infiltrates, and edema are seen histologically at three to 12 months. The severity of lung injury due to drugs or radiation appears to correlate with the rapidity of the withdrawal of glucocorticoid therapy. However, this timing may also reflect the emergence of the underlying inflammatory response rather than enhanced injury. Radiation fibrosis may occur (usually after six to nine months); lung function may not stabilize for up to two years. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=see_link\">",
"     \"Radiation-induced lung injury\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Drug-induced injury",
"    </span>",
"    &nbsp;&mdash;&nbsp;Acute, drug-induced lung disease may reflect hypersensitivity to chemotherapeutic agents, sulfonamides, or other agents.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"       Methotrexate",
"      </a>",
"      ,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"       bleomycin",
"      </a>",
"      , and",
"      <a class=\"drug drug_general\" href=\"UTD.htm?23/45/24279?source=see_link\">",
"       procarbazine",
"      </a>",
"      can cause a syndrome of nonproductive cough, fever, dyspnea, and pleurisy with skin rash and blood eosinophilia. Chest radiographs generally demonstrate diffuse reticular infiltrates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=see_link\">",
"       \"Methotrexate-induced lung injury\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=see_link\">",
"       \"Bleomycin-induced lung injury\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?9/20/9546?source=see_link\">",
"       Cyclophosphamide",
"      </a>",
"      may cause a syndrome of pulmonary disease with interstitial inflammation and pulmonary fibrosis that occurs subacutely over weeks to months. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=see_link\">",
"       \"Cyclophosphamide pulmonary toxicity\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      <a class=\"drug drug_general\" href=\"UTD.htm?5/39/5753?source=see_link\">",
"       Sirolimus",
"      </a>",
"      (rapamycin) used for immune suppression may be associated with a form of interstitial pneumonitis in transplant recipients [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/37\">",
"       37",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=see_link&amp;anchor=H20#H20\">",
"       \"Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents\", section on 'Rapamycin and analogs'",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Other common drugs causing lung injury include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/53/20314?source=see_link\">",
"       cytarabine",
"      </a>",
"      , but fever is less often associated with these other drug-induced forms of pneumonitis.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Drug toxicity may be related to the cumulative dose of the agent (eg,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?38/15/39159?source=see_link\">",
"     bleomycin",
"    </a>",
"    over 450 mg, BCNU, CCNU) and to the age of the patient. Synergistic pulmonary toxicity is seen when certain chemotherapeutic agents are used in combination with radiation therapy (eg, bleomycin,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?37/16/38144?source=see_link\">",
"     mitomycin",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?10/10/10408?source=see_link\">",
"     busulfan",
"    </a>",
"    ) or oxygen (bleomycin).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Other mimics of infection",
"    </span>",
"    &nbsp;&mdash;&nbsp;A variety of other noninfectious processes can mimic infection in immunocompromised patients:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Alveolar proteinosis may be associated with hematologic malignancies or can coexist with infection due to Nocardia, PCP, or less often with cryptococcosis, aspergillosis, tuberculosis, or histoplasmosis. The presentation of patients with pulmonary infarction can also resemble infection; chest radiographs tend to have segmental pleural-based infiltrates. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=see_link\">",
"       \"Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      In patients with primary connective",
"      <span class=\"nowrap\">",
"       tissue/collagen",
"      </span>",
"      vascular diseases, infection may be difficult to distinguish from the effects of the primary disease or toxicities of therapy. Systemic lupus erythematosus and rheumatoid arthritis are associated with a variety of pulmonary infiltrates. The pulmonary-renal syndromes (Goodpasture's syndrome and granulomatosis with polyangiitis [Wegener&rsquo;s]) may present with pulmonary hemorrhage, consolidation, nodular lesions, and patchy infiltrates, and may progress to cavitation. Sarcoidosis is generally associated with hilar lymph node enlargement and interstitial infiltrates, but nodular disease and superinfection are common. Histology may be required to differentiate infection from non-infectious pulmonary processes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=see_link\">",
"       \"Pulmonary manifestations of systemic lupus erythematosus in adults\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=see_link\">",
"       \"Clinical manifestations and diagnosis of sarcoidosis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=see_link&amp;anchor=H14577579#H14577579\">",
"       \"Differential diagnosis and evaluation of glomerular disease\", section on 'Acute glomerulonephritis and pulmonary hemorrhage'",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=see_link\">",
"       \"Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Therapy for rheumatic disease (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/6/4200?source=see_link\">",
"       penicillamine",
"      </a>",
"      , gold salts, antiinflammatory agents) may cause acute or chronic reticulonodular pulmonary infiltrates associated with fever, dyspnea, and cough. Anti-tumor necrosis factor (TNF) therapies have been used in a variety of rheumatologic conditions with the activation of latent intracellular infections including tuberculosis, aspergillosis, and other infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=see_link\">",
"       \"Overview of lung disease associated with rheumatoid arthritis\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors and mycobacterial infections\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=see_link\">",
"       \"Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Acute respiratory distress syndrome is usually the result of severe pneumonia or ongoing infectious or inflammatory extrapulmonary processes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=see_link\">",
"       \"Acute respiratory distress syndrome: Clinical features and diagnosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Transfusion-associated leukoagglutinin reactions (transfusion-related lung injury [TRALI]) are uncommon, but transient pulmonary infiltrates may occur following transfusions. Virtually all blood products have been implicated in TRALI. Infusions of whole blood, platelets, packed red blood cells, and fresh frozen plasma are the most commonly identified precipitating causes, but case reports have also implicated transfusions of allogeneic stem cells, cryoprecipitates, intravenous immunoglobulin, and granulocytes. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=see_link\">",
"       \"Transfusion-related acute lung injury (TRALI)\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     INITIAL EVALUATION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Recognition that infection is present in immunocompromised hosts is often delayed because the usual signs of infection are missing due to the muted inflammatory response. As an example, sputum production and radiographic changes may be absent in the neutropenic patient with pneumonia. In one series of cancer patients with pneumonia, neutropenic patients produced purulent sputum far less often than those without neutropenia (8 versus 84 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/25\">",
"     25",
"    </a>",
"    ]. Many infections are recognized only when fever, clinical symptoms (eg, cough, pleurisy, confusion), unexplained hypotension, or radiologic abnormalities develop after immune suppression or neutropenia is reversed.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420151\">",
"    <span class=\"h2\">",
"     Hospital admission",
"    </span>",
"    &nbsp;&mdash;&nbsp;The first decision to make in an immunocompromised patient with possible infection is whether or not hospital admission is appropriate. Any sign of invasive infection in immunocompromised patients requires at least a brief hospitalization (eg, one to three days) in order to undertake a careful evaluation. An immunocompromised patient with localizing signs (eg, headache, altered mental status, rash, dyspnea, chest pain, redness or pain over an indwelling catheter site, pulmonary infiltrates) merits consideration for emergency admission.",
"   </p>",
"   <p>",
"    Certain subgroups of immunocompromised patients are highly susceptible to infection. These include patients with:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Aggressive tumors (eg, new leukemia or lymphoma or uncontrolled metastatic cancer)",
"     </li>",
"     <li>",
"      Recent hematopoietic cell transplant (HCT) recipients and allogeneic HCT recipients with significant graft-versus-host disease (GVHD)",
"     </li>",
"     <li>",
"      Recent infections, especially due to CMV, or with known colonization with fungi or resistant bacteria",
"     </li>",
"     <li>",
"      Absolute neutrophil count (ANC) below",
"      <span class=\"nowrap\">",
"       500/microL,",
"      </span>",
"      and especially those below",
"      <span class=\"nowrap\">",
"       100/microL,",
"      </span>",
"      or those in whom the ANC is falling rapidly or expected to fall below",
"      <span class=\"nowrap\">",
"       100/microL",
"      </span>",
"     </li>",
"     <li>",
"      High-dose glucocorticoid therapy or recent intensification of immunosuppression (eg, in solid organ transplant recipients being treated for rejection)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These patients are generally considered to be at higher risk of infection and are best managed as inpatients until clinically stable. Patients with frank rigors or hypotension should also be admitted. A very low threshold should also exist for admission and treatment of splenectomized patients with fever. Patients with a history of recent or recurrent infection after organ transplantation (eg, Pseudomonas spp or Stenotrophomonas maltophilia infections in lung transplant recipients with cystic fibrosis or CMV infection in any solid organ transplant recipient) or with anatomic predisposition to infection (eg, bronchiectasis) merit consideration for hospitalization. Immunocompromised patients with fever without a clear etiology are considered at high risk without admission and careful follow-up must be assured.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420166\">",
"    <span class=\"h2\">",
"     Diagnostic approach",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial evaluation for immunocompromised patients with fever with or without pulmonary findings should include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Rapid assessment of vital signs including oxygen saturation",
"     </li>",
"     <li>",
"      Complete blood count with differential",
"     </li>",
"     <li>",
"      Electrolytes, blood urea nitrogen, and creatinine",
"     </li>",
"     <li>",
"      Blood cultures (minimum of two sets, with at least one peripheral set and one set from any indwelling catheter)",
"     </li>",
"     <li>",
"      Urine sediment examination and culture",
"     </li>",
"     <li>",
"      Sputum for Gram stain, fungal smears, and cultures",
"     </li>",
"     <li>",
"      Imaging of the lungs (chest radiography or whenever possible, chest computed tomographic [CT] scanning) and imaging of any symptomatic site (eg, abdomen)",
"     </li>",
"     <li>",
"      Skin examination, looking for evidence of metastatic infection",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h1\">",
"     DIAGNOSIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since the differential diagnosis of pulmonary infiltrates in the immunocompromised host is broad, historical (eg, epidemiologic) and radiologic clues may be useful in narrowing the possibilities. Nevertheless, sampling tissue is frequently required in order to make a definitive diagnosis, especially in distinguishing infectious from noninfectious causes.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Historical clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;Historical features are often useful in making a preliminary diagnosis and in selecting the initial empiric antimicrobial regimen. Some of these include:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Travel and occupation: Exposures to mycobacteria, endemic fungi (eg, Histoplasma capsulatum, Coccidioides spp), Rhodococcus equi (horse breeders), or Cryptococcus neoformans (eg, spelunkers and pigeon breeders), or exposure to soil (eg, Aspergillus spp or Nocardia spp in landscapers and gardeners)",
"     </li>",
"     <li>",
"      Prolonged duration of neutropenia (higher risk for gram-negative infections, Aspergillus spp, and Fusarium spp)",
"     </li>",
"     <li>",
"      Past history of frequent antimicrobial exposure (increased risk for organisms with resistance to various antimicrobials used previously)",
"     </li>",
"     <li>",
"      Potential or witnessed aspiration (risk for anaerobic infection)",
"     </li>",
"     <li>",
"      Presence of potential pulmonary pathogens in prior cultures, particularly molds (Aspergillus spp, Fusarium spp), Pseudomonas spp, or Stenotrophomonas spp",
"     </li>",
"     <li>",
"      Cardiac abnormalities (endocarditis), indwelling catheters or intravascular clot (bacteremic seeding of the lungs)",
"     </li>",
"     <li>",
"      Metastatic tumors, particularly intrathoracic malignancies",
"     </li>",
"     <li>",
"      Diabetes mellitus with sinopulmonary infection (mucormycosis) (see",
"      <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=see_link\">",
"       \"Mucormycosis (zygomycosis)\"",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Many organisms are linked to specific immune deficits (",
"      <a class=\"graphic graphic_table graphicRef57336 \" href=\"UTD.htm?11/32/11789\">",
"       table 1",
"      </a>",
"      ).",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420612\">",
"    <span class=\"h2\">",
"     Hypoxemia",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence or absence of hypoxemia can assist in the differential diagnosis of pulmonary infiltrates in immunocompromised patients. Hypoxemia with an elevation in lactic dehydrogenase and minimal radiographic findings are common in PCP, whereas the absence of hypoxemia with pulmonary consolidation is more common in nocardiosis, tuberculosis, and fungal infections until late in the course of disease.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h2\">",
"     Radiographic clues",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presence or absence of pulmonary infiltrates should be defined by chest radiography or CT scan since the pattern of involvement can be helpful in establishing the etiology of the process. A chest radiograph is not sufficient to exclude pulmonary involvement if there are any respiratory symptoms or historical features that suggest a possible pulmonary process. The threshold for performing a chest CT should be very low in immunocompromised hosts.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Chest radiography",
"    </span>",
"    &nbsp;&mdash;&nbsp;The initial findings and evolution of the chest radiograph provide important clues to both the differential diagnosis of pulmonary infection and the appropriate diagnostic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/38\">",
"     38",
"    </a>",
"    ]. The following radiographic parameters are useful in developing clinical-radiographic-pathologic correlations [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/8\">",
"     8",
"    </a>",
"    ]:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Time of appearance, rate of progression, and time to resolution of pulmonary radiographic abnormalities in relation to clinical events.",
"     </li>",
"     <li>",
"      Distribution of radiologic abnormalities: An abnormality confined to one anatomic area is considered focal, whereas widespread lesions are considered diffuse. Abnormalities that are present in more than one area, but are discrete, are termed multifocal. Findings may be located centrally, peripherally or both, particularly on CT scans.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Three types of pulmonary infiltrates are common:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Consolidation, with a substantial replacement of alveolar air by tissue density material, typically with air bronchograms and a peripheral location of the abnormality (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef80265 \" href=\"UTD.htm?31/2/31779\">",
"       image 3",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Peribronchovascular (or interstitial) distribution, in which the infiltrate is predominantly oriented along the peribronchial or perivascular bundles (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66492 \" href=\"UTD.htm?27/21/27988\">",
"       image 4",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Nodular, space-occupying, nonanatomic lesions with well-defined, more or less rounded edges surrounded by aerated lung",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Other findings may include: pleural fluid, atelectasis, cavitation (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef79874 \" href=\"UTD.htm?1/39/1648\">",
"     image 5",
"    </a>",
"    ), lymphadenopathy, and cardiac enlargement. The location of pleural fluid can be a clue; bilateral effusions are more common in congestive heart failure and fluid overload, and unilateral in necrotizing or granulomatous infection (especially in association with lymphadenopathy or cavitation).",
"   </p>",
"   <p>",
"    This classification system for radiographs can be combined with information about the rate of progression of the illness to generate a differential diagnosis. Several examples are illustrative:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      A focal or multifocal consolidation of acute onset will probably be caused by a bacterial infection. In contrast, similar multifocal lesions with a subacute to chronic progression are more commonly due to fungal, tuberculous, or nocardial infections.",
"     </li>",
"     <li>",
"      Large nodules are usually a sign of fungal or nocardial infection in this patient population, particularly if they are subacute to chronic in onset.",
"     </li>",
"     <li>",
"      Subacute disease with diffuse abnormalities, either of the peribronchovascular type or miliary micronodules, are usually caused by viruses (especially CMV), P. jirovecii, or, in the lung transplant recipient, rejection (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef66794 \" href=\"UTD.htm?25/0/25605\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      The presence of cavitation suggests a necrotizing infection which can be caused by fungi, Nocardia spp, mycobacteria, certain gram-negative bacilli (most commonly Klebsiella pneumoniae and Pseudomonas aeruginosa), and anaerobes [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/8\">",
"       8",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      The appearance of invasive pulmonary aspergillosis is heterogeneous. The most common features include patchy infiltrates, nodules, cavitation, and pleural-based wedge-shaped lesions [",
"      <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/27,32,33\">",
"       27,32,33",
"      </a>",
"      ]. In neutropenic patients, the initial appearance may be nodules with surrounding hypoattenuation (the \"halo sign\") followed by cavitation (the \"air-crescent sign\") following the return of neutrophils. The halo sign may also be observed with other infections that cause infarction (eg, other angioinvasive fungi, Nocardia spp, Pseudomonas aeruginosa) and malignancies. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=see_link&amp;anchor=H429431#H429431\">",
"       \"Epidemiology and clinical manifestations of invasive aspergillosis\", section on 'Imaging'",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    The depressed inflammatory response of the immunocompromised transplant patient may greatly modify or delay the appearance of a pulmonary lesion on radiography, especially if neutropenia is present. As an example, fungal invasion, which causes a less exuberant inflammatory response than does bacterial infection, will often be very slow to appear on conventional chest radiography.",
"   </p>",
"   <p>",
"    The following table reviews the radiographic appearances of pulmonary disorders in HIV-infected patients (",
"    <a class=\"graphic graphic_table graphicRef73151 \" href=\"UTD.htm?31/18/32044\">",
"     table 2",
"    </a>",
"    ).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Chest CT",
"    </span>",
"    &nbsp;&mdash;&nbsp;CT frequently reveals abnormalities even when the chest radiograph is negative or has only subtle findings. CT can also help to define the extent of the disease. Precise knowledge of the extent of infection at the time of diagnosis allows for subsequent assessment of the response to therapy. This is especially relevant for opportunistic fungal and nocardial infections. Therapy should be continued until all evidence of infection is eliminated. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link&amp;anchor=H617627#H617627\">",
"     \"Treatment and prevention of invasive aspergillosis\", section on 'Duration'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=see_link\">",
"     \"Treatment of nocardiosis\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The morphology of the abnormalities found on CT scan can be useful in developing a differential diagnosis:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Cavitary CT lesions are suggestive of infections with mycobacteria, Nocardia spp, Cryptococcus spp, Aspergillus spp, and some gram-negative bacilli (Pseudomonas aeruginosa, Klebsiella spp).",
"     </li>",
"     <li>",
"      Rapidly expanding pulmonary lesions with cavitation",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      hemorrhage are associated with the Mucorales, especially in diabetics.",
"     </li>",
"     <li>",
"      Opacified secondary pulmonary lobules in the lung periphery are suggestive of bland pulmonary infarcts or septic or hemorrhagic Aspergillus infarcts (if cavitary).",
"     </li>",
"     <li>",
"      Opacities in a peribronchial (or interstitial) distribution are suggestive of fluid overload, viral infection such as CMV (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef50696 \" href=\"UTD.htm?38/17/39185\">",
"       image 7",
"      </a>",
"      ), or P. jirovecii infection (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef58132 \" href=\"UTD.htm?20/52/21313\">",
"       image 8",
"      </a>",
"      ), and, in the lung transplant recipient, allograft rejection.",
"     </li>",
"     <li>",
"      Dense regional or lobar consolidation on CT is usually seen in bacterial pneumonia or invasive fungal infection.",
"     </li>",
"     <li>",
"      Lymphadenopathy is not a common finding in immunosuppressed patients other than in those with lymphoma or post-transplant lymphoproliferative disorder associated with Epstein-Barr virus (EBV). Lymphadenopathy may be observed with acute viral infections (CMV, EBV), sarcoidosis, and infections due to mycobacteria, Cryptococcus spp, and with drug reactions (eg,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?4/58/5034?source=see_link\">",
"       trimethoprim-sulfamethoxazole",
"      </a>",
"      ). Positron emission tomography-CT (PET-CT) may differentiate infection from tumor.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    CT scans will frequently detect multiple patterns simultaneously, in contrast to conventional radiographs, which can raise the possibility of dual or sequential infection of the lungs. In a patient being treated for PCP, for example, the appearance of acinar, macronodular, or cavitary lesions is highly suggestive of a complicating infection, often secondary Aspergillus invasion of lung tissue compromised by the primary process.",
"   </p>",
"   <p>",
"    Another important use of the CT scan is to identify the site for optimal sampling and assist in defining the most appropriate invasive procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/39\">",
"     39",
"    </a>",
"    ]. Thus, CT can provide precise guidance for needle biopsy or for thoracoscopic or open lung excision [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/39-45\">",
"     39-45",
"    </a>",
"    ]. CT can also help to predict whether bronchoscopy is likely to be useful. As an example, the demonstration of a feeding bronchus in association with a pulmonary nodule greatly increases the diagnostic yield when bronchoscopy is performed (60 versus 30 percent when the feeding bronchus is not visible). If CT demonstrates centrally located diffuse opacities, a bronchoscopic approach is the procedure of choice.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Invasive procedures",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420235\">",
"    <span class=\"h3\">",
"     Skin and CSF sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;As discussed above, a number of infections, especially those due to mycobacteria, Nocardia spp, and Cryptococcus spp, generally enter via the lungs, but metastasize to other sites. These other sites may be more accessible than the lungs for establishing a microbiologic diagnosis. Thus, skin lesions or cerebrospinal fluid (CSF) may demonstrate Cryptococcus spp or mycobacterial infection before the microbiologic results from sputum or lung biopsy specimens are available. (See",
"    <a class=\"local\" href=\"#H1420650\">",
"     'Site of entry'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H1420242\">",
"    <span class=\"h3\">",
"     Lung sampling",
"    </span>",
"    &nbsp;&mdash;&nbsp;An invasive diagnostic procedure such as bronchoscopy with bronchoalveolar lavage (BAL)",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    transbronchial biopsy, percutaneous needle biopsy, video-assisted thorascopic biopsy (VATS), or open lung biopsy is frequently required to obtain a sample of sputum or lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/40-44,46-49\">",
"     40-44,46-49",
"    </a>",
"    ]. The selection of the optimal procedure is determined both by the nature (ie, focal or diffuse) and location of the pulmonary lesion and the skills available locally. Diffuse lesions may be sampled by transbronchial biopsy, whereas nodules are better located by CT-guided percutaneous needle biopsy, VATS, or open lung biopsy. VATS is also very useful for sampling of peripheral pulmonary lesions.",
"   </p>",
"   <p>",
"    BAL is most useful for microbiologic diagnosis in HIV-infected patients due to the large numbers of organisms (eg, P. jirovecii, mycobacteria), that are often present in these hosts compared with other compromised individuals. Conversely, transbronchial biopsy should often accompany BAL in non-HIV-infected immunocompromised hosts without specific contraindications to avoid the need for multiple sequential procedures. In particular, BAL alone is less often useful for the diagnosis of invasive fungal infection than for PCP or bacterial processes. Further, biopsy allows distinction between colonization and invasion of fungal (or viral) infection, and may detect underlying processes such as bronchiolitis obliterans and drug-induced lung injury. Bronchial brushings do not generally add much information in immunocompromised patients. BAL fluid may be tested for Aspergillus galactomannan antigen, potentially aiding in the diagnosis of pulmonary aspergillosis [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/50,51\">",
"     50,51",
"    </a>",
"    ]. &nbsp;",
"   </p>",
"   <p>",
"    In patients in whom transbronchial biopsy is not feasible, VATS or open lung biopsy will often provide the best means for establishing a diagnosis. One study from Memorial Sloan Kettering Cancer Center evaluated the results of lung biopsy (either via thoracotomy or VATS) in 63 patients with hematologic malignancies: 40 percent of patients had active malignancy at the time of the procedure [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/36\">",
"     36",
"    </a>",
"    ]. Only six percent of patients were neutropenic at the time of the biopsy. Open lung biopsy resulted in a specific diagnosis in 62 percent of these cases and in a change of therapy in 57 percent. Patients with focal abnormalities by chest radiography were more likely than those with diffuse findings to obtain a specific diagnosis following biopsy (79 versus 32 percent). Forty-six percent of patients who underwent bronchoscopy with BAL, 50 percent of the eight patients who underwent transbronchial biopsy, and 50 percent of patients who underwent needle aspiration had specific diagnoses made after lung biopsy. The procedure resulted in complications in 13 percent of cases, including two with major complications. However, the mortality was improved at 30 and 90 days post-procedure for those in whom a specific diagnosis was made compared to those without a specific diagnosis, especially in patients who had undergone hematopoietic cell transplantation (8 versus 62 percent 90 day-mortality).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h2\">",
"     Microbiologic assays",
"    </span>",
"    &nbsp;&mdash;&nbsp;Routine sputum samples should be collected for cultures and staining whenever possible. Induced sputum specimens are most useful for diagnosing mycobacterial infections and PCP, and for cytologic evaluation [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/52\">",
"     52",
"    </a>",
"    ]. In many cases, bronchoscopy with BAL is required to obtain adequate specimens. Diagnostic studies that can be performed on BAL fluid are presented in the following table; this table refers to lung transplant recipients, but these studies are also applicable to other immunocompromised patients (",
"    <a class=\"graphic graphic_table graphicRef70685 \" href=\"UTD.htm?28/8/28813\">",
"     table 3",
"    </a>",
"    ).",
"   </p>",
"   <p>",
"    In addition to microbiologic testing of sputum samples, various other assays can be performed on a variety of other types of samples and can be used as adjuncts to culture-based techniques:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Nasal washings or swabs (direct fluorescent antibody [DFA] and viral cultures) may be used for the diagnosis of community-acquired viral infections due to influenza, parainfluenza, adenovirus, metapneumovirus, and respiratory syncytial virus.",
"     </li>",
"     <li>",
"      Urinary antigen tests may be used to diagnose Legionella pneumophila, Histoplasma capsulatum, and Streptococcus pneumoniae infections.",
"     </li>",
"     <li>",
"      Various antigen detection and PCR-based assays can be performed using serum samples (and in some cases, on other types of samples such as CSF",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      BAL fluid). Examples include CMV antigenemia and polymerase chain reaction (PCR), cryptococcal antigen, human herpes virus-6 PCR, Aspergillus galactomannan antigen, and 1,3-beta-D-glucan.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    In the case of CMV or Aspergillus infection, the finding of the agent or antigens in the lungs may be the basis of therapy in immunocompromised patients with consistent clinical syndromes and radiologic findings (\"probable disease\"). However, such evidence is indirect and should not be considered diagnostic in the absence of histopathologic correlation. Many of these assays are more useful for screening of asymptomatic patients than for diagnosis; the sensitivity and specificity of each assay should be ascertained. As an example, the presence of CMV viremia indicates CMV reactivation, but is not provide information about the presence of invasive disease. Conversely, the absence of CMV viremia may mitigate against the diagnosis of invasive CMV pneumonitis. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=see_link\">",
"     \"Diagnosis of invasive aspergillosis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"     \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=see_link\">",
"     \"Cytomegalovirus infection in renal transplant recipients\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=see_link\">",
"     \"Viral load testing for cytomegalovirus in solid organ transplant recipients\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The decision of which studies to send depends upon the individual patient's clinical findings and on availability at specific hospital laboratories.",
"   </p>",
"   <p>",
"    Serologic techniques are generally of little use in the diagnosis of active infection in immunocompromised patients because such patients may be unable to generate an adequate immune response to a new pathogen, or they may have made a response to a previous infection before they became immunocompromised. Thus, both a negative and a positive result may be uninterpretable.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Pursuit of a unifying diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;While it is always appealing to make a single diagnosis and initiate therapy, it is important to remember that multiple simultaneous processes are common in the immunocompromised patient. The occurrence of multiple simultaneous infections or conditions can complicate and delay appropriate therapy (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef60143 \" href=\"UTD.htm?22/22/22895\">",
"     image 9",
"    </a>",
"    ). As an example, CMV infection may complicate the treatment of graft rejection or venoocclusive disease, or contribute to the pathogenesis of PCP or Aspergillus pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/53\">",
"     53",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h1\">",
"     SELECTION OF INITIAL THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Algorithms exist for empiric antibiotic therapy in immunocompromised hosts [",
"    <a class=\"abstract\" href=\"UTD.htm?24/51/25402/abstract/54,55\">",
"     54,55",
"    </a>",
"    ]. In practice, most initial therapy is empiric while awaiting diagnostic studies. However, with careful attention to individual patient characteristics, a limited differential diagnosis can be established and empiric antibiotic therapy tailored to treat the most likely pathogens and minimize toxicity and cost. This may also avoid unnecessary broad-spectrum antimicrobial coverage. Antimicrobial agents used for prophylaxis should be avoided in empiric therapy as resistance may emerge. &nbsp;",
"   </p>",
"   <p>",
"    The management of specific infections is discussed separately:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Empiric treatment of patients with febrile neutropenia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=see_link\">",
"       \"Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=see_link\">",
"       \"Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Community-acquired pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults who require hospitalization\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=see_link\">",
"       \"Treatment of community-acquired pneumonia in adults in the outpatient setting\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=see_link\">",
"       \"Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Invasive aspergillosis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=see_link\">",
"       \"Treatment and prevention of invasive aspergillosis\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Pneumocystis pneumonia. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=see_link\">",
"       \"Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=see_link\">",
"       \"Treatment of Pneumocystis infection in HIV-infected patients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      CMV pneumonitis. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=see_link\">",
"       \"Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Mycobacterial infections. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=see_link\">",
"       \"Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=see_link\">",
"       \"Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=see_link\">",
"       \"Rapidly growing mycobacterial infections in HIV-negative patients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=see_link\">",
"       \"Tuberculosis in solid organ transplant candidates and recipients\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=see_link\">",
"       \"Treatment of pulmonary tuberculosis in the HIV-infected patient\"",
"      </a>",
"      .)",
"     </li>",
"     <li>",
"      Infections in lung transplant recipients. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=see_link\">",
"       \"Fungal infections following lung transplantation\"",
"      </a>",
"      and",
"      <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=see_link\">",
"       \"Bacterial infections following lung transplantation\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H882523\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The spectrum of immunocompromised hosts has expanded due to the increased survival of solid organ and hematopoietic cell transplant recipients and patients with congenital immune deficits or autoimmune disorders, and the epidemic of human immunodeficiency",
"      <span class=\"nowrap\">",
"       syndrome/acquired",
"      </span>",
"      immunodeficiency syndrome",
"      <span class=\"nowrap\">",
"       (HIV/AIDS).",
"      </span>",
"      (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Novel immunosuppressive therapies create a diverse set of immune deficits that create the substrate for opportunistic infections. These patients are defined by their susceptibility to infection with organisms of low native virulence for immunologically normal hosts. Pulmonary infection remains the most common form of tissue-invasive infection in these hosts. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early diagnosis and specific therapy of opportunistic infections is the cornerstone of successful treatment. The general rule is to be aggressive in pursuing a specific microbiologic diagnosis in immunocompromised patients with pulmonary infiltrates; invasive diagnostic techniques are often required. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H18\">",
"       'Diagnosis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The incidence and severity of pneumonia vary with the characteristics of the affected individual, including the nature of the immune deficits (",
"      <a class=\"graphic graphic_table graphicRef57336 \" href=\"UTD.htm?11/32/11789\">",
"       table 1",
"      </a>",
"      ), and epidemiologic exposures. Aspiration remains an important source of pulmonary infection in all immunocompromised patients. (See",
"      <a class=\"local\" href=\"#H3\">",
"       'Epidemiology and risk of pneumonia'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Recognition that infection is present in immunocompromised hosts is often delayed because the usual signs of infection are missing due to the muted inflammatory response. (See",
"      <a class=\"local\" href=\"#H17\">",
"       'Initial evaluation'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most immunocompromised patients with any sign of possible invasive infection should be hospitalized for evaluation. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'General principles'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H1420151\">",
"       'Hospital admission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Certain subgroups of immunocompromised patients are highly susceptible to infection. These include patients with:",
"     </li>",
"     <li>",
"      Aggressive tumors (eg, new leukemia or lymphoma or uncontrolled metastatic cancer)",
"     </li>",
"     <li>",
"      Recent hematopoietic cell transplant (HCT) recipients and allogeneic HCT recipients with significant graft-versus-host disease",
"     </li>",
"     <li>",
"      Recent infections, especially due to CMV, or with known colonization with fungi or resistant bacteria",
"     </li>",
"     <li>",
"      Absolute neutrophil count (ANC) below",
"      <span class=\"nowrap\">",
"       500/microL,",
"      </span>",
"      and especially those below",
"      <span class=\"nowrap\">",
"       100/microL,",
"      </span>",
"      or those in whom the ANC is falling rapidly or expected to fall below",
"      <span class=\"nowrap\">",
"       100/microL",
"      </span>",
"     </li>",
"     <li>",
"      High-dose glucocorticoid therapy or recent intensification of immunosuppression (eg, in solid organ transplant recipients being treated for rejection)",
"      <br/>",
"      <br/>",
"      These patients are generally considered to be at higher risk and are best managed as inpatients until clinically stable. Patients with a history of frank rigors or hypotension also should be admitted. A very low threshold should also exist for admission and treatment of splenectomized patients with fever. (See",
"      <a class=\"local\" href=\"#H1420151\">",
"       'Hospital admission'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      The presence or absence of pulmonary infiltrates should be defined by chest radiography or CT scan since the pattern of involvement can be helpful in establishing the etiology of the process. A chest radiograph is not sufficient to exclude pulmonary involvement if there are any respiratory symptoms or historical features that suggest a possible pulmonary process. The threshold for performing a chest CT should be very low in immunocompromised hosts. (See",
"      <a class=\"local\" href=\"#H20\">",
"       'Radiographic clues'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Invasive procedures are frequently required to obtain tissue or sputum in order to make a specific diagnosis. The differential diagnosis of pulmonary infiltrates in immunocompromised patients is so broad and includes both infectious and noninfectious conditions, making the sampling of tissue essential for diagnosis in the majority of patients. (See",
"      <a class=\"local\" href=\"#H23\">",
"       'Invasive procedures'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most initial therapy is empiric while awaiting diagnostic studies. However, with careful attention to individual patient characteristics, a limited differential diagnosis can be established and empiric antibiotic therapy tailored to treat the most likely pathogens and minimize toxicity and cost. This may also avoid unnecessary broad-spectrum antimicrobial coverage. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Selection of initial therapy'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/1\">",
"      Ettinger NA, Trulock EP. Pulmonary considerations of organ transplantation. Part I. Am Rev Respir Dis 1991; 143:1386.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/2\">",
"      Masur H, Shelhamer J, Parrillo JE. The management of pneumonias in immunocompromised patients. JAMA 1985; 253:1769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/3\">",
"      Ramsey PG, Rubin RH, Tolkoff-Rubin NE, et al. The renal transplant patient with fever and pulmonary infiltrates: etiology, clinical manifestations, and management. Medicine (Baltimore) 1980; 59:206.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/4\">",
"      Rosenow EC 3rd, Wilson WR, Cockerill FR 3rd. Pulmonary disease in the immunocompromised host. 1. Mayo Clin Proc 1985; 60:473.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/5\">",
"      Rosenow EC 3rd. Diffuse pulmonary infiltrates in the immunocompromised host. Clin Chest Med 1990; 11:55.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/6\">",
"      Winston DJ, Emmanouilides C, Busuttil RW. Infections in liver transplant recipients. Clin Infect Dis 1995; 21:1077.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/7\">",
"      Fishman JA. Infection in solid-organ transplant recipients. N Engl J Med 2007; 357:2601.",
"     </a>",
"    </li>",
"    <li>",
"     Greene, R. The radiology of pulmonary infection. In: Fishman's Pulmonary Diseases and Disorders, 4th, Fishman, AP, Elias, JA, Fishman, JA, et al (Eds), McGraw-Hill, New York 2008. p.2017.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/9\">",
"      Collin BA, Ramphal R. Pneumonia in the compromised host including cancer patients and transplant patients. Infect Dis Clin North Am 1998; 12:781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/10\">",
"      Groll AH, Shah PM, Mentzel C, et al. Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 1996; 33:23.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/11\">",
"      Fishman JA, Dey BR, Hasserjian RP. Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 10-2004. A 58-year-old man with acute myeloid leukemia and Fever after chemotherapy. N Engl J Med 2004; 350:1339.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/12\">",
"      Costa SF, Alexander BD. Non-Aspergillus fungal pneumonia in transplant recipients. Clin Chest Med 2005; 26:675.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/13\">",
"      Marr KA, Carter RA, Crippa F, et al. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/14\">",
"      Kotloff RM, Ahya VN, Crawford SW. Pulmonary complications of solid organ and hematopoietic stem cell transplantation. Am J Respir Crit Care Med 2004; 170:22.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/15\">",
"      Bodey GP, Buckley M, Sathe YS, Freireich EJ. Quantitative relationships between circulating leukocytes and infection in patients with acute leukemia. Ann Intern Med 1966; 64:328.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/16\">",
"      Carlisle PS, Gucalp R, Wiernik PH. Nosocomial infections in neutropenic cancer patients. Infect Control Hosp Epidemiol 1993; 14:320.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/17\">",
"      Castagnola E, Fontana V, Caviglia I, et al. A prospective study on the epidemiology of febrile episodes during chemotherapy-induced neutropenia in children with cancer or after hemopoietic stem cell transplantation. Clin Infect Dis 2007; 45:1296.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/18\">",
"      Issa NC, Fishman JA. Infectious complications of antilymphocyte therapies in solid organ transplantation. Clin Infect Dis 2009; 48:772.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/19\">",
"      Koo S, Marty FM, Baden LR. Infectious complications associated with immunomodulating biologic agents. Infect Dis Clin North Am 2010; 24:285.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/20\">",
"      Rodriguez M, Fishman JA. Prevention of infection due to Pneumocystis spp. in human immunodeficiency virus-negative immunocompromised patients. Clin Microbiol Rev 2004; 17:770.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/21\">",
"      Bodey GP, Rodriguez V, Chang HY. Fever and infection in leukemic patients: a study of 494 consecutive patients. Cancer 1978; 41:1610.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/22\">",
"      HERSH EM, BODEY GP, NIES BA, FREIREICH EJ. CAUSES OF DEATH IN ACUTE LEUKEMIA: A TEN-YEAR STUDY OF 414 PATIENTS FROM 1954-1963. JAMA 1965; 193:105.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/23\">",
"      Chanock S. Evolving risk factors for infectious complications of cancer therapy. Hematol Oncol Clin North Am 1993; 7:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/24\">",
"      Coker DD, Morris DM, Coleman JJ, et al. Infection among 210 patients with surgically staged Hodgkin's disease. Am J Med 1983; 75:97.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/25\">",
"      Sickles EA, Greene WH, Wiernik PH. Clinical presentation of infection in granulocytopenic patients. Arch Intern Med 1975; 135:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/26\">",
"      Talcott JA, Finberg R, Mayer RJ, Goldman L. The medical course of cancer patients with fever and neutropenia. Clinical identification of a low-risk subgroup at presentation. Arch Intern Med 1988; 148:2561.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/27\">",
"      Patterson TF, Kirkpatrick WR, White M, et al. Invasive aspergillosis. Disease spectrum, treatment practices, and outcomes. I3 Aspergillus Study Group. Medicine (Baltimore) 2000; 79:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/28\">",
"      Junghanss C, Marr KA, Carter RA, et al. Incidence and outcome of bacterial and fungal infections following nonmyeloablative compared with myeloablative allogeneic hematopoietic stem cell transplantation: a matched control study. Biol Blood Marrow Transplant 2002; 8:512.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/29\">",
"      Marr KA, Carter RA, Boeckh M, et al. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100:4358.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/30\">",
"      Ison MG, Hayden FG, Kaiser L, et al. Rhinovirus infections in hematopoietic stem cell transplant recipients with pneumonia. Clin Infect Dis 2003; 36:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/31\">",
"      Alangaden GJ, Wahiduzzaman M, Chandrasekar PH, Bone Marrow Transplant Group. Aspergillosis: The most common community-acquired pneumonia with gram-negative Bacilli as copathogens in stem cell transplant recipients with graft-versus-host disease. Clin Infect Dis 2002; 35:659.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/32\">",
"      Marr KA, Patterson T, Denning D. Aspergillosis. Pathogenesis, clinical manifestations, and therapy. Infect Dis Clin North Am 2002; 16:875.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/33\">",
"      Ascioglu S, Rex JH, de Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34:7.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/34\">",
"      Konoplev S, Champlin RE, Giralt S, et al. Cytomegalovirus pneumonia in adult autologous blood and marrow transplant recipients. Bone Marrow Transplant 2001; 27:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/35\">",
"      Nguyen Q, Champlin R, Giralt S, et al. Late cytomegalovirus pneumonia in adult allogeneic blood and marrow transplant recipients. Clin Infect Dis 1999; 28:618.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/36\">",
"      White DA, Wong PW, Downey R. The utility of open lung biopsy in patients with hematologic malignancies. Am J Respir Crit Care Med 2000; 161:723.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/37\">",
"      Hamour IM, Mittal TK, Bell AD, Banner NR. Reversible sirolimus-associated pneumonitis after heart transplantation. J Heart Lung Transplant 2006; 25:241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/38\">",
"      Donowitz GR, Harman C, Pope T, Stewart FM. The role of the chest roentgenogram in febrile neutropenic patients. Arch Intern Med 1991; 151:701.",
"     </a>",
"    </li>",
"    <li>",
"     Greene, R. Transthoracic needle aspiration biopsy. In: International Radiology, Athanazoulis, C, Pfister, R, Greene, R, et al (Eds). WB Saunders, Philadelphia 1981. p.587.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/40\">",
"      Jaffe JP, Maki DG. Lung biopsy in immunocompromised patients: one institution's experience and an approach to management of pulmonary disease in the compromised host. Cancer 1981; 48:1144.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/41\">",
"      Janzen DL, Adler BD, Padley SP, M&uuml;ller NL. Diagnostic success of bronchoscopic biopsy in immunocompromised patients with acute pulmonary disease: predictive value of disease distribution as shown on CT. AJR Am J Roentgenol 1993; 160:21.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/42\">",
"      McKenna RJ Jr, Mountain CF, McMurtrey MJ. Open lung biopsy in immunocompromised patients. Chest 1984; 86:671.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/43\">",
"      Toledo-Pereyra LH, DeMeester TR, Kinealey A, et al. The benefits of open lung biopsy in patients with previous non-diagnostic transbronchial lung biopsy. A guide to appropriate therapy. Chest 1980; 77:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/44\">",
"      Westcott JL. Percutaneous transthoracic needle biopsy. Radiology 1988; 169:593.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/45\">",
"      Scott WW Jr, Kuhlman JE. Focal pulmonary lesions in patients with AIDS: percutaneous transthoracic needle biopsy. Radiology 1991; 180:419.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/46\">",
"      Moore EH, Shepard JA, McLoud TC, et al. Positional precautions in needle aspiration lung biopsy. Radiology 1990; 175:733.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/47\">",
"      Naidich DP, Sussman R, Kutcher WL, et al. Solitary pulmonary nodules. CT-bronchoscopic correlation. Chest 1988; 93:595.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/48\">",
"      Perlmutt LM, Johnston WW, Dunnick NR. Percutaneous transthoracic needle aspiration: a review. AJR Am J Roentgenol 1989; 152:451.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/49\">",
"      Plunkett MB, Peterson MS, Landreneau RJ, et al. Peripheral pulmonary nodules: preoperative percutaneous needle localization with CT guidance. Radiology 1992; 185:274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/50\">",
"      Maertens J, Maertens V, Theunissen K, et al. Bronchoalveolar lavage fluid galactomannan for the diagnosis of invasive pulmonary aspergillosis in patients with hematologic diseases. Clin Infect Dis 2009; 49:1688.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/51\">",
"      Clancy CJ, Jaber RA, Leather HL, et al. Bronchoalveolar lavage galactomannan in diagnosis of invasive pulmonary aspergillosis among solid-organ transplant recipients. J Clin Microbiol 2007; 45:1759.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/52\">",
"      Fishman JA, Roth RS, Zanzot E, et al. Use of induced sputum specimens for microbiologic diagnosis of infections due to organisms other than Pneumocystis carinii. J Clin Microbiol 1994; 32:131.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/53\">",
"      George MJ, Snydman DR, Werner BG, et al. The independent role of cytomegalovirus as a risk factor for invasive fungal disease in orthotopic liver transplant recipients. Boston Center for Liver Transplantation CMVIG-Study Group. Cytogam, MedImmune, Inc. Gaithersburg, Maryland. Am J Med 1997; 103:106.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/54\">",
"      Sileri P, Pursell KJ, Coady NT, et al. A standardized protocol for the treatment of severe pneumonia in kidney transplant recipients. Clin Transplant 2002; 16:450.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?24/51/25402/abstract/55\">",
"      Segal BH, Freifeld AG, Baden LR, et al. Prevention and treatment of cancer-related infections. J Natl Compr Canc Netw 2008; 6:122.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 1401 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [0604-118.195.65.243-684EC2BD62-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25402=[""].join("\n");
var outline_f24_51_25402=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H882523\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      GENERAL PRINCIPLES",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      EPIDEMIOLOGY AND RISK OF PNEUMONIA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      Neutropenia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354232681\">",
"      Glucocorticoids",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354232690\">",
"      Biologic agents and lymphocyte depletion",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H354232721\">",
"      T-cell suppression",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Autoimmune and inflammatory conditions",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1418604\">",
"      HIV infection/AIDS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1418611\">",
"      Transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      ETIOLOGY OF PULMONARY INFILTRATES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Infectious",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1420650\">",
"      - Site of entry",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Noninfectious",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Radiation-induced injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Drug-induced injury",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Other mimics of infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      INITIAL EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1420151\">",
"      Hospital admission",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1420166\">",
"      Diagnostic approach",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      DIAGNOSIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Historical clues",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H1420612\">",
"      Hypoxemia",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      Radiographic clues",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Chest radiography",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Chest CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Invasive procedures",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1420235\">",
"      - Skin and CSF sampling",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H1420242\">",
"      - Lung sampling",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      Microbiologic assays",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Pursuit of a unifying diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      SELECTION OF INITIAL THERAPY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H882523\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/1401\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1401|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?4/10/4266\" title=\"diagnostic image 1\">",
"      CMV pneumonitis 2",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?7/19/7472\" title=\"diagnostic image 2\">",
"      Peripheral lung abscesses CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?31/2/31779\" title=\"diagnostic image 3\">",
"      Nocardia pneumonia CXR CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?27/21/27988\" title=\"diagnostic image 4\">",
"      RSV in neutropenia PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?1/39/1648\" title=\"diagnostic image 5\">",
"      Aspergillus lung abscess PA",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?25/0/25605\" title=\"diagnostic image 6\">",
"      Interstitial pneumonitis CXR",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?38/17/39185\" title=\"diagnostic image 7\">",
"      CMV pneumonitis 1",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?20/52/21313\" title=\"diagnostic image 8\">",
"      Interstitial pneumonitis CT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?22/22/22895\" title=\"diagnostic image 9\">",
"      CMV and Legionella PA",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/1401|TAB\">",
"      <a href=\"#\" title=\"TABLES\">",
"       TABLES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?11/32/11789\" title=\"table 1\">",
"      Infections by immune deficit",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?31/18/32044\" title=\"table 2\">",
"      Differential diagnosis of pulmonary infiltrate",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_table\" href=\"UTD.htm?28/8/28813\" title=\"table 3\">",
"      BAL studies in immunocompromised hosts with pneumonia",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/16/10505?source=related_link\">",
"      Acute respiratory distress syndrome: Clinical features and diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/43/20154?source=related_link\">",
"      Approach to the HIV-infected patient with pulmonary symptoms",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/30/12778?source=related_link\">",
"      Bacterial infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/5/15449?source=related_link\">",
"      Bacterial pulmonary infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/31/12794?source=related_link\">",
"      Bleomycin-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/25/21914?source=related_link\">",
"      Clinical manifestations and diagnosis of sarcoidosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/62/8168?source=related_link\">",
"      Clinical manifestations and etiology of pulmonary alveolar proteinosis in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/6/3178?source=related_link\">",
"      Clinical manifestations, diagnosis, and treatment of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/25/7577?source=related_link\">",
"      Clinical presentation and diagnosis of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/30/21990?source=related_link\">",
"      Cyclophosphamide pulmonary toxicity",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/2/29738?source=related_link\">",
"      Cytomegalovirus infection in renal transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?3/52/3913?source=related_link\">",
"      Diagnosis of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/31/27130?source=related_link\">",
"      Differential diagnosis and evaluation of glomerular disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/42/41640?source=related_link\">",
"      Epidemiology and clinical manifestations of Scedosporium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/51/34616?source=related_link\">",
"      Epidemiology and clinical manifestations of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?19/32/19974?source=related_link\">",
"      Evaluation for infection before hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/62/31718?source=related_link\">",
"      Evaluation for infection before solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?15/34/15914?source=related_link\">",
"      Fungal infections following lung transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/37/28249?source=related_link\">",
"      Glucocorticoid effects on the immune system",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/47/29433?source=related_link\">",
"      Infection in the solid organ transplant recipient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/5/9306?source=related_link\">",
"      Methotrexate-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/46/6890?source=related_link\">",
"      Mucormycosis (zygomycosis)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/18/6439?source=related_link\">",
"      Mycology, pathogenesis, and epidemiology of Fusarium infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?30/30/31207?source=related_link\">",
"      Nontuberculous mycobacterial infections in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/30/25066?source=related_link\">",
"      Overview of infections following hematopoietic cell transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/21/26969?source=related_link\">",
"      Overview of lung disease associated with rheumatoid arthritis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/29/36310?source=related_link\">",
"      Parasitic pulmonary infections in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/59/6073?source=related_link\">",
"      Prevention of cytomegalovirus infection in lung transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/57/32666?source=related_link\">",
"      Prophylaxis of infections in hematopoietic cell transplant recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/29/10714?source=related_link\">",
"      Prophylaxis of infections in solid organ transplantation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?20/49/21273?source=related_link\">",
"      Pulmonary infections in immunocompromised patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?10/60/11210?source=related_link\">",
"      Pulmonary manifestations of systemic lupus erythematosus in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/49/29466?source=related_link\">",
"      Pulmonary toxicity associated with antineoplastic therapy: Molecularly targeted agents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/33/24090?source=related_link\">",
"      Radiation-induced lung injury",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?5/25/5530?source=related_link\">",
"      Rapidly growing mycobacterial infections in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/14/21738?source=related_link\">",
"      Respiratory tract involvement in granulomatosis with polyangiitis (Wegener's)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?27/39/28282?source=related_link\">",
"      Transfusion-related acute lung injury (TRALI)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?9/4/9289?source=related_link\">",
"      Treatment and prevention of Pneumocystis pneumonia in non-HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/18/28970?source=related_link\">",
"      Treatment and prevention of invasive aspergillosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/37/22106?source=related_link\">",
"      Treatment and prevention of neutropenic fever syndromes in adult cancer patients at low risk for complications",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/60/27593?source=related_link\">",
"      Treatment of Pneumocystis infection in HIV-infected patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?24/24/24969?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults in the outpatient setting",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/1/40986?source=related_link\">",
"      Treatment of community-acquired pneumonia in adults who require hospitalization",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?35/63/36858?source=related_link\">",
"      Treatment of hospital-acquired, ventilator-associated, and healthcare-associated pneumonia in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/52/40778?source=related_link\">",
"      Treatment of neutropenic fever syndromes in adults with hematologic malignancies and hematopoietic cell transplant recipients (high-risk patients)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/55/29560?source=related_link\">",
"      Treatment of nocardiosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?2/24/2441?source=related_link\">",
"      Treatment of nontuberculous mycobacterial infections of the lung in HIV-negative patients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/35/19002?source=related_link\">",
"      Treatment of pulmonary tuberculosis in the HIV-infected patient",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?12/26/12712?source=related_link\">",
"      Tuberculosis in solid organ transplant candidates and recipients",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?23/38/24169?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors and mycobacterial infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?31/49/32538?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: Risk of bacterial, viral, and fungal infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/12/44230?source=related_link\">",
"      Viral load testing for cytomegalovirus in solid organ transplant recipients",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f24_51_25403="Risk factors coronary disease";
var content_f24_51_25403=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F78429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F78429&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=0\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    National Cholesterol Education Program-Adult treatment panel III risk factors",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Positive risk factors",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Age: male &ge;45, female &ge;55 or premature menopause without estrogen replacement therapy",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Family history of premature coronary heart disease: definite myocardial infarction or sudden death before age 55 years in male first-degree relative and before age 65 in female first-degree relative",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Current cigarette smoking",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Hypertension: blood pressure &gt;140/90 mmHg, or an antihypertensive medication",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HDL cholesterol &lt;40 mg/dL (1.03 mmol/L)*",
"       </td>",
"      </tr>",
"      <tr>",
"       <td class=\"subtitle1_single\">",
"        Negative risk factors&bull;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        HDL cholesterol &ge;60 mg/dL (1.55 mmol/L)",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    Status based on presence of risk ractors other than low-density lipoprotein cholesterol",
"    <div class=\"footnotes\">",
"     * Confirmed by measurements on several occasions.",
"     <br>",
"      &bull; If the HDL cholesterol level is &gt;60 mg/dL, subtract one risk factor.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"     Data from: Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001; 285:2486.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25403=[""].join("\n");
var outline_f24_51_25403=null;
var title_f24_51_25404="Pruritus topical therapy";
var content_f24_51_25404=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50432&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Topical therapies for pruritus",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Medication",
"       </td>",
"       <td class=\"subtitle1\">",
"        Dose",
"       </td>",
"       <td class=\"subtitle1\">",
"        Notes",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Barrier repair creams/moisturizers/emollients",
"       </td>",
"       <td>",
"        Not applicable",
"       </td>",
"       <td>",
"        Low pH products may be particularly useful",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Topical corticosteroids",
"       </td>",
"       <td>",
"        Variable",
"       </td>",
"       <td>",
"        Not directly antipruritic, may be useful in pruritus due to inflammatory skin dermatoses",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"2\">",
"        Topical calcineurin inhibitors",
"       </td>",
"       <td>",
"        Tacrolimus 0.03% and 0.1% ointment",
"       </td>",
"       <td rowspan=\"2\">",
"        Particularly useful in anogenital pruritus, may experience transient burning and stinging",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Pimecrolimus 1% cream",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Doxepin",
"       </td>",
"       <td>",
"        5% cream",
"       </td>",
"       <td>",
"        Avoid in children, 20 to 25 percent risk of sedation",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Menthol",
"       </td>",
"       <td>",
"        1 to 3% cream or lotion",
"       </td>",
"       <td>",
"        Useful in patients who report cooling as an alleviating factor",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Capsaicin",
"       </td>",
"       <td>",
"        0.025 to 0.1% cream",
"       </td>",
"       <td>",
"        Particularly useful in neuropathic itch, may experience initial transient burning",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td>",
"        Salicylic acid",
"       </td>",
"       <td>",
"        2 to 6%",
"       </td>",
"       <td>",
"        Useful in lichen simplex chronicus, avoid in acute inflammatory dermatoses and children",
"       </td>",
"      </tr>",
"      <tr class=\"divider_top\">",
"       <td rowspan=\"4\">",
"        Local anesthetics",
"       </td>",
"       <td>",
"        Pramoxine 1 to 2.5%",
"       </td>",
"       <td>",
"        Useful for pruritus on face and that associated with CKD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lidocaine patch 5%",
"       </td>",
"       <td>",
"        Useful in neuropathic pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Eutectic mixture of lidocaine 2.5% and prilocaine 2.5%",
"       </td>",
"       <td>",
"        Useful in neuropathic pruritus",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        5% urea + 3% polidocanol",
"       </td>",
"       <td>",
"        Both moisturizing and anesthetic properties, not available in the United States",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     CKD: chronic kidney disease; %: percent.",
"    </div>",
"    <div class=\"reference\">",
"     Patel T, Yosipovitch G. Therapy of pruritus. Expert Opin Pharmacother 2010; 11:1673. Copyright &copy; 2010 Informa Healthcare. Reproduced with permission of Informa Healthcare.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25404=[""].join("\n");
var outline_f24_51_25404=null;
var title_f24_51_25405="RBC antigens ethnic popul";
var content_f24_51_25405=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F78046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F78046&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=6\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Genetic differences in RBC antigens in different ethnic populations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Antigen",
"       </td>",
"       <td class=\"subtitle1\">",
"        Present",
"       </td>",
"       <td class=\"subtitle1\">",
"        White, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Black, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Native American, percent",
"       </td>",
"       <td class=\"subtitle1\">",
"        Asian, percent",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"5\">",
"        Rh",
"       </td>",
"       <td>",
"        D",
"       </td>",
"       <td>",
"        85",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        99",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        C",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        19",
"       </td>",
"       <td>",
"        46",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        c",
"       </td>",
"       <td>",
"        80",
"       </td>",
"       <td>",
"        81",
"       </td>",
"       <td>",
"        53",
"       </td>",
"       <td>",
"        27",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        E",
"       </td>",
"       <td>",
"        30",
"       </td>",
"       <td>",
"        11",
"       </td>",
"       <td>",
"        40",
"       </td>",
"       <td>",
"        22",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        e",
"       </td>",
"       <td>",
"        98",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        59",
"       </td>",
"       <td>",
"        78",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Kell",
"       </td>",
"       <td>",
"        K",
"       </td>",
"       <td>",
"        9",
"       </td>",
"       <td>",
"        3.6",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        k",
"       </td>",
"       <td>",
"        99.8",
"       </td>",
"       <td>",
"        99.99",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Duffy",
"       </td>",
"       <td>",
"        Fy",
"        <sup>",
"         a",
"        </sup>",
"       </td>",
"       <td>",
"        63",
"       </td>",
"       <td>",
"        10",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        99.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Fy",
"        <sup>",
"         b",
"        </sup>",
"       </td>",
"       <td>",
"        83",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        9.2",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Kidd",
"       </td>",
"       <td>",
"        Jk",
"        <sup>",
"         a",
"        </sup>",
"       </td>",
"       <td>",
"        77",
"       </td>",
"       <td>",
"        91",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        73",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Jk",
"        <sup>",
"         b",
"        </sup>",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        43",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        77",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Lewis",
"       </td>",
"       <td>",
"        Le",
"        <sup>",
"         a",
"        </sup>",
"       </td>",
"       <td>",
"        22",
"       </td>",
"       <td>",
"        23",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Le",
"        <sup>",
"         b",
"        </sup>",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"4\">",
"        MNSs",
"       </td>",
"       <td>",
"        M",
"       </td>",
"       <td>",
"        78",
"       </td>",
"       <td>",
"        70",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        N",
"       </td>",
"       <td>",
"        72",
"       </td>",
"       <td>",
"        74",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        S",
"       </td>",
"       <td>",
"        55",
"       </td>",
"       <td>",
"        31",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        s",
"       </td>",
"       <td>",
"        89",
"       </td>",
"       <td>",
"        97",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        P",
"       </td>",
"       <td>",
"        P1",
"       </td>",
"       <td>",
"        79",
"       </td>",
"       <td>",
"        94",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td rowspan=\"2\">",
"        Lutheran",
"       </td>",
"       <td>",
"        Lu",
"        <sup>",
"         a",
"        </sup>",
"       </td>",
"       <td>",
"        7.6",
"       </td>",
"       <td>",
"        5.3",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Lu",
"        <sup>",
"         b",
"        </sup>",
"       </td>",
"       <td>",
"        99.8",
"       </td>",
"       <td>",
"        99.9",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"       <td>",
"        &nbsp;",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Anne Secord, MD, Qun Lu, MD, and Dennis Goldfinger, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25405=[""].join("\n");
var outline_f24_51_25405=null;
var title_f24_51_25406="Pathways endothelial cell";
var content_f24_51_25406=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ONC%2F76708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ONC%2F76708&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 559px\">",
"   <div class=\"ttl\">",
"    The pathways within the endothelial cell that contribute to renal cell carcinoma progression",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 539px; height: 421px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Vascular endothelial growth factor (VEGF) binds to its receptors inducing vascular growth. Several agents block VEGF either by binding to it (antibodies), blocking receptor signaling (small molecules) or by blocking at several steps inside the endothelial cell.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Atkins, Michael. Nephrology Forum: Management of advanced renal cancer. Kidney Int 2005; 67:2069. Copyright &copy; 2005 Blackwell Publishing.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25406=[""].join("\n");
var outline_f24_51_25406=null;
var title_f24_51_25407="Heaney needle holder";
var content_f24_51_25407=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=OBGYN%2F57317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=OBGYN%2F57317&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Heaney needle holder",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 236px; height: 450px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAHCAOwDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD6pooooAKKKKACiiigAooooAKKKKACiikVgyhlIIPQigBaKKKACiis/wAQ6rBoOganq92kr22n2st3KsQBdkjQsQoJAzgHGSKANCiuJXxxqLAY8A+LufVLMf8AtxTz411IDP8AwgXiz/yS/wDkmgDs6K41fGept08BeK/xNiP/AG5p3/CYap/0IXin/vqx/wDkmgDsKK5NfFerMePAnib8ZtPH/t1SnxTq/OPAniTP/XfT/wD5KoA6uiuUXxRrBHzeA/EgPtcaef8A26pp8U61njwF4jI97nT/AP5KoA62iuUPijWMceBPEhPvPp3/AMlVXbxX4jDDZ8PddI9Te2A/9uKAOzori38V+JAPk+HmuE+99YD/ANr1qeDvEUviCHUhd6Vc6Teafd/ZJ7a4ljkYN5UcoIaNmUgrKvf1oA6CiiigAooooAKKKKACiiigAooooAKKKKAPlHxRqmpeG/iz4vs76HWZtJmmZr+e2DOk1jcxEsjsRuUxIsjRMGCx+TIMAO7BPgdruq/Dbx7Y+HvEU9tNofjFEv7KeAfu455CQoAUbFZiAjKuQDswdoyez/aMgS28TeHGdZDaa+o0q82nPMcySwbRsfn551PyPuDkbW4FeY+PdCutS+CN3e3Vw7al4U1kvEzK6SR29wI96E5Id/POS4ZvuNhuaAPsqiua+G3iePxn4E0XX4goN7bhpVVSAsqkrIozzgOrAHuBmuloAK5X4sf8ks8Zf9gW9/8ARD11Vcr8WP8AklnjL/sC3v8A6IegDqqKKKAK2p31vpem3d/fSCK0tYXnmkIJ2IoLMePQA15fF4m1nUppWu9Sa0a3Bk1SDTZrWNfD8RQuhuWm3tK+M52AINjfLxlvUdSs4tQ066srgZhuYnhcYB+VgQevsa8Ta+jB0mAG5mjtWiurJGncz6ZJHFIklxqzmdS0aurDggYj2DrtIB3/AIM8U3N59gt9VVpLfUYzNpOq7FjTUItoddyZ/dzFMvtwNyqzAJhkTta8GC2t0v2i41KBF1aS0MurWjRs/iW8SEiJbQPLi3eKRYyCQFMigHaoIPqngPXLrV9I8jWYha+ILDZDqVrkZjkKBg3ykjDKQw2lgCSuSVNAHS0UUUAFFFFABXGfD/cdc8e7+v8Ab36fYrTH6V2dcn4KIbxD47K9P7bQfj/Z9nmgDrKKKKACiiigAooooAKKKKACiiigAooooA8h/aZ0eXWfB+gw2xiNyNetBEkiK6yM+6MIQ3GCZBnORgc1lfDWw07xB/aMdzHK9t4y8NwyzSPKJDLJC0sE5yHYggTQcE5GcEKQVXufjCmdA0aVY/Nmh1/S5Ik3Bdz/AGuMYyfUEivI/gnLbaZ8Sjor3pnvdOur/SIJ7niSS2R5CLePD4Kx+QkhG3I+0ADYFzIAdD+yTeXVv4R17wtqcqtfeH9Ult2iDZ8pG7D2MizHP1r3WvnnwfBF4U/a38T2DboYNfsDdWy44lkOyRz0HdJ+fb1zX0NQAVyvxY/5JZ4y/wCwLe/+iHrqq5X4sf8AJLPGX/YFvf8A0Q9AHUqNqgDoBilpFO5QR0IzS0AFeV+NLf7N42ghuPt4tLqW2vIYtFgxdXRSTy5IZyow9mhl8yQPkkznBwMH1SuU+JdjJc+GpLqC8v7GWxcXDXFgQJ1hHEwTKtk+WXIXBywXvigDzTR9SnfyiNRtInuntra7vLa5kj0a4h2Ogs9JbzRifC4yuCGDnI+7R4c1JfDmp6dcWINlp+nQR2t5ocjo99p+ntuInvXaZiVjcpIgH+rilkG3ByF06wmj1m1t4bfTIb2waGX+yXjL6JpsRumCy2rLAN16TkAkglnk/u7BFZ/Z44LG1vINdv7WcwsLCSNz4gvVWaaMvqKsw32WWOAw24dQcdCAe9UVwfwd1ttR8MtptzqemaneaQ4tWu9OufPhuItoMUikkt935DuJO+N+T1rvKACiiigArkfA6eX4g8eDGM64jfnYWZ/rXXVyvg3/AJGPx3/2Go//AE3WdAHVUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBwfxkRpPDmkKrsmde0wFk4Yf6XHyPfOPSvDLTU57b9qaPw6l1c/ZV1G/k+WRlKG5tyx2AkqmCxb5QCx5bJwF9z+NU723gy3niA3xavprgkZAIvISCR3Ga8IvZnh/bKt7IRh5E1Ez+apIJWWxj+Urnb8oXqACcnOeMAGl441d7X47/AAn8SQtLcG5jGjTfalWOVZlmkt594XKhlaZs7cqSp2kjBr6hr5V/at01vC1r8PZbR5GsdNvLow4+VoVLQvHEp9FVCq+yrnJGa+qqACuV+LH/ACSzxl/2Bb3/ANEPXVVyvxY/5JZ4y/7At7/6IegDprZSlvErdVQA/lUlMhfzIUf+8oNPoAKQgMCGAIPBB70tGBnOBnpmgD5/m02G01c+F7PR9G1q7tbgSDwy8SW0LbJF26k05Q7pPIe3Rl6E+bgPyKbJLbXWh3epQ6xqt1pSMbW88W2tu9vrJl+1A/ZI1EG4xZKLwQoOQOF2V1/xY0UX+qLBeWM+s6Rq1qIpdGhm8hrq4gfzIgsm9AuVaVmyeRAuMniuQ1S9ZbrWfEs2sRx31kZrKbxd9middAQTRuLD7JvYTyfMyGVQT+8A3NzgA2/Dc114Y8e6XDeWMGni5hayubXRoj/ZFpAbiX7M28quLhppDGVA58wkha9nr5+1eymDX+iaRo0WnXl8l1NpnhpDF5d4xlXGqPcKmYXUNuEYYMvlKqsOh9u8M6oNZ0K0vtvlyupSeLOTFMhKSxn3V1ZT7qaANOiiigArlPBeR4i8d55P9tR/+m+zrq65TwZz4j8d8jH9sx/+m+zoA6uiiigAooooAKKKKACiiigAooooAKKKKAPP/jxHdy/DO9XTLc3V+byw+zwBgpkk+2w7VyemTgZrN8LfDCFfHtx8QfFzxS+J7hgYre3Yi2sh5YiVQTzK4UY3nAJPCggGus+IZA0G0DMFzq+mYznr9ug44rN8XX/2q7vNH1VGg07y8yeU26SWB9qi5iIG5HhmxuxkIrK5OSoAB4R+21rMgvNA0TfbvAYmu/L8uQSRtuK7t2djAgEAYyMMT95a+rY3WSNXQhkYAgjoRXyF+1Rf2Wm+P9Ni8S6ZHrly3h1YUZJ3tVinMso88KuSeVyEJI5IOeDX1f4cW4Xw9pa3rq90LWITOuMM+wbiMcdc9OKANCuV+LH/ACSzxl/2Bb3/ANEPXVVyvxY/5JZ4y/7At7/6IegDprdAlvGg6KoA/KpKis232kDZzuRTn8KloAKKKKAOU+JVg974bDwiXzLa4jkLQsyyrEx8ucxspBD+TJLtI74rzPUr+LTLiF7bU4ba/gS7iivUZ5LTQwY1IGqATsr3L/dDv96Qk4faor2/UrY3unXVqJpoDPE8Qlhco6bgRuVh0IzkHtXg/k3ySaTf3Nukd1cQLdWstkjfZLm5+yqzTa1hB8qTISjcMMMcDaTQAmp2i31rd6fHp0c9jrdzPdHREuljHiuYpFJ9qgnM7G2iUqH2g42DHzE7V7n4R67b3Wq+LdDjuraa40+/M7xW8XlrbGbJeA8kM6SK+51OGLZOCTXHC4urlbxLp75/7R3tqIku3B1JmtchNDYyjMe4A8gFlZQSQu2tnwnqkQ8caRDC9rcPaeZpLLGy+ZpcDwLKlpcHznZ5g9tjzOVJEgyGO0AHsFFFFABXJ+CgF8RePFzn/idRn89Ps66yuU8Ggf8ACSeOz3OsxD/ynWdAHV0UUUAFFFFABRRRQAUUUUAFFFFABRRRQBzfxARX0O03H7uraaw+v22Cl1RZ7TxJYyeZKLO8kCh9xPkTqPukf3JEDKckBXRCAWfIj+IxI8P2mELf8TjS+Aen+n2/NaWkXX9rWLpfwKl1bTeVcRYO1ZUIYMpIBIPyup9CO9AHyb+2ciJ8TfD088gMB01FZAu4gCaQk7cjOQemR06ivrbw4c+HtLIOQbWLn1+QV80/tO6Db6/8TrSG7u4bG2g0mza4u5l3CCKTUDCZB8wC7fMySxwRxx1H0f4N8weEND85Ckn2GDch/hPlrkUAbFcr8WP+SWeMv+wLe/8Aoh66quV+LH/JLPGX/YFvf/RD0AdLZrstIFxjaijH4VLUdud1vGR0Kg/pUlABRRRQAV4bqdlZaTqixMfsa6lqM0KrBCjxa9OZbpEsbsiB9kaIYxluNrscEpuT3KvC/EZt7Xxd4ke71G30Syl1WCwu9Ruo45IruB4IZP7O2MwI3m4lkMoHygNkgc0AVVtrtbqaL5bbUIIbeLUUkWURaUj27IU0LZF8szLnhd2Sqj5+TVeW7vZTp00T3220azvYYQz/AG5Yoljkml1lT/y0aO2KRMBg7iucNxZ8PWDJc6boqaNFHe6eYLmLwuZ4XHhtC0qm9W68thPISVkEbZbL5IOBjLMTanp+m6kupy33h3VIFsE1K0gMWoa5fSb4U+2gRKVtkAkUKSeFQlnOAAD6Roqh4fvH1DQdNvZCpe5topmK9CWUHj86v0AFcl4McnxR49TAwNYhP56faf4V1tcj4LUjxV4+bsdXhH5afaf40AddRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHJ/EYu1jolvGu7z9asARjJwk6ykj0x5efoDUqteWnjfZgyQ3UJJO1RmNejZz1jY7CAOVnjOTsapfFsQm1DwvGxIU6qG49Vt52H6qKi1XSL621Wa+0QRZuP30kchOBcooVXGDwHj3RsecfuyBw2QDwT9p/5/FHieLew/4o63fGOONWi7+tfT8EflQRxlixRQu498DrXg3xVX+0PGviKU206pN8OL50WRSrbhMrBSvUMDjI98V7fot4uo6NYXqEMlzbxzAjuGUH+tAF2uV+LH/JLPGX/YFvf/RD11Vcr8WP+SWeMv8AsC3v/oh6AOjsFKWNurdVjUH8qnqGzfzbOCQdHjVvzFTUAFFFFABXiviW7urDx54jls76HS5UuLaZtQ1Td/ZcMQS2DLKPMVTOSPkzzgEAqfmHtVeHeP0hvvFuu2xW2uruGQT2+m6lFu0y4KWsTPJdOY2EexDlTuTJOMkE0AZhgtb20sNKbw7qtzZW8nn2Pg3ULtIr7zEuGBv2lefcYsMyiNsqzc42jzKSxu0h1a08QHxNaygzR2V943toIWOostwV/s1LVS2zIKN56jkRg8rzRfwtajU2vZdfu0mMkcx2yL4junWeJnisPlj3WAzuIA4BfheMWtQvbqHUri5l1XT9Ov7RLmKbxNp6BtM0tPtSt9lmgafY1y5OW43AugAbb5igHpXwfkmb4baHFdRiKe0iayeMf8szC7RbfcjZjPfGa7GuS+FsUUHhEw22fIi1LUY48uX+UXs4HzHJPAHJJ+p611tABXI+DCP+Ep8fDA3f2vCSfb+z7SuurkfBakeKvHzdjq8I/LT7T/GgDrqKKKACiiigAooooAKKKKACiiigAooooA4/xZIreO/A1szHd9pu7hVB/u2zpk+3739RWv4t8T6P4R0Z9U8Q30dnZqwQFuWkc5IRFHLMcHgc4BPQGuf8YOIviX8P2IGZJL6EEjPJty+OnH+r9un4Hyn4tawbL9qz4dRXTefZJbRrHBIcoks8k0W8DoGyIznr8i+goAyvH3xB1+yOqeOtS8D3dhp1zaP4b06PUbryJGWXfKZpIfLLH/VJxvUDOAWyWX3n4SkN8K/BpH/QGsx/5ASuA/a805b34N3NwykmwvYLhSGxgkmLJ9eJSMe+e1dh8C7xr74P+EZnVEK6fHDhTkYjGwH6kLk+9AHdVyvxY/5JZ4y/7At7/wCiHrqq5X4sf8ks8Zf9gW9/9EPQB0WnoI7C2QdFiUD8hViqejuZdIsXbq0CMfxUVcoAKKM0UAFeF+NGguvE/iewuHgu2vdRNnF4fnAVNbZdOtpEjMpBMLRs4cOCoJKgkcEe6V4b4pu3HiLxXp73SW1hqetJbTW8qof7ZDadbR/YYmMqtG7EkeZtABK5cYKsAZd1aQSQ6xeO1xFBpTTJqF9ZQOmoaDiJCtjpzCABoxyC4wPLZ2+XduZb/T76OdJI4lhnkE88UUscg0ZIhCspm1xCqbbplJbOOGCEj5RmS0juFu1j8tRe+H7JPLhlWMnwTFJaMN275vtxIQEA5PyAnaWqaS1tLy0spIrKFrTWJ0lgZbAmHxXK1uD5t4q2x+zASMXG7Az5jgDAkAB6z4DZH0O5eMlkbU9QIOc/8vk3T2roq4j4MPNJ8PrV7mMRSteXxMQl81Y/9Mmwqvk7lAwA2eQAa7egArkPBchPizx9H8u1dWgb3ydPtB/QV19cl4MjA8UePZO7axCv5afZ/wCNAHW0UUUAFFFFABRRRQAUUUUAFFFFABRRRQBwXitPO+L3gFGfCRW2p3AXHVwkKA/98yv+dfN37T+tNpf7QejajHNGz6XDZzKFGTGUlaQBhzzzn6EV9Oa7psd58VPCN1JJIr2On6lKiq+AxZrWMhhjkYcnqOQOtfKnx40Wbxf+01daBZusNxcm1txI4LAEwI2SB7H9KAPpr9oTTG1f4MeK7ZDgpafauPSF1lP6JWf+y+xf4F+GCSDxcDj2uZRW9rd2PF3wZvr2K2b/AIm+gPOkGRuHm25YLnpn5sZrkf2S5ll+CumIoGYbi4RsevmFufwYUAex1yvxY/5JZ4y/7At7/wCiHrqq5f4qY/4Vh4w3Yx/Y95nP/XB6ANzRcDR7AL93yI8f98irlZ3hwk+HtLLdTaxZ/wC+BWjQAUUUUAFeK6rcxw69eqtxZ28t9rUgku9RnmjtlhCpC0UDo6qt8dp8vBDhQ/IFe1V8efFbxh4907xfrsehwQ3Hhy3vJ5rUXFhBPsKsyTMu9S2BJHNk+x7YoA9J01f7Rk0HT4LWS8+xSWl3aaBqNwyanpDKz5v7pjPmVRnPlED5XiUBOdzdNki2NftqVtc2+uXVtZ3GvyJEYvFcwWWFbLyAsgt4wQEZwvIVjg53V2vhDwu+t+G9J1nU9evbm61O2tL28K2lki3MgRXTdiDcVVsFQWOMdTXgCfFP4haXLe69pXg3SL+0sEk0wa6ujzqPs0Tk7cpJtRARnAwoI55FAH0Z8DoxF8K9AUQrBmOR/JXGIi0rnYMcYGcfhXdVi+CNPi0nwbodhbxtHFbWUMQVh83CDr7+vvmtqgArjPBUh/4TX4gxEcDU7ZwfrYWw/wDZa7OuJ8EHPjv4idMjUbUfh9ht/wD69AHbUUUUAFFFFABRRRQAUUUUAFFFFABRRRQBztw7N8Q7BMfLHpdwc+haaD/4ivmrwQh1r9s7VrtHUpY3F2zZBOdkRgwPcEj8q+jrdjL8UL9WU7bbRrcoQOMyzzbs/wDflcfjXgf7NsEmpfH/AOI+uRIfsqvdISMEBprreoz9I27dj+IB7Z8IbKKy8CtoZ82aDTL6+05RcYZmhjuZVjDev7vZ2GfpXAfsabl+FuowujJJDrE0bhux8qE/1r1Lwi0aa14vt4htEWqq23HTfaW7k++WZj+fpXj37JV1GNR+IumWzM1ra6qJYi2CSrmVQSQcHiIf4nNAH0PXL/FNN/wx8Xp/e0e8H/kB66iuY+KLbPhn4ubjjSLs8/8AXF6ANjQGD6FprLjabaMjH+6Kv1neG0MXh3S42BDLaxKQRgghBWjQAUUUUAFeQ+LPh3eOviq3s7GO/sdailFvJFMI7myll81nUo+I5IjJNI+/IkHmFQGAXb69RQB8kaJ4+1nS/GVi0/jKx0bSvDdpaaZq2jahIS0rRIq3KwRqrCRg0bAPuznAB2nn0fwP4G12D4Ur4HvNOvLH+0FL6pfXk1vJ5Ydl85IQjSF3YBtrMFC7t2SRtPmPj/wFE/wSuPHCtGt1qkEF7dxrwDPJOD5oOWyG342DAywOeMV9fUAFFFFABXEeCUVfHnxEYffbULXP0+wwY/rXb1x3gpP+Ku8fzZyG1WBR+Gn2p/8AZqAOxooooAKKKKACiiigAooooAKKKKACiiigDndPiH/CwNcuFlUk6dYwmPaQVKyXTZz3BEg/I14T+xLaStpXi/VXQiO6u4Yg5JOWRXYj0481fz+leo67qcltp3xV1G3kmin021MSOpAZWjsVmDIe3M35iuZ/ZB0ifTPhAk9wAF1K+mvIhnPyYSPn05iNAHpWlRRweO/EKRBw09pZXUhK/KWJnj4PrtiXI7ceteN/s/wJoXxt+KmhxsArzrcorHDbRI5GB1IAmHPTp6ivYZrURfEqzu0Zg1zpE8UigHBEU0JQk5xkec+OO55ryvwlC8X7YnjVmxibQ43X6AWi/wAwaAPeqgvrS3v7K4s72FJ7W4jaKWKQZV0YYZSO4IJFT0UAcM3wl8CMio3hmxZVAChtxwBwOpoX4S+A16eFtNx7xk/1ruaKAOEPwh+H5OT4S0nP/XGnr8JvAKnjwjo342ymu4ooA4r/AIVR4B/6FDRP/ARf8Kd/wq3wHjH/AAh+hf8AgFH/AIV2dFAHHD4X+BA+4eD9Az72EZH5Yp//AArLwL/0J3h71/5B0X/xNddRQByQ+GvgYHI8HeHPx02E/wDstOPw48Dn/mTfDf8A4K4P/ia6uigDlB8OPA4GP+EN8N/+CuD/AOJrb0TRNK0G1e20PTLHTbd3MjRWdukKM2ANxCgAnAAz7CtCigAooooAKKKKACiiigAooooAKKKKACiiigDxD4o302n/AAn+LOoNG6G61DyFK/LuUxWtrnk9PlOfXmu8+DFulr8JfB8ccaxg6XbyYXuWjDE/iST+NeSfHjU0X9nq/wDKuH26jr9xEvH+tH26eQKcjsI89vuj6V9B6RYx6ZpVlYQcxWsCQJ/uqoUfyoAz9bVE1/w7P5UrStcS24dCAEVoHc7uOQTEvTHOPpXm+rGe0/as0SRCqwX3hqS3bLcvsmdyAM+yH8/evRvFs32W3027GMw6jbIP+2sggP6SmuB+JPlWvx1+E95IFUOdSt2kIxkmABFz9WOB70Aet0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUmRnHcc0tABRRRQAUUUUAFFFUtbvE0/Rb+9kbYltbyTM2cYCqSTk/SgD51+Lipd+EvhH4eYpEdb1qG7JVCMb25Psc3PPPWvpevlvxJHLqXjT9nzRCspubOxtr6QucMQFiY5B7j7O2f8a+pKAOf8fwRT+D9TediqWqC9BC7jugYTLx9Yx7+nNcJ8fkWDUPhvqhkCfZvFNpEx4GEk3bjnrj5enf8K9P1iwj1TSL7T5ywiu4HgcqSDtZSpwRyOteRfHMf2j8BrHWispksGsNUAVfnHzIGI9CFkY9e3WgD2miiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACub+JUZm+HfieFWKtNplzEpAyQWiZR6dzXSVzPxGQS+GVhZnVZtQsISUOCA95Cp/nQB4vqU39oftkeHbSEmRdF0swy4GNubeVgTz/02Tp6ivo6vn/4dWN3L+1h8Q7+6jVRb2McOC24/OIDGR9UjP0zivoCgAryvWNNCfADxVpSu8q2VnqdvEBgttheYRrwP7qoMfhXqlczpNml2PFumTljbyXrx4ywO2W3iZsenMjdD+vQAm+Hupza14C8OandFWuLzTreeUqu0b2jUtgdhkmugrzn9ne/fUfgx4XllBEkVu1sQeo8qRowD+CCvRqACiiigAooooAKKD7UUAFFFFABRRSDOeQPzoAWiiigAooooAKKKKACiiigAooooAKKKKACuV8dMz3fhWyQkfa9ZiB9CIopbjn/vzx74rqq5fxDELrxx4TiZWP2Y3d8uDwCsQhyR6YuCPxFAHnvwUcah8Xfi7qYRdg1CCyRuhzEJEcY/Bee9e1V4v+zDNHqOk+NtYjG7+0PE13KJMffQhGB44/jbp717RQAVzemloviBrsO5/KlsLK4CkjG8vcIxHfokec8dMd66SueujHB8QNOwUWW6025VgcZYRSwlccZ481+/fpQBxX7OiGy8N+JtGDs8Gj+I7+whLH+BWVhgduXJwPX3r1avLvhcRafE/wCKelqwZYtQtb37uDme3DHpxj5fr616jQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFBP60AFFFFABRRRQAUUUUAFcH4yvLiy8RX+oxcR6T4bvJi4GSjyOjLxxn/AI9279veu8ryX4j6kkNr8VbgzN5dt4chsxgFtkzLdNjHbPnRZPuM9KAF/ZYtIrX4H6A8cSpJcPcTSkfxt57qCf8AgKqPwr1muI+CFhHpvwh8IwRBQr6bDcHaMcyr5h/VzXb0AFYWvJFHr3hy6eUxyfaZbZRzhw8LsR9cxqfwrdrC8YW8c+n2cjtse31C0mSTaCUxOgbr0yrMpPoxoA5DTJxY/tFa5YRsAup+Hba/kUIOWinkiB3fR/xz7V6ZXmXimWHTfj54Gn8tfP1bTdQ08uqDcRH5cwDH0GGx15J9c16bQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABXg/xx22vwt+K17CQst1qNpDuz95QlmhH/oyveK+fvjDayT+C9F0qUES6543Nu6TEbvLNxMqleemEjwTnhqAPbvDFh/ZXhrSdPyp+yWkMGVGB8iBeB2HFadFFABWH44iabwbriIGMn2KZk29dwQlcfiBW5TJ4kuIJIZVDRyKUZT3BGDQB558SzaW3jH4aazKBuTWHso5hyQLi1lXaB0wzKnPbFejV4t8RbiG0+BPhvW8lBoVxpV6BMpdlaOaONge+RubJxzg+te00AFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAyaVIYXllYLGilmY9gOSa8A1lX1Gf4DafcFTPe3H9sSudxHmRwrM4APYtIcZ6cV7P45ufsXgrxBdb1j8nT7iTey7guI2OSO/0rz3X7Hz/j98PdPslWO30HSb28ZFXCiN1FuoA7c7fyoA9dooooAKKKKAPHvifaw6r8B/HFjKZI/sc145VVAKmO5M0Yx/dKhPwNeo+HdQTV/D+malErpHeWsVwqucsA6BgD781jxafaam/jDR7jbsvpMTIvJ8uW2jjyQRjna/HI4/Cs/4HalHqnwi8JzxIyCLT47RlbqGhHlN/wCPRmgDuKKKKACiiigAooooAKKKKACiiigBCQoJYgAckntS0UUAFFFFABRRRQAUUUUAFFFFABRRRQBzvxAXzfCtzbEgC7lt7Q56fvZkj59vnrjNMf7f+0zrMqMxXTPDcNm4PADST+bwO/AHP/1q63xzBNdz+GbSF3RZdYheQquRtiSSbB9ATEBn3HrXJfDfbc/Gn4r3sbCSLzdOtUfB+Vo7ch1B9mPIoA9VooooAKKKKAMOJoYfHF0rHFxd6dEVGB8ywySbj68Gdfzrmvgpdibw/rliCpbTPEGp2jbUKgH7S8nHqP3g/l2rd1eEReO/Dt6do3W15Y5yckv5Uo4xg/6g9x+OTWF8PSLX4gfEjTY4lijXULa+UABdxmtY9zbQAOWjb5upIOckE0Aeg0UUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAHO6mrT+OdCj4McFpd3J4ztfMMa89siSTr1wfSuT+CEMrTeP7+cNm68U3qxtjCtHGVjUr6/dIz6j2rodOKyfEvxFcycR2mmWVuHcYCkvcSPg9MYMX/AHz274n7PEst18JdJvrhGSe/mu7xwW3HMlzKw578EUAekUUUUAFFFFAGJ4l8xLjQ549xWLUE3gDPDxyR/wA5BXHWcgsv2jdStYogial4Zhu5XwfnkiuWjHfrtcfkPx6zx48kPhqa5heWNrWa3uWMQyxSOZHcfiqsD7E1zPjKKe2+Mfw7vrdcR3Kahp9y3qpgEyD/AL6hJoA9GooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAPObvUJdP8NfFDWin+pluZITjG5YbKJMDPbfG/tnNa/wAHrVbP4U+EIVXZ/wASq2crjGGaNWb9Sa4nxLqcq/s1eIdWn2xHVLW8ukEp/wCWd3M7Rr167JUA98D2r1rSLFNL0mysIWZorWBIFZupCqFBP5UAW6KKKACiiigDO8R2v27w9qlptZ/PtZYtq9TuQjA/OuF+KN7DceCfDHifzXhisdW0zUt6SeWAkkixPnI5UxzuMHHXJPGD6XXl3i2yh1j9nvV7OBGP2XSpUjVQWYS2oO3HOSQ8IweuaAPUaKoeH9Sj1nQdN1SAYivbaO5QZzw6hh/Or9ABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABWX4r1CTSfC+sajCpeW0s5rhFHcohYD9K1K5X4jTsuiWlskyw/ar+2SV2m8oCBJBNcZbIwPIimzzQBw3xdjs4Ph14b8IJIki3OraXossaP9zDRvsYjodqqccHBBHFex18n6vrJ8RfFfwJpMg1SG3l119ZSO8R4POhJEsD+UcqVA8yNX3bsKysqgKK+sKACiiigAooooAK57wtbxR22s6dJFuji1G53rIVYOJm885A7Hzuh/GuhrmtCQW3jPxRAGz5/wBlviMHgtGYep4/5dxwP60AY3wKkvF+GGk2GqMh1HSmm0u4VG3BWt5niAz3+VFrvq4D4eT29r44+ImiQQNEYNTg1H7uFYXNtGSR65kjlJPqa7+gAooooAKKKKACiiigAooooAKKKKACiiigAoooNABRRRQAUUUUAFeVfGqc6jr3gXwpDJGjatqMsl0HOFayjgcXKE9t0cjKD15OCOteq18x+KfFM9/+0vPdWjytZeHNIvIYxasryTSrC5cRqwI83zZBHgggmMdelAHM+EvFDfEHWPD/AIhvXjj17wzr5mu/3i5bS7mcHeXYkskDsVwPlVHHTrX2FXxZ4cstF8L6ldeNLTRJtZgu9dutEtdKsr0CCYSwRywBQq5dH3OpjYEBXUEEqQ3tPhP4oRWmkytLd2F1pmnadHc3YnuZEn01z0tJJXTE8n3lUHa/7oh9zHewB7VRXI6J4zk1LUjYS6BqVpcrbrdSJJLbsYEbG0SgSZjY5JCsOdj4ztNXfBPjPQvG2my33hy+S7hhk8mUAFWjfGcEH69RkHsTQB0NFZXibXrLw5pEmo6h5zRqyxpFbxNLLNIxCpHGi8szEgAD6nABNedP8SvGepR3yeHfhfrgl8tTZyapNHaqzHOTIrEbccHaGJPT5etAHrVeeeJXe6u/G9xp7p9os7KztITKmVS9jMs8ffk/6RAePWsA6f8AF3xcWsNcutF8JaSJl8240qSSS+kRecRtuKqrHjJwwx0IyD197bjwT4f0+20WK5e2SctczSwPdmUsSzvMy5kDOxJMoVwCSWG2gDCgvfL+LvhjWd86WnijQXtBAYSoE8LC4QuexMckwAP9w9a9Qryf4g2kEfw30fW9FhaOz8MajDrQgtJI5RNDEzCZVcNgjy5JTk8krz1zXqdpcwXlpDdWc0U9tMiyRSxOGSRCMhlI4IIIIIoAlooooAKKKKACiiigAooooAKKKKACiiigAoorn/GutjRdJHl3Vta3l2xhgmuTiOLCM8krZ42xxpJIQSAdm3ILA0AWdW16GxvIrK3tbvUb9yCbazVWaJTnDyFmVUXg4LMN2CFyQRXPX/jq10/fb6zrPhLRtSCMRb3WsKzKedu4EIevXGcYOM15p4Ks9U+KV7NLY3WoaT8Nop382RWMV54jm+68kkihWEZwFbGBgbABj9365pXw/wDB+lRLHp/hfRYNsflbhZRl2XGMMxG5vcknPegB39peIXtI7jT7HRdUhdch4dRaPP8Au/u2B5zzuFU7vx5Bpl3NBr2heItOWNVYXI097uCTJx8r2/mY57OFPtTj8OvDdvMbjQ7BfD97gAXOjYtG4ORuVRskGf4ZFZT3FJp+tapoV/aaT4veGeO4Kw2mtQp5UdxKeBFNHkiKRj90glHPA2MVQgGDefFWy1y1ns/h9DdarqhJhe5ltJbe00495bmSRVChQGbYMs23bgZzXzVrsNv8PfitbaxetdS6ZqEFxG95KjTSvK8bRvLIjEbiZCWdMjG54/vKa+19agN1o9/bqJC0sEiARrGzHKkcCT5CfZ/l9eM14dfeEbDWNb0TwbqVvFPqN3arfalGUKjT9NV428hCH4aSaKNPlPyqrtjczSSAHi/hzU5fEvw+tjY6Jqeqa7Z+MBrV5Hp+nyzfuZEy211BVclANrEE4HXBre1bwhrOpXd9fp8P9de9vfFh1sPPZxZ+w5YmF8ufnLNnYRt755r6+06wtNMsYbLTbWC0s4RtjggjCIg9Ao4FWaAPkC++G7Prfihrrwz4ug0TXNRt7uySxtwG8ndIZYpIkbagVpFK+YBxHwQTz6B+yR4D1zwfpfiW68RWcljNfTwwx28ow+2IOS/+6TLgf7p9q9/ooA5f4hadqN/pFvLo8bT3dpOZfIjm8iSVGikidY5cjy5NsrMrEgblGSAcjiLPxz4nDrHd+G/GTwx4QtHolvHK/HBZjcsp9TtUDPTHSvX6KAOBTxrqkcEUg8GeMpo/vPvt7MORg8YE6kHOD0PTFcq/iyyad9VnOveG7ve0St4msZLJMNkpGLtVaMKGLECXzRycKK9opk0Uc0LxTIskUilXRxkMDwQR3FAHIaRqt3Y3b2+p2EQubiUDhUgml4HP3tk2ARlkYHnHlrjBz9KsdZ+HsN5a2Flc6/4VQmWxtbUp9tsASS0ADsqywg52HcHXIXDjBFy105PD2qDQUtLebw9qAaXT7eb/AFdrcp85txkHEbBTIgAOzy5AOPLVben65pui+Eb3XdXbUNH06FpJJ4dVfc9qVbYVGC2QSMoFLBty7MhgKAKsXjPVrtZlsPAniT7Qg+X7Y1rbxkkZGWMxOPdVbHpWH4k8da5pAhTWbzwP4WkYGRhf6nJezFQOggVIcnpyHP0OaoaLN4s+K6W+qNd3vhHwS7b7e3tm8vUdRjyCsjSj/UISBgJyw3ckFWruvCfgHwr4S2Hw7oFhYzIpQXCRBptp6gytlyOB1NAHl8fxGju/lX4taHayzgeW8vh54YVOc8NJKB045Y+vFdvY+IvE9jYpfXdrpninRWG9dR8PMRMUx977OzMHGf8AnnKSeyHpXf1xmu+CkgM+qeCBa6H4iLCUyRx7Le9IJJjuY14cNlhvwXTcSp6ggHR+H9a03xFo1rquiXkV7p90m+KaI8EehHUEHgqcEEEEAitCvA73Wf8AhEPF+meM9Pt207RtYvf7K8U6R1+xXx5FwQvy5zgs44dSrDd5gNe+UAFFFFABRRRQAUUUUABzjjrXgP7SmpXd3a3ej6SZDfXP2PRYArlAZLyVpHUnpnbaxryQAJWz1r36vnP4nl7n4xeCYP3v2WbxS0zru4Z4LezCN+B3/maAPdPB2gW3hbwrpWh2QHkWFukAYADeQPmc47scsfcmtiiigAqnrOmWetaVd6bqkC3FldRmKWJiRuU+45B9CMEHkc1cooA5bwFq15dxarpGryLNqmiXf2Kadcf6QhjSSKYgcBmjkXcBxvDY4xXnf7N1w/iS/wDHnjW5jeOfV9VEEcch3FIIo1MYzyD8sqjIODtGOMVveJC2g698StStEKvL4bgv8jndNGt2mQBjPypEOo6D8K37Ldmtr8E9Bk2sJblp5pCxPzHzXVTz/sIg/CgD1iiiigAooooAKKKKACiiigDl/iVCp8J3GoCPfNpEkeqRc7SDAwkYA9tyB0PqGI715j8b7uTxV8VfAvw4Df8AEuuZRqmpxnO2eKMswjbBHBEUnfqVPUCvbNVtBf6ZeWbHC3ELwk+m5SP6182eAtSHiD9pfRdQ1YyPdnwvbzwbchUle3Rm47LiSXj1IoA+moYo4YUihRY4o1CoiDAUDgADsKfRRQAUUUUAeS/F7QUvjrmm+XH9n8SaLMpzx/p1piS3PB5LKz7jgnECDPFdf8KdXn174a+GtTu5PNuriwiM0m8OXcKAzE+pIJI7HjtSeOZfJ1Twc5UFG1jynyATh7S5TjI9WHT/AOtXP/s5wJZfCmw0+GVp4bG7vbaOZo/LMqrdS4cpk7SfTJx60AemUUUUAFFFFABRRRQAV4J42jH/AAuj4em5hwIda1LPzAZ3Q25Rj36sg/IdxXvdeF/G6xn03UrfX1sTdppmt6bqm6E4nVHxA8agcuDJBakrjnd2IyAD3SikBDAFSCDyCO9LQAUUUUAeSfGnUbGw8PeP5bva5bw/BabDg4eZ7lEJ9MMQcnH19O3+Gmmvo/w78M6dNGsc9tptvHKqnIEgjXfz3+bNeZ/EWOLWt2j26CS48W+I47FkZysn2O0QLcMo3fdRopTxgHzOQd3PuFABRRRQAUUUUAFFFFABRRRQAV8yadpdzpn7SXhXV1jWz0u8k1DSo4UypC2yTRpvGAMPtVlA67fUGvpuvnb48Pc6LdNq32EuNA16w1yCVMtut5EKSRk/wAywHPUHenSgD6Joqvp17b6lp9rfWMqz2lzEs0Mq9HRgCrD2IINWKACiiigDkvHgDal4PDukcS6x5sjv0RUtLlyT6fdAyemaxv2e1i/4VPpU1tbXFrbXM93cQwzsWdInuZWjyTyfkKnPOc571gfHrxFdaRp2t6jpki+boWkHIyfknvZkgikGONyIk5wf+einFen+E9Hj8PeF9I0aA7o7C0itgxUAtsQLuIHc4yfrQBrUUUUAFFFFABRRRQAVxPxK0gapDDbyEx22pQT6PNNt3C3M6gxTkZGSssaKvIwZc5HWu2qtqVnHqFhPaTFlSVCu5DhkPZlPZgcEHsQDQByXwg1pdV8GQWchn/tHQ3OjagJm3sLiBQjnf/GDw27vnscgdtXmOrJrGg+IT4k0uxXUb2O08nXdLtZdk15GrKI7uCPAV5QiuMMQSB5YbKiuz8PeK9D8QjbpOpW09wFLSWu8LPDggMJIj86EEgEMARketAG3WH4x1WfS9GI09Q+q3ji0sIypYNO4O0sB/AoDOx7KjHtVjV9cs9MkjgkMlxey4EVnbJ5kz5OAdo+6uRy7YUdyK8Q8T6lrnxC8ZXnhjwzcxR6ikJt9U1KI+Zb6HbO3zwxsMeZdSbcOcgKF2LgrI4ANf4UWEfiD4i6nrts7T+G/DNuNA0SWQhzPIADc3BbJ3MWGPMAAcP6g17ZWX4Y0HT/DGgWWjaNbi30+zTZFGOe5JJPckkknuSa1KACiiigAooooAKKKKACiiigAriviPpMV3FDdXAUWMsMul6i2SCtrcbR5g7ZSRYiS3yhDKa7Wo7mCG6t5be5ijmglQxyRyKGV1IwVIPBBHGKAPMvgdq8tvaan4I1aP7PqvhuXyY42fJls2JMMgyzHGPlxk4ATpuAr1GvFPEHhbUtG8RwXmjukWv28XkaTeXGWg1GFVOy2uXwdkyElVfIMqHG4sSY+403x9poFtaa7HNpOrt+7e0lR5NrjAOHC8rkjDMF3DmgDs6p6xqVtpGmz3185WCFcnapZmJOFVVHLMxIVVHJJAGSRWVd+L9LjmS3sjc6ndyfcgsIGmJ5I+Zx8kYyCMuyj3rx7xXrGvePfFU2geH5o/wC1rbIxbzsbXQgVw0txInEt5neqIvyxtkgll30AM8L2d546+KMcM8l1/ZmgXT6nrhEjeTNqzFRHa/eAdbdYo1DhcHyjkDeCfoWud8AeENL8DeF7TQ9FiCQQjdJIR888h+9I57scfgAAMAAV0VABRRRQAUUUUAFFFFABRRRQBma3otvq32eR3lt7y2YvbXcG0SwEjB2kgggjgqQQe4OBXLatpvjOVfs81p4P8QWx433yS2jY7AoFmVj1yRtH+yK7yigDzR/CHi/XbX+z9a1vTvD+hYaJtP8ADcBWR4sfKhuJB8oHGdka5GRxXbeF/Duk+FdHh0rw/YxWNhFkrFHk5J6kk5LE+pJNatFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFAEdxDFc28sFxEksEqlJI5FDK6kYIIPBBHauafwf5Ihj0jX9a0u1hUKlvC8Nwi4zgr9ojkZcA4wpAA4xXU0UAcXqXgFdZQw6/4m8SalZMCr2huY7WORSCCr/Zo42YEE5BOK3/DHh7SfC+jw6VoFjFY2EP3Io8nnuSTksT3JJJrVooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKAP/Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f24_51_25407=[""].join("\n");
var outline_f24_51_25407=null;
